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Poorly soluble crystalline drug candidates are often made amorphous to increase their solubility
with the intent to enhance oral bioavailability, thus improving the likelihood of becoming a
commercial drug product.

Currently, considerable time, material and effort are expended to

determine whether an amorphous approach will provide the required bioavailability improvement.
However, often the solubility enhancement of the amorphous form is not fully realized in vivo due
to solution-mediated phase transformation (SMPT). This study investigated the effects of key
factors, through experimentation and modeling, that affect SMPT and model the potential effects
of SMPT on bioavailability.

Sparsely parameterized biopharmaceutical models were developed to quickly obtain estimates of
the bioavailability from in vitro dissolution data for compounds that precipitate in the
gastrointestinal tract. The models highlight the complex effects of drug absorption rate on
expected in vivo drug peak concentration and duration in the small intestinal lumen from where
orally administered drug is absorbed, depending on whether the peak concentration or the peak
duration is assumed to better translate from in vitro to in vivo. Furthermore, a model with limited
number of input variables allowed us to quantify variation in bioavailability based on known
variations of one or more model input parameters.

Mary Susan Kleppe, Ph.D- University of Connecticut, 2018

The differences in SMPT of a supersaturating system were compared in biorelevant media and a
medium without surfactants. Amorphous spironolactone underwent SMPT to a channel hydrate
in all three media which was confirmed by the decrease in dissolution rates assessed in a flowthrough dissolution apparatus, as well as by the appearance of crystals on the amorphous solid
surface detected by polarized light microscopy. Longer duration of supersaturation was found in
both biorelevant media, compared to the medium without surfactants.

The contribution(s) of the molecular mobility of the hydrated amorphous drug and degree of
supersaturation to the rate of SMPT of amorphous spironolactone. The degree of supersaturation
was not the sole determinant of SMPT. Rather, mobility of the solid at/near the dissolution surface
of amorphous material, relative to 37°C (i.e., physiological relevant temperature) is more likely to
be govern the extent and time course of dissolution enhancement by amorphous drugs.
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CHAPTER 1
Introduction, Objectives and Organization of the Dissertation
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INTRODUCTION
A significant fraction of drug candidates suffer from limited aqueous solubility and/or poor
dissolution properties (e.g., Biopharmaceutical/Developability Classification System (B/DCS) II &
IV compounds) in their crystalline forms.1-4 In the amorphous (i.e., non-crystalline, glassy) form,
solids can dissolve to achieve supersaturated drug concentrations.5-9 The supersaturated state
is of interest, because the increase in concentration can drive higher drug flux across the intestinal
mucosa, potentially resulting in greater oral bioavailability.10-13

However, compounds in

supersaturated states are thermodynamically unstable and the system can return to the
equilibrium (low concentration) state by crystallization. Crystallization of a more stable form on
the surface of the metastable form, while in solution, (i.e., solution-mediated phase
transformation, SMPT), can greatly reduce the apparent solubility and dissolution rate
enhancement of an amorphous solid.13-16 In the pharmaceutical industry, considerable time,
material and effort are expended to determine whether an amorphous approach will provide the
required bioavailability improvement.

Early prediction of the potential for success of the

amorphous route would reduce experimentation time and development costs for solid oral dosage
forms of poorly soluble drugs.

Biopharmaceutical models have been developed to help predict in vivo performance, i.e., to
estimate in vivo drug absorption from in vitro drug concentration-time data.17-27

These

biopharmaceutical models base their prediction of absorbed drug dose on physicochemical
properties of the drug (solubility, pKa, physical state), physiological properties (absorption rate
constant, local pH, transit time) and dosage form.28 Current models range from simple equations
to complex computer simulations.

For instance, a simple model may use as few as four

parameters to estimate drug absorption (e.g., the Maximum Absorbable Dose (MAD) model
considers only the absorption rate constant and solubility of a drug, and volume and transit time
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through the small intestine),29-30 whereas computer models (e.g., GastroPlusTM, Stella®,
Intellipharm® and Simcyp®) may utilize over twenty parameters.18, 28, 30-35

While there are several biopharmaceutical models in the literature that are reported to be capable
of handling precipitating drug, most require a large number of parameters to predict in vivo
absorption.31, 36 To date, there are no closed-form equations like the MAD that take into account
the effect of precipitation in the intestinal lumen on bioavailability for compounds that are expected
to undergo phase conversion in the gastrointestinal tract. It would be useful to have a model that
is capable of approximating the magnitude of the effect of formulation changes on oral drug
absorption of amorphous compounds, based on a limited number of in vitro parameters in order
to speed the screening of promising B/DCS II/IV drugs during development.36

A range in values of bioavailability is expected due to variation in physiological parameters, such
as small intestinal fluid volume, absorption rate constant, and gastrointestinal transit time.

In

addition, for supersaturating formulations, there can be variation in the degree of supersaturation
that is reached in vivo and the period over which the supersaturation is sustained. All of these
factors can produce variation in bioavailability across the population, which may be acceptable
for some drugs and unacceptable for others, based on the therapeutic range of the drug. An
approach to quantify the potential variation using sparsely parameterized mathematical models
would be an additional tool for formulators and those making decisions on investment of resources
for developing a new drug.

Additionally, formulation scientists employ dissolution testing to help screen drug candidates and
formulations that produce the most suitable drug release profile.

However, aqueous buffer

solutions often used for dissolution testing (e.g., Simulated Intestinal Fluid without pancreatin,
USP) do not mimic physiological conditions in the gastrointestinal tract, contributing to poor in
3

vitro in vivo correlation.37 The properties of gastrointestinal fluids, e.g. pH, buffer capacity, and
surfactant concentration, can profoundly influence the solubility and dissolution rate of a drug
compound, especially for B/DSC II/IV compounds. Many authors have found that the presence
of surfactants can significantly alter the duration of the supersaturated state, either prolonging or
delaying SMPT by affecting the nucleation and/or crystal growth rates. 38-44

For some drugs there is a poor correlation between predictors of crystallization rate of the
amorphous form in the dry state vs. “wet” state (i.e., during dissolution). For example, amorphous
spironolactone (SPIR) is considered an intermediate to slow re-crystallizer in solid state. However,
crystallization starts immediately (to a channel hydrate) upon exposure to an aqueous medium
during dissolution.45

In addition to the factors that affect crystallization tendency in the solid state, such as molecular
weight and rigidity8,

46

, two mechanisms for crystallization of amorphous solids in aqueous

environments have been suggested. One mechanism is based on a thermodynamic argument
and the other has a kinetic basis. However, the two mechanisms predict conflicting effects of
temperature on the rate of crystallization. The thermodynamic-based mechanism suggests that
a higher degree of supersaturation provides a greater driving force for crystallization.47-49
Hancock and Parks5 first developed an equation for quantifying the solubility advantage (or
maximum degree of supersaturation) of amorphous compounds based on thermal properties of
amorphous and crystalline forms of drugs.5 Murdande et. al expanded on the Hancock and Parks
model by including experimental data for heat capacity, water sorption of amorphous solids, and
differences in the extent of ionization due to the different concentrations achieved by crystalline
and amorphous forms.8 Both the Hancock and Parks model and the Murdande et. al theoretical
approach predict an inverse relationship between degree of supersaturation and temperature.
Thus, this thermodynamic mechanism predicts a decrease in the rate of crystallization as
4

temperature increases.

The kinetic mechanism is based on molecular mobility in the solid. As water is absorbed into the
amorphous solid during dissolution, particularly near the surface of the dissolving solid, the glass
transition temperature (𝑇𝑔 ) of the amorphous phase is reduced and mobility within the solid
increases. If the 𝑇𝑔 of the hydrated amorphous drug (𝑇𝑔ℎ𝑦𝑑(𝑟𝑎𝑡𝑒) ) decreases to near or below the
temperature of dissolution, there would be sufficient mobility in the amorphous material to
crystallize.50-51 This mechanism predicts that the crystallization rate increases as the dissolution
temperature increases.5, 7

OBJECTIVE
The overall objective of this dissertation was to evaluate the effects of key factors, through
experimentation and modeling that affect SMPT and model the potential effects of SMPT on
bioavailability. Specific aims are:

1. To develop sparsely parameterized models that can be used to quantitatively explore the
effects of precipitation on bioavailability of poorly soluble drugs.

2. To extend and optimize the models to investigate variability in the dosage form (i.e.,
degree and duration of supersaturation) along with known physiological variation (e.g.,
small intestinal transit time) using the models to estimate probability distributions of
bioavailability of a drug product.

3. To quantify the effects of bile salt (i.e., sodium taurocholate) and lecithin on SMPT of
supersaturating systems (using the amorphous form of a poorly soluble drug as a model).
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4. To evaluate the effects of temperature on SMPT of supersaturating systems (using the
amorphous form of a poorly soluble drug as model) and to explore the potential
contributions of two mechanisms of SMPT that suggest opposite temperature effects.

ORGANIZATION OF CHAPTERS
Chapter 2 presents the development of closed form analytical solutions that relate in vitro
concentration profiles to the amount of drug absorbed using several alternate assumptions and
only six parameters. Three parameters define the key features of the in vitro drug concentration
time profile. An additional three parameters focus on physiological parameters. Absorption
models were developed based on alternate assumptions; the drug concentration in the intestinal
fluid: 1) peaks at the same time and concentration as in vitro, 2) peaks at the same time as in
vitro, or 3) reaches the same peak concentration as in vitro. The three assumptions provide very
different calculated values of bioavailability. Case 1 applies to B/DCS IV compounds, which have
both low solubility and very low absorption rate constants. Cases 2 and 3 apply to B/DCS II
compounds, which have low solubility but absorption rate constants that leads to depletion of drug
from gastrointestinal fluid.

Chapter 3 investigates the variability in the dosage form (i.e., degree and duration of
supersaturation) along with known physiological variation (e.g., small intestinal transit time) using
the mathematical models described in Chapter 2, to estimate a probability distribution of
bioavailability of a product. The reported variations in physiological parameters provide the major
contribution to variation in oral bioavailability in supersaturating dosage forms (i.e., those in which
drug precipitates in the intestinal lumen). The assumptions regarding the translation of in vitro
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dissolution profiles to in vivo release also have a major impact on predictions of variation in
bioavailability.

Chapter 4 compares SMPT of a supersaturating system in biorelevant media (i.e., Fasted State
Simulated Intestinal Fluid and Fed State Simulated Intestinal Fluid) vs. USP compendial medium,
which is also known as Simulated Intestinal Fluid without pancreatin.

Amorphous SPIR

underwent SMPT to the same channel hydrate of SPIR in all three media which was confirmed
by the decrease in dissolution rates assessed in a flow-through dissolution apparatus, as well as
by the appearance of crystals on the amorphous solid surface detected by polarized light
microscopy. Longer duration of supersaturation which may lead to greater in vivo oral drug
absorption was found in both biorelevant media, compared to compendial.

The effects of temperature on SMPT of amorphous SPIR to channel hydrate explored in Chapter
5. Dissolution rates were determined over a range of temperatures for a single compound, rather
than determining the dissolution rates of compounds with different glass transition temperatures,
to eliminate the complications of molecular structural factors. SMPT occurred at each dissolution
temperature, faster at the higher temperatures than at the lower, strongly supporting a mobilityrelated mechanism for the rate of SMPT during dissolution.

There was a change in the

temperature dependence of the conversion times from the lower to higher temperatures,
suggesting a glass transition temperature within range of dissolution temperatures. However, the
experimentally determined glass transition temperature of the hydrated amorphous state was well
outside the region where the sudden change in slope suggested a glass transition. It was
postulated that the surface mobility is greater than in the bulk, such that the glass transition
temperature of the hydrated amorphous state at the surface where SMPT occurs was expected
to be lower than that of the bulk.

7

Chapter 6 provides a summary of the project, the significance of the findings and suggested
future directions for this area of research.
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CHAPTER 2
Mathematical Models to Explore Potential Effects of Supersaturation and
Precipitation on Oral Bioavailability of Poorly Soluble Drugs*

*This is a published manuscript from The AAPS Journal (2015, 1-16), used intact for this thesis
chapter.
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ABSTRACT
Poorly soluble drugs are increasingly formulated into supersaturating drug delivery systems which
may precipitate during oral delivery. The link between in vitro drug concentration profiles and oral
bioavailability is under intense investigation. The objective of the present work was to develop
closed form analytical solutions that relate in vitro concentration profiles to the amount of drug
absorbed using several alternate assumptions and only six parameters. Three parameters define
the key features of the in vitro drug concentration time profile. An additional three parameters
focus on physiological parameters. Absorption models were developed based on alternate
assumptions; the drug concentration in the intestinal fluid: 1) peaks at the same time and
concentration as in vitro, 2) peaks at the same time as in vitro, or 3) reaches the same peak
concentration as in vitro. The three assumptions provide very different calculated values of
bioavailability. Using Case 2 assumptions, bioavailability enhancement was found to be less than
proportional to in silico examples of dissolution enhancement. Case 3 assumptions lead to
bioavailability enhancements that are more than proportional to dissolution enhancements. Using
Case 1 predicts drug absorption amounts that fall in between Case 2 and 3. The equations
developed based on the alternate assumptions can be used to quickly evaluate the potential
improvement in bioavailability due to intentional alteration of the in vitro drug concentration versus
time curve by reformulation. These equations may be useful in making decisions as to whether
reformulation is expected to provide sufficient bioavailability enhancement to justify the effort.
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INTRODUCTION
The Biopharmaceutical Classification System (BCS) was designed to group compounds into one
of four categories based on both solubility and permeation rate, in order to accelerate the drug
development process 1. The majority of compounds currently in development are classified as
BCS II, highly permeable and poorly soluble, requiring formulation strategies to increase solubility
and dissolution rates 2.

One approach to increase solubility is to formulate the BCS II compounds in the amorphous state,
where the amorphous solid produces a highly supersaturated solution. Once a maximum
concentration is reached, precipitation can reduce the concentration to at/near crystalline
solubility 3. It is often assumed that the higher the amorphous peak concentration, the higher the
bioavailability. However, a higher degree of supersaturation does not always lead to increased
absorption, indicating that this parameter alone is not a suitable predictor of bioavailability for
potential amorphous formulation 4-5.

Over the past 25 years, mathematical models have been developed to estimate in vivo drug
absorption from in vitro drug concentration-time data 6-16. These biopharmaceutical models base
their prediction of drug absorption on physicochemical properties of the drug (solubility, pKa,
physical state), physiological properties (absorption rate constant, local pH, transit time) and
dosage form

17

. Current models range from simple equations to complex computer simulations.

For instance a simple model may use as few as four parameters to estimate drug absorption (e.g.,
the Maximum Absorbable Dose (MAD) model considers only the absorption rate constant and
solubility),

18-19

whereas computer models (e.g., GastroPlusTM, Stella®, Intellipharm® and

Simcyp®) may utilize over twenty parameters 7, 17, 19-24.
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While there are several biopharmaceutical models in literature that are reported to be capable of
handling precipitating drug, most require a large number of parameters to reliably predict in vivo
absorption 2, 20. To date, there are no simple equations like the MAD in the literature that take into
account the effect of precipitation in the intestinal lumen on bioavailability. It would be useful to
have a model that has the capability of estimating the magnitude of the effect of formulation
changes on oral drug absorption of amorphous compounds, based on a limited number of in vitro
parameters in order to speed the screening of promising BCS II drugs during development 2.

The objective of the current work was to develop sparsely parameterized mathematical models
relating in vitro drug concentration-time profile (often referred to as a dissolution profile) of the
amorphous form of a model drug to an estimate of in vivo drug concentration-time profile. To
obtain in vivo luminal concentration-time profiles from in vitro dissolution profiles, precipitation
was assumed to be Dependent-on-Time or Dependent-on-Concentration. Closed-form equations
describing absorption were derived based on each set of assumptions.

MODEL DEVELOPMENT
Parameterization of In Vitro Drug Concentration-Time Profiles
During in vitro drug dissolution from amorphous powders and formulations, precipitation often
occurs after maximum supersaturation is reached (Figure 1) 4. A supersaturation ratio is defined
here as the maximum drug concentration over the plateau concentration. Similar ratios of
maximum supersaturation have been used as predictors of the oral bioavailability enhancement
of the amorphous form, with variable success 5, 25.

Each in vitro drug concentration-time profile of an amorphous form differs in concentration at
peak, duration of the peak, peak shape and plateau concentration (Figure 1).

Previous

investigators have modeled the supersaturation in vitro dissolution curve 26-27. However, our goal
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of obtaining a closed-form analytical solution for the bioavailability of an amorphous formulation
demands a more parsimonious parameterization of the in vitro curves. Here, we seek to capture
the main features of each curve with a minimum number of parameters, allowing rapid
characterization. Of course the use of biological relevant medium and volumes will provide better
input 28-33. To be sure, there is some loss in accuracy when a minimum number of parameters is
used to characterize a wide variety of peak shapes. The simplicity and time-savings gained from
using few parameters on which to base an estimate of bioavailability is thought to outweigh any
real or suspected accuracy obtained from describing the experimental dissolution curve in greater
detail.

It would initially seem that characterizing the in vitro concentration vs. time profile using the area
under the curve (AUC) would be the simplest and most direct approach. When there is negligible
depletion of drug from intestinal fluids due to low absorption rate constant, as is the case for BCS
IV compounds, the in vivo concentration vs time profile mirrors in vitro. The AUC of the in vivo
concentration vs time profile can be determined from the in vitro curve when using biologically
relevant medium and volumes. The total amount of drug absorbed is simply the product of in vivo
AUC, intestinal fluid volume and absorption rate constant. However, the main focus of the
proposed model is to estimate the amount of drug absorbed for BCS II compounds. BCS II drugs
have significant absorption rate constants which leads to significant depletion of drug from
gastrointestinal fluid, so that the total amount of drug cannot be directly calculated from AUC
without underestimating amount of drug absorbed.

Several other approaches to characterizing the in vitro drug concentration-time curves were
considered.

One approach is to identify the maximum concentration (𝐶𝑔 𝑚)1, plateau drug

The subscript g denotes in vitro (Latin for “in glass”). See Table 1 for full description of the
nomenclature.
1
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concentration following the peak (𝐶𝑔 𝑝), the time to the maximum concentration (𝑇𝑔 𝑚) and time to
reach plateau concentration (𝑇𝑔 𝑝) directly from the in vitro drug concentration profile (Figure 2(a)).
This approach is simple and uses only 4 parameters to characterize the peak as a general
Euclidian triangle. However, this approach underestimates the area under the experimental peak
in the dissolution profile (by 14, 39 and 42%, respectively for in vitro profiles shown in Figure 1).
Additionally, the time to reach the plateau is not easily identified, particularly for nonlinearly
decline to the plateau concentration.

A second approach is to approximate the peak as an isosceles triangle (Figure 2(b)) where the
maximum concentration (𝐶𝑔 𝑚), the plateau concentration (𝐶𝑔 𝑝), and the time to peak (𝑇𝑔 𝑚) are
identified directly from the in vitro drug concentration profile. Using this approach, the time to
reach the plateau concentration (𝑇𝑔 𝑝) can be calculated from the relationship between two similar
triangles. The use of isosceles triangles provides simplicity in the development of the model and
in the resulting equations used to estimate the bioavailability. However, this approach more
severely underestimates the area under the experimental peak than does the first approach.

A third approach combines advantages of the first two. The maximum drug concentration (𝐶𝑔 𝑚)
and the plateau drug concentration (𝐶𝑔 𝑝) following the peak are identified directly from the in vitro
drug concentration profile. However, in this approach, 𝑇𝑔 𝑚 and 𝑇𝑔 𝑝 are not determined directly
from inspection of time points on the profile. Rather, the width of the peak is characterized by its
full width at half maximum.

In order to obtain 𝑇𝑔 𝑚 and 𝑇𝑔 𝑝, first, the concentration at half the height of the peak (𝐶𝐻𝑀 ) that
extends beyond the lower plateau concentration (𝐶𝑔 𝑝) is determined (Equation 1).
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𝐶𝐻𝑀 =

(𝐶𝑔 𝑚 − 𝐶𝑔 𝑝)
+ 𝐶𝑔 𝑝
2

(1)

At the half maximum concentration (𝐶𝐻𝑀 ), the width of the peak (𝑇𝐻𝑀 ) is identified by subtracting
the time to reach 𝐶𝐻𝑀 initially (𝑇𝑎 ) from the time (𝑇𝑏 ) at which the concentration declines to 𝐶𝐻𝑀
(Figure 2(c)). The full width at half maximum (𝑇𝐻𝑀 ) of the experimental drug concentration time
profile is a measure of duration of the peak and is used to define the length of the base of the
isosceles triangle corresponding to the drug peak. There are several advantages of this approach.
First, it requires only three parameters (𝐶𝑔 𝑚, 𝐶𝑔 𝑝, and 𝑇𝐻𝑀 ) to characterize the in vitro curve2. The
value of 𝑇𝑔 𝑚 can be calculated using similar triangles (Equation 2, Figure 3) from the two
concentrations, 𝐶𝑔 𝑚 and 𝐶𝑔 𝑝 , and the full width at half maximum (𝑇𝐻𝑀 ).

𝑇𝑔 𝑚 =

𝑇𝐻𝑀
𝐶𝑔 𝑝
(1 − 𝐶 𝑚)
𝑔

(2)

As shown in Figure 3, the time to reach the plateau concentration (𝑇𝑔 𝑝) can be calculated from
𝑇𝑔 𝑚, 𝐶𝑔 𝑚 and 𝐶𝑔 𝑝 (Equation 3) rather than identified directly from the experimental curve.

𝑇𝑔 𝑝 = 2(𝑇𝑔 𝑚) −

(𝐶𝑔 𝑝)(𝑇𝑔 𝑚)
𝐶𝑔 𝑚

(3)

2

Furthermore, it retains the benefits of using an isosceles triangle to approximate the peak. For
example, the width of the base of the isosceles triangle which lies at 𝐶𝑔 𝑝 is exactly twice 𝑇𝐻𝑀 as
shown in Figure 3. Additionally, the width of the base of the larger isosceles triangle is twice
𝑇𝑔 𝑚, the time to reach the apex of the isosceles triangle.
20

Using this heuristic approach, the area under the 3-parameter approximation (𝐶𝑔 𝑚, 𝐶𝑔 𝑝 and 𝑇𝐻𝑀 )
of the dissolution curve differs from the area under the experimental dissolution profile by only 9%
for the case of indomethacin, 12% for the case of hydrochlorothiazide and 26% for the case of
danazol (Figure 1). Several other drug dissolution profiles

34

were evaluated and the difference

in area under the curve is 14±7%. It should be noted that the time to peak using the isosceles
triangular approximation will not always equal the time to peak concentration from the in vitro drug
concentration-time profile. However, the simplicity in the derivation of bioavailability equations
using the isosceles triangle to approximate the experimental data is thought to outweigh the loss
in fidelity in the description of all aspects of the peak shape.

Indeed, there are a myriad of other ways to approximate the variety of shapes of in vitro
concentration-time profiles. For some curves, a peak drug concentration is reached quite rapidly
and maintained for a period of time until very rapid precipitation occurs, resulting in a
concentration-time profile that may be better parameterized using a rectangular approximation as
illustrated in Figure2(d). However, with this approach another parameter, a “lag” time, or the time
to reach in vitro peak concentration, 𝐶𝑔 𝑚, is often needed Figure2(e). For some profiles (e.g.,
hydrochlorothiazide and danazol in Figure 1), a rectangular shape would overestimate the area
under the curve. Using a rectangular approximation without the “lag” time (Figure2(d)) would allow
peak approximation using just three parameters, as was achieved using the isosceles triangular
approximation (Figure 3). However, the area under the curve is often more severely
overestimated than without the use of a “lag” time parameter.
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Another approach would be to characterize in vitro profile by either the triangle or rectangular
approximation, whichever fits best. However, this would eliminate the ability to use a single
system to compare drug concentration-time curves of a single drug from different formulations.
Later in the text, the isosceles triangular approximation is compared to an equivalent rectangular
approximation in order to identify any bias imposed by the use of the triangular approximation.

Relationship Between In Vitro Drug Concentration Profile and Drug Concentration in
Intestinal Fluid
A

one-tank model

9

is used to calculate amount of drug absorbed from the 3-parameter

approximation of the in vitro concentration profile. Originally, the one-tank model was used to
describe dissolution-limited absorption, with no precipitation. Here, it is extended to include
precipitation.

USP Apparatus II has been traditionally used to assess in vitro drug dissolution, where a quantity
of drug powder (𝑋𝑔 𝑜) is dispersed in a medium of a constant volume (𝑉𝑔 ). For supersaturating
drug forms, such as the amorphous form considered here, the amount of excess solid (𝑋𝑔 𝑒(𝑡))
and the amount of drug in solution (𝑋𝑔 𝑠(𝑡)) change with time as a result of dissolution and
precipitation. The total amount of drug in the vessel (𝑋𝑔 𝑜) remains constant (Figure 4(a) and
Equation 4).

𝑋𝑔 𝑜 = 𝑋𝑔 𝑠(𝑡) + 𝑋𝑔 𝑒(𝑡)

(4)
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This process is more complicated in vivo 35. For the simplest case where the dose administered
in vivo (𝑋𝑙 𝑜) 3 is introduced directly into the small intestines (by, for example, an enteric-coated
dosage form), many of the processes in vivo (Figure 4(b)) and in vitro (Figure 4(a)) are similar,
where the amount of drug in solution (𝑋𝑙 𝑠(𝑡)) and amount of excess solid (𝑋𝑙 𝑒(𝑡)) vary with time
and depend on the volume available for dissolution in the luminal fluid (𝑉𝑙 ).

However, in vivo, as dissolution and precipitation are occurring, absorption is also taking place,
such that there is depletion of the dose (𝑋𝑙 𝑜) from the intestinal lumen. The total amount of drug
in vivo (𝑋𝑙 𝑜) is then equal to the amount of drug in solution (𝑋𝑙 𝑠(𝑡)), amount of drug in the solid
(𝑋𝑙 𝑒(𝑡)) as well as amount absorbed (𝑋𝑙 𝑎(𝑡)), Equation 5.

𝑋𝑙 𝑜 = 𝑋𝑙 𝑠(𝑡) + 𝑋𝑙 𝑒(𝑡) + 𝑋𝑙 𝑎(𝑡)

(5)

There are two major differences between the in vitro and in vivo systems. Due to depletion of
dissolved drug via absorption, the concentration of drug in solution (𝑋𝑙 𝑠(𝑡)⁄𝑉𝑙 ) in the small
intestine will be lower than the concentration of drug during in vitro dissolution (𝑋𝑙 𝑠(𝑡)⁄𝑉𝑔 )

36

.

Furthermore, the in vitro fluid volume (𝑉𝑔 ) is traditionally much greater than small intestinal fluid
32

volume (𝑉𝑙 ). Using USP Apparatus (Type 1 or 2), the volume ranges from 250 mL to 1L

, while

the volume of the small intestinal fluid has been reported to be only 45 to 320 mL 37. The lower in
vivo volume can result in a significantly lower amount of drug in solution in vivo

22

. This is

The subscript 𝑙 denotes in vivo (Latin for “within the living”). See Table 1 for full description of
the nomenclature.
3
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particularly important for amorphous formulations where the degree of supersaturation and
excess remaining solid can influence the time course of precipitation 3.

Precipitation is a function of both concentration and time; the peak concentration and its duration
depend on the drug, drug form, dose and formulation components (the exact dependence of
which is the focus of intense current investigation) 5, 28-29, 38-43. If both the peak drug concentration
and duration of that peak in vivo were equal to the values determined from the in vitro dissolution
profile (Figure 5(a)), bioavailability would be proportional to the area under the in vitro
concentration-time curve, adjusting for volume, of course.

Alternatively, assuming drug precipitation is dependent on time, absorption would deplete the
concentration of dissolved drug resulting in a peak drug concentration in vivo that is lower than in
vitro. In this case, the bioavailability would be less than proportional to the area under the in vitro
dissolution curve. Using the 3-parameter isosceles triangular approximation of the dissolution
curve, this is equivalent to assuming precipitation occurs at the same time in the small intestine
as determined in vitro (Figure 5(b)).

In contrast, assuming drug precipitation is dependent on concentration, the drug concentration in
vivo would eventually reach the same peak in vitro concentration. However, depletion due to
absorption of drug from the small intestine would prolong the time to peak. The extended period
of elevated drug concentration would result in greater absorption compared to that predicted from
the in vitro dissolution area under the curve. Using the isosceles triangular approximation, this
case is equivalent to in vivo precipitation occurring at the same concentration as observed in vitro
(Figure 5(c)).
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It is not known with certainty whether the concentration profiles are the same in vitro and in vivo,
or whether it is the in vivo peak drug concentration or the duration of the elevated concentration
that corresponds better the in vitro dissolution profile. However, the drug concentration behavior
in vivo is likely bracketed by assumptions a) equivalent duration of the peak in vitro and in vivo,
(Figure 5(b)) and b) equal peak concentrations in vitro and in vivo, (Figure 5(c)). Potential
bioavailability enhancement that could be achieved by formulation changes which alter the drug
peak concentration and/or duration should be within these two extremes. Therefore, derivation of
closed-form analytical equations based on these assumptions allows us to easily quantify
potential effects of precipitation on bioavailability of supersaturating drug delivery systems.

Three Cases for In Vivo Dissolution Behavior
Depending on the drug properties and the conditions in the small intestine, three cases based on
the above assumptions can be explored using the isosceles triangular approximation of the in
vitro dissolution.

Case 1.

The drug concentration in small intestinal fluid (𝐶𝑙 𝑠(𝑡)) mirrors the in vitro drug
concentration vs. time curve (𝐶𝑔 𝑠(𝑡)). Using the 3-parameters characterizing the
in vitro curve, the peak drug concentration (𝐶𝑙 𝑚1) in vivo occurs at the same time
and concentration as seen in vitro (𝐶𝑔 𝑚) (Figure 5(a)). This scenario is limited to
drugs with low absorption rate constants, such as is the case for BCS IV
compounds.

Case 2.

The duration of the elevated drug concentration in vivo corresponds to the in vitro
dissolution behavior. Using the isosceles triangle approximation, the peak drug
concentration in vivo (𝐶𝑙 𝑚2 ) occurs at the same time (𝑇𝑙 𝑚2 = 𝑇𝑔 𝑚) in vitro, but due
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to absorption, the peak drug concentration in vivo (𝐶𝑙 𝑚2 ) is lower than in vitro
(𝐶𝑔 𝑚) (Figure 5(b)). This scenario is more consistent with precipitation being a
Dependent-on-Time phenomenon and is referred to below as the Dependent-onTime Precipitation case.

Case 3.

Precipitation in vivo (𝐶𝑙 𝑚3 ) occurs at the same concentration (𝐶𝑔 𝑚) as seen in
vitro, but due to absorption, the time to reach peak concentration in vivo (𝑇𝑙 𝑚3 )
occurs at a later time than in vitro (𝑇𝑔 𝑚) (Figure 5(c)). This scenario is more
consistent with precipitation being a Dependent-on-Concentration phenomenon
and is referred to below as the Dependent-on-Concentration Precipitation case.

Development of Mathematical Equations Describing Drug Absorption for Precipitating
Drugs
The following conditions were specified to further simplify the model:
1. Drug dissolution and absorption occur in the small intestine only.
2. The small intestinal lumen can be considered a single mixing tank at a constant
volume.
3. Drug absorption is a first order process with respect to concentration.
4. Once drug precipitation is complete, drug concentration remains constant.4
5. There is excess solid drug remaining at the end of absorption.
6. Drug precipitation is non-pH dependent.

4

Drug precipitates to what is thought to be very small particles, perhaps in the nanometer
range. These many minute drug particles have a very large surface area, making it less likely
that dissolution is rate-limiting.
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A first order absorption rate (𝑘𝑎 ) constant is used to relate the amount of drug in solution in vivo
(𝑋𝑙 𝑠(𝑡)) to the amount absorbed (Equation 6)

𝑑𝑋𝑙 𝑎(𝑡)
𝑑𝑡

= (𝑘𝑎 )(𝑋𝑙 𝑠(𝑡))

(6)

where 𝑋𝑙 𝑎(𝑡) is the amount absorbed.

The amount of drug in solution in small intestinal fluid at any time (𝑋𝑙 𝑠(𝑡)) is equal to its
concentration (𝐶𝑙 𝑠(𝑡)) times small intestinal fluid volume (𝑉𝑙 ). Equation 6 becomes:

𝑑𝑋𝑙 𝑎
= (𝑘𝑎 )(𝑉𝑙 ) (𝐶𝑙 𝑠(𝑡))
𝑑𝑡

(7)

Equation 7 can be applied to the isosceles triangular approximation of the dissolution curve to
derive equations of amount of drug absorbed, for each of the three cases described. The 3parameter approximation to the concentration profile has two discontinuities. For simplicity in the
derivation of the amount of drug absorbed, the profile is divided into three phases (Figure5). Drug
absorbed during each phase is calculated separately.
•

Phase i: The period between initial drug release and peak concentration.

•

Phase ii: The time from peak drug concentration to the plateau concentration.

•

Phase iii: The period over which the plateau concentration extends (where the drug in
solution is in equilibrium with the solid drug).
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The total amount of drug absorbed is the sum of drug absorbed during each phase. Equations
describing the total amount of drug absorbed for each model assumption (i.e., Case 1, 2 and 3)
are presented below. Details of their deviation are found in Supplemental 1.

Case 1
In this simplest case, the concentration of drug in solution in vivo is equal to the concentration of
drug in solution in vitro (𝐶𝑙 𝑠(𝑡) = 𝐶𝑔 𝑠(𝑡)) at all times during small intestinal transit, 0 < 𝑡 < 𝑇𝑙 𝑟,
(Figure 5(a)).5 The total amount of drug absorbed (𝑋𝑙 𝑎(𝑡)) can be determined from the in vitro
dissolution profile (𝐶𝑔 𝑠(𝑡)) using Equation 7. Equation 8 describes the total amount of drug
𝑇𝑟

absorbed during all three phases for Case 1, 𝑋𝑙 𝑎1 |0𝑙 , as illustrated in Figure5(a) 6.

2

𝑇𝑟
𝑋𝑙 𝑎1 |0𝑙

= (𝑘𝑎 )(𝑉𝑙 ) {(𝐶𝑔 𝑚)(𝑇𝑔 𝑚) +

(𝐶𝑔 𝑝) (𝑇𝑔 𝑚)
2(𝐶𝑔 𝑚)
(8)

+ (𝐶𝑔 𝑝) (𝑇𝑙 𝑟 − 2(𝑇𝑔 𝑚)) }

This approach uses the three parameters obtained from the in vitro concentration-time profile:
𝐶𝑔 𝑚, 𝑇𝑔 𝑚 and 𝐶𝑔 𝑝 (Figure 2(c) and 3; Equation 2). Since the in vivo and in vitro drug concentration

5

Neglect for the purpose of this simple case, the reduction in drug concentration in the lumen
due to absorption. This is handled in Case 2 and Case 3.
𝑇𝑟

𝑋𝑙 𝑎1 |0𝑙 is also equal to the product of 𝑘𝑎 and AUC of the in vivo concentration vs. time profile
since the assumption is made that in vivo drug concentration vs. time curve mirrors the in vitro.
6
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vs. time profiles are assumed to be equal for Case 1, the corresponding in vivo parameters equal
those determined in vitro (i.e., 𝐶𝑙 𝑚1 = 𝐶𝑔 𝑚, 𝑇𝑙 𝑚1 = 𝑇𝑔 𝑚, 𝐶𝑙 𝑝 = 𝐶𝑔 𝑝 and 𝑇𝑙 𝑝1 = 𝑇𝑔 𝑝) 7.

Case 2
The Dependent-on-Time Precipitation case assumes the peak duration in vivo corresponds to the
in vitro time to peak in the absence of absorption. Using the 3-parameter approximation of the in
vitro dissolution time profile, this assumption translates to the time to peak in vivo equaling the
time to peak in vitro (𝑇𝑙 𝑚2 = 𝑇𝑔 𝑚), as shown in Figure 5(b). There are two equations (9a and 9b)
𝑇𝑟

for calculating the amount of drug absorbed (𝑋𝑙 𝑎2 |0𝑙 ) using Case 2 assumptions depending on
𝐶 𝑚

the supersaturation ratio ( 𝐶𝑔 𝑝 ).
𝑔

When

𝐶𝑔 𝑚
𝐶𝑔 𝑝

> (𝑘𝑎 )(𝑇𝑔 𝑚) (i.e., the supersaturation ratio is sufficiently higher relative to the

product of the 𝑘𝑎 and 𝑇𝑔 𝑚). When 𝑇𝑔 𝑚 is prolonged or absorption is rapid, the peak
concentration in vivo is far below in vitro, reducing the enhancement.

𝑇𝑟

𝑋𝑙 𝑎2 |0𝑙 = 𝑉𝑙 {𝐶𝑔 𝑚 (2 −

When

𝐶𝑔 𝑚
𝐶𝑔 𝑝

𝑇𝑙 𝑝2
) − 𝐶𝑔 𝑝 + (𝑘𝑎 )(𝐶𝑔 𝑝)(𝑇𝑙 𝑟 − 𝑇𝑙 𝑝2 )}
𝑇𝑔 𝑚

(9a)

≤ (𝑘𝑎 )(𝑇𝑔 𝑚),

𝑇𝑟

𝑋𝑙 𝑎2 |0𝑙 = 𝑉𝑙 {(𝐶𝑔 𝑚 − 𝐶𝑙 𝑚2 ) + (𝑘𝑎 )(𝐶𝑔 𝑝)(𝑇𝑙 𝑟 − 𝑇𝑔 𝑚)}

(9b)

The subscript 𝑔 denotes in vitro (Latin for “in glass”) and the subscript 𝑙 denotes in vivo (Latin
for “within the living”). A second subscript indicates the case (see Table 2).
7
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where
(𝐶𝑔 𝑚)

𝐶𝑙 𝑚2 = (𝑘

𝑎 )(𝑇𝑔 𝑚)

(1 − 𝑒 −(𝑘𝑎)(𝑇𝑔 𝑚) )

(10)

(𝐶𝑔 𝑚)

𝑇𝑙 𝑝2 = 𝑇𝑔 𝑚 +

𝐶𝑙 𝑚2 +(𝑘 )(𝑇
1
𝑎
𝑔 𝑚)
𝑙𝑛
[
]
(𝐶
𝑚)
𝑔
𝑘𝑎
𝐶𝑔 𝑝+(𝑘 )(𝑇
𝑚)
𝑎
𝑔

(11)

With depletion due to absorption, the in vivo concentration will be lower than the concentration in
solution in vitro (𝐶𝑔 𝑠(𝑡)), as shown in Figure 5(b). While the time to peak remains unchanged
(𝑇𝑙 𝑚2 = 𝑇𝑔 𝑚) in Case 2, we note that the peak drug concentration in vivo (𝐶𝑙 𝑚2 ) is lower than the
peak concentration in vitro (𝐶𝑔 𝑚) (Equation 10). As in Case 1, the plateau concentration in vivo
(𝐶𝑙 𝑝) remains equal to that in vitro (𝐶𝑔 𝑝), i.e., 𝐶𝑔 𝑝 = 𝐶𝑙 𝑝. However the time to reach the plateau in
vivo (𝑇𝑙 𝑝2 ) is less than that observed in vitro (𝑇𝑔 𝑝) (Equation 11), again due to absorption. The
time to reach plateau concentration (𝑇𝑙 𝑝2 ) is generally greater than 𝑇𝑔 𝑚. However, when the
supersaturation ratio (𝐶𝑔 𝑚⁄𝐶𝑔 𝑝) drops below the product of 𝑘𝑎 and 𝑇𝑔 𝑚, then 𝑇𝑙 𝑝2 < 𝑇𝑔 𝑚,
eliminating phase ii. The total amount of drug absorbed is calculated from phase i and iii only
(Equation 9b).

Case 3
The Dependent-on-Concentration Precipitation case, assumes drug concentration reaches the
same peak value in vivo as in vitro (𝐶𝑙 𝑚3 = 𝐶𝑔 𝑚). The total amount of drug absorbed during all
𝑇𝑟

three phases (𝑋𝑙 𝑎3 |0𝑙 ) is determined by Equation 12a or 12b, depending on the time to peak
(𝑇𝑙 𝑚3 ) relative to small intestinal transit time (𝑇𝑙 𝑟).
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When the time to peak is smaller than the small intestinal transit time (i.e., 𝑇𝑙 𝑚3 < 𝑇𝑙 𝑟),

𝑇𝑟

𝑋𝑙 𝑎3 |0𝑙 = 𝑉𝑙 {𝐶𝑔 𝑚 {2 (

𝑇𝑙 𝑚3
𝑇𝑙 𝑝3
1−𝑀
+
+ 𝑀}
)−
𝑇𝑔 𝑚
𝑇𝑔 𝑚 (𝑘𝑎 )(𝑇𝑔 𝑚)
(12a)

+ (𝑘𝑎 )(𝐶𝑔 𝑝)(𝑇𝑙 𝑟 − 𝑇𝑙 𝑝3 )}

When the time to peak is equal or greater than the small intestinal transit time, (i.e., 𝑇𝑙 𝑚3 ≥ 𝑇𝑙 𝑟),

𝑇𝑟

𝑋𝑙 𝑎3 |0𝑙 =

(𝑉𝑙 )(𝐶𝑔 𝑚)
(𝑇𝑔 𝑚)

[𝑇𝑙 𝑟 + (

(𝑒 −(𝑘𝑎 )(𝑇𝑙 𝑟) −1)
)]
𝑘𝑎

(12b)

Where

𝑇𝑙 𝑚3 =

1
1
𝑙𝑛 (
)
𝑘𝑎
1−(𝑘𝑎 )(𝑇𝑔 𝑚)

𝑇𝑙 𝑝3 = 𝑇𝑙 𝑚3 +

1
𝑙𝑛[𝑀]
𝑘𝑎

(13)

(14)

(𝐶𝑔 𝑚)

𝑀=[

𝐶𝑔 𝑚+(𝑘 )(𝑇
𝑎
𝑔 𝑚)
(𝐶𝑔 𝑚)

𝐶𝑔 𝑝+(𝑘 )(𝑇
𝑎
𝑔 𝑚)

]

(15)

In the absence of absorption, as in Case 1, the concentration of drug in solution in vivo (𝐶𝑙 𝑠(𝑡))
would equal the concentration of drug in solution in vitro (𝐶𝑔 𝑠(𝑡)). However, as in Case 2,
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absorption results in a depletion in drug concentration in solution in vivo (𝐶𝑙 𝑠(𝑡)). Therefore, the
peak drug concentration in vivo occurs at a later time (𝑇𝑙 𝑚3 ) than the time derived from the in vitro
profile (𝑇𝑔 𝑚), such that 𝑇𝑙 𝑚3 > 𝑇𝑔 𝑚, (Equation 13). When the value of 𝑇𝑙 𝑚3 is greater than the
small intestinal transit time (𝑇𝑙 𝑟), phase i completely dominates the absorption profile (Equation
12(b)).

In all three cases, the extent of drug absorption can be calculated from closed-form analytical
equations. Only 6 parameters are required to obtain solutions, 3 of which are determined from in
vitro concentration vs. time profiles.

From these equations, the potential bioavailability

enhancement that could be gained from reformulation efforts to modify supersaturation peak
duration and/or concentration may be quantitatively explored a priori.

METHODOLGY
The amount of drug absorbed using the assumptions corresponding to each case described
above were calculated from Equations 8, 9 and 12 for three drug constructs in a patient described
by average physiological parameters. The value for small intestinal fluid volume (𝑉𝑙 ) is 70 mL
and the transit time (𝑇𝑙 𝑟) is 180 min, which represent median values from the literature 44-48. The
plateau concentration (𝐶𝑔 𝑝) was set to 10 µg/mL to reflect the low solubility values for many BCS
II compounds, particularly those for which dissolution enhancement strategies, such as
amorphization, are sought.

The values of the remaining three parameters -- absorption rate constant (𝑘𝑎 ), peak drug
concentration reached during in vitro dissolution performance evaluation (𝐶𝑔 𝑚), and the
parameter reflecting drug concentration peak duration in vitro, (𝑇𝑔 𝑚)– were explored over wide
ranges. The 𝑘𝑎 values for BCS II and IV compounds were found to range from 0.0003 to 0.08
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min-149. The ranges for both 𝐶𝑔 𝑚 and 𝑇𝑔 𝑚 values were chosen based on experimental data 34. A
3x6x5 full-factorial design for each case was utilized where 𝑘𝑎 was evaluated at three levels,
0.001, 0.01 and 0.1 min-1, 𝐶𝑔 𝑚 ranged from 20 to 100 µg/mL in 20 µg/mL increments
corresponding to maximum supersaturation ratio (𝐶𝑔 𝑚/𝐶𝑔 𝑝) from 2 to 10, and 𝑇𝑔 𝑚 was evaluated
in 10 min increments from 10 to 60 min.

RESULTS
The mathematical models (Equation 8, 9 and 12) were developed to quickly evaluate the potential
improvement in bioavailability due to intentional alteration of the in vitro drug concentration versus
time curve by reformulation. These equations may be useful in making decisions as to whether
reformulation is expected to provide sufficient bioavailability enhancement to justify the effort.

The models were applied to drug constructs with a range of absorption rate constant. As will be
shown below, the relationship between in vitro dissolution profile and bioavailability is dependent
on 𝑘𝑎 . Therefore, the results for low, moderate and high 𝑘𝑎 values are presented in separate
sections. Within each section, the bioavailability enhancement gained by prolonging 𝑇𝑔 𝑚 and
increasing 𝐶𝑔 𝑚⁄𝐶𝑔 𝑝 will be discussed in detail using the assumptions used in Cases 1, 2 and 3.

Drugs with a Low Absorption Rate Constant (𝒌𝒂 = 0.001 min-1)
The absorption half-life corresponding to 𝑘𝑎 of 0.001 min-1 is nearly 12 hrs, which is 4 times the
small intestinal transit time and 6-36 times the time period during which drug is in supersaturated
state, ~2(𝑇𝑔 𝑚). The three plots (Figure 6 (a), (d) and (g)) showing the amount of drug absorbed
for each case are superimposable when the absorption rate constant is low, since there is
negligible drug depletion from the intestinal lumen. Thus, for poorly permeable compounds, the
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simpler Case 1 equation (Equation 8) provides the same prediction of amount of drug absorbed
as would the more complex equations for Cases 2 and 3 (Equation 9 and 12).

For these poorly permeable compounds, an increase in peak duration (𝑇𝑔 𝑚) and/or peak height
relative to the plateau (𝐶𝑔 𝑚⁄𝐶𝑔 𝑝) generally result in an increase in the total amount of drug
absorbed. However, at lower peak concentrations, 𝐶𝑔 𝑚⁄𝐶𝑔 𝑝 = 2, sustaining the duration of the
peak (i.e., increasing 𝑇𝑔 𝑚 from 10 to 60 min) does little to improve the amount of drug absorbed
(i.e., less than 7% increase8). Similarly, when the peak concentration cannot be sustained (i.e.,
𝑇𝑔 𝑚 = 10 min), there is only about a 40% improvement in the amount of drug absorbed when
efforts are made to raise the in vitro peak drug concentration from 2 to 10 times the plateau (or
drug solubility) over the short supersaturation period. These results are not surprising since the
peak duration and extent of supersaturation are very low in each of these two scenarios. In
contrast, when the in vitro peak drug concentration is high (e.g., 10 times the plateau
concentration), increasing the peak duration, 𝑇𝑔 𝑚, from 10 to 60 min increases the amount of
drug absorbed by 150% of the original value. Furthermore, when the peak duration is longer
(e.g., 𝑇𝑔 𝑚9 = 60 min), the bioavailability enhancement is increased by about 250% when the peak
concentration is raised 5 times (i.e., 𝐶𝑔 𝑚⁄𝐶𝑔 𝑝 from 2 to 10).

Figure 7 (a), (d) and (g) details the amount of drug absorbed in each absorption phase for each
case illustrated in Figure 5. When phase i and ii dominate, (i.e., when the duration of the peak is

8

Percent change is expressed as a percent of the difference between new valve and the
original valve relative to the original valve. For example if absorption increases from 5 to 10
milligrams, the percent increase is 100%.
9

𝑇𝑔 𝑚 is equal to the width of the peak at half maximum and not equal to the actual peak width
at its base, which is about 2 times 𝑇𝑔 𝑚.
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long, e.g., 𝑇𝑔 𝑚 = 60 min), the increase in amount of drug absorbed is more closely proportional
to in vitro peak drug concentration. However when phase iii dominates, as is the case when the
duration of the peak is short (e.g., 𝑇𝑔 𝑚 =10 min), reformulation strategies taken to increase
𝐶𝑔 𝑚⁄𝐶𝑔 𝑝, will result in a less than proportional increase in drug absorption that may not be worth
the development effort.

Drugs with an Intermediate Absorption Rate Constant (𝒌𝒂 = 0.01 min-1)
Next, we consider drugs which have the same in vitro dissolution profiles as explored above, but
now which have an order of magnitude greater absorption rate constant. Figure 6 (b), (e) and (h)
shows about an order of magnitude increase in amount of drug absorbed over Figure 6 (a), (d),
and (g), respectively.

In fact, for Case 1, where the assumption is that the in vivo drug

concentration time profile mirrors exactly that observed in vitro, increasing 𝑘𝑎 by one order of
magnitude will increase drug absorption by exactly one order of magnitude (Figure 6 (a), (b) and
(c) and Equation 8). In contrast, when the drug concentration time profile in vivo does not exactly
mirror that in vitro, but rather differs in the manner described by either Case 2 or 3, the amount of
drug absorbed is not proportional to 𝑘𝑎 .

In Case 2, where the in vivo peak is Dependent-on-Time and corresponds to in vitro time to peak,
the amount absorbed is less than proportional to the absorption rate constant, whereas using the
Case 3 assumptions, the amount of drug absorbed is more than proportional to 𝑘𝑎 . This contrast
is most clearly seen when the peak concentration and peak duration are both large (Figure 6 –
(d) vs. (e) and (g) vs (h)). In this example, two drugs with the same in vitro dissolution profiles
are characterized by 𝑇𝑔 𝑚 = 60 min and 𝐶𝑔 𝑚⁄𝐶𝑔 𝑝 = 10. The drug with a 𝑘𝑎 of 0.01min-1 (versus
0.001 min-1) results in a 700% higher amount of drug absorbed using Case 2 assumptions (Figure
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6 (d) vs. (e))10. In contrast, using Case 3 assumptions, the extent of drug absorption is 1200%
greater (Figure 6 (g) vs. (h)). In comparison, for Case 1, the increase in absorption is exactly one
order magnitude greater or 900% (Figure 6 (a) vs. (b)). Therefore, the increase in amount of drug
absorbed one would expect for drugs with larger absorption rate constants (assuming the same
in vitro dissolution profile) is highly dependent on the relationship between the in vitro and in vivo
dissolution profiles (i.e., Case 2 vs Case 3 assumptions). Until we can reliably extrapolate in vitro
dissolution to in vivo, it is useful to quantitatively explore the effect of these two extremes in
behavior on the potential range of amount of drug absorbed.

Assuming that the peak duration in vivo corresponds to the peak duration of in vitro (Dependenton-Time Precipitation-- Case 2), the duration of phase ii (Figure 5(b)) is greatly reduced due to
the depletion of drug by absorption, with much of drug absorption taking place from the lower
concentration in phase iii (Figure 7(e)).

The time to reach plateau concentration, 𝑇𝑙 𝑝2 , is

dramatically reduced as 𝑘𝑎 increases (Figure 8(a)). This shorter time to the plateau concentration
is also due to the lower in vivo peak drug concentration (𝐶𝑙 𝑚2) at higher values of 𝑘𝑎 Figure 8(b)).
Values of 𝐶𝑙 𝑚2 can be lower than 𝐶𝑔 𝑝. This occurs when the maximum supersaturation ratio
(𝐶𝑔 𝑚⁄𝐶𝑔 𝑝) is less than the product of 𝑘𝑎 and 𝑇𝑔 𝑚 resulting in no phase 2.

In contrast, we can explore the alternative assumption that the peak drug concentrations in vivo
and in vitro reach equal values (Dependent-on-Concentration Precipitation– Case 3). In this case,
drug depletion by absorption lengthens the time to reach in vivo peak concentration. Therefore,
as the in vitro peak duration increases (i.e., higher 𝑇𝑔 𝑚), phase i dominates (Figure 7 (g) vs. (h))

10

Nota bene the z-axis (total amount of drug absorbed) are different for each 𝑘𝑎 valve. For
𝑘𝑎 =0.01 min-1 (panels (a), (d), (g)) y = 0 to 0.6 milligrams, for 𝑘𝑎 = 0.01 min-1 (panels (b), (e), (h))
y = 0 to 6 milligrams and for 𝑘𝑎 = 0.1 min-1 (panels (c), (f), (i)) y = 0 to 120 milligrams.
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since time to maximum concentration (𝑇𝑙 𝑚3 ) increases and eventually exceeds the intestinal
transit time (𝑇𝑙 𝑟) (Figure 8(c)) (Equation 12b).

Drugs with Large Absorption Rate Constant (𝑘𝑎 =0.1min-1)
Case 1 assumptions do not account for depletion of dissolved drug due to absorption. So, the
trends in amount of drug absorbed (Figure 6(c)) are similar to those seen for the low (Figure 6(a))
and intermediate (Figure 6(b)) absorption rate constants, only an order of magnitude higher than
for 𝑘𝑎 = 0.01 min-1. However, an absorption half-life corresponding to 𝑘𝑎 of 0.1 min-1 is less than
10 min, which is short compared to the small intestinal transit time. Therefore, Case 1 is much
less appropriate to use for high absorption rate constant drugs, due to depletion through
absorption.

Using Case 2 and Case 3 assumptions, where the in vivo drug concentration profiles do not mirror
those in vitro, the effect of enhancing the in vitro drug concentration profile has more interesting
consequences on drug absorption. For the case in which the duration of the in vitro peak drug
concentration corresponds to in vivo, Case 2, the amount of drug absorbed is fairly insensitive to
alterations in the in vitro dissolution profile as characterized by 𝑇𝑔 𝑚 and 𝐶𝑔 𝑚 (Figure 6 (f) vs. (d)).
This result can be traced to the reduction in the time to plateau, 𝑇𝑙 𝑝2 , by depletion due to
absorption (Figure 8 (a) and (b) and Equation 9(b)); little to no drug is absorbed in phase ii at the
highest value of 𝑘𝑎 (Figure 7 (f) vs. (d)). For drugs with very high absorption rate constants,
formulation efforts to increase the duration of the peak would actually lead to a slight decrease in
drug absorption, assuming Dependent-on-Time Precipitation, Case 2.

The opposite is true for Case 3, which assumes the in vivo peak drug concentration reaches the
in vitro value. Drugs with very high 𝑘𝑎 (0.1 min-1) have in vivo peak durations, 𝑇𝑙 𝑚3 , that exceed
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the small intestinal transit time (180 min) (Figure 8(c)). Consequently, when absorption half-life
approaches 𝑇𝑔 𝑚, 𝑇𝑙 𝑚3 approaches infinity, phase i completely dominates (Figure 7(i)) the
absorption profile. Therefore, the total amount of drug absorbed can be found from Equation 12b.
As in the case of drugs with intermediate absorption rate constants (𝑘𝑎 =0.01 min-1), we also find
some counterintuitive consequences of altering the in vitro drug concentration profile for drugs
with very high absorption rate constants (𝑘𝑎 =0.1min-1). According to Equation 12(b), drug
absorbed is proportional to 𝐶𝑔 𝑚⁄𝑇𝑔 𝑚. Thus, a decrease in peak duration results in greater
amount of drug absorbed. This counterintuitive result can be explained by examining the phases
of absorption in more detail. For a given dissolution enhancement, 𝐶𝑔 𝑚⁄𝐶𝑔 𝑝, a shorter peak
duration in vitro translates to a shorter time to peak (using the isosceles triangular approximation)
which provides more drug in solution sooner. When the absorption rate constant is very high, a
large amount of drug is absorbed, maintaining the in vivo drug concentration below in vitro peak
concentration that presumably “triggers” precipitation, in this case. The consequence is that the
in vivo drug concentration remains supersaturated for the duration of the intestinal transit time.

Sensitivity of the Absorption Estimate to Geometry of Peak
The above results are based on the 3-parameter isosceles triangular approximation of the in vitro
drug concentration peak. To assess any bias imposed by this approximation, an alternative
equivalent rectangular peak shape was explored. The rectangular peak was considered to
represent the opposite extreme to the single time point at 𝐶𝑔 𝑚 in the triangular approximation.
Using a rectangular shape to approximate the peak, maximum drug concentration ranges from t
=0 to the end of phase ii (Supplemental 2). A comparison of triangular and rectangular peak
approximations was performed for Case 2 since Case 2 generally includes all three phases unlike
Case 3 which remains in phase i when the product of 𝑘𝑎 and 𝑇𝑔 𝑚 is large.
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The amount of drug absorbed calculated from the triangular peak approximation differed from
either rectangular approximations by -10 to 30% (Supplemental 4). The bias introduced by using
the triangular peak approximation is small compared to the effect of maximum peak concentration,
peak duration and absorption rate constant shown in the previous section Figure7). This analysis
provides the confidence to use the 3-parameter isosceles triangular approximation to
quantitatively explore drug absorption for supersaturating drug delivery systems using Equations
8, 9 or 12, depending on the assumptions one wishes to make regarding the relationship of in
vivo dissolution and in vitro dissolution behavior. More details can be found in Supplemental 3.

DISCUSSION
Reports show that measures of enhanced dissolution are not always predictive of enhanced
bioavailability

5, 25

. Potential reasons for the discrepancies were explored quantitatively using

absorption models that require limited data. The closed-form equations developed here can also
be used to determine the potential effects of key dissolution and physiological parameters on
bioavailability for a promising new chemical entity with limited solubility.

The in vitro peak drug concentration and peak duration produced by supersaturating dosage
forms are highly dependent on the drug, drug form, formulation components and solution
composition

5, 28-33, 38-39, 50-52

. To bracket a range of bioavailability that could be reasonably

expected from supersaturating dosage forms, two alternative assumptions were used: either a)
the duration of the peak drug concentration in vivo corresponds to the in vitro data or b) the drug
concentration in vivo reaches the peak concentration observed during in vitro dissolution. When
we assumed that the duration of the in vivo peak corresponds to the in vitro peak duration (i.e.,
Case 2), drug absorption was predicted to be less sensitive to alterations in the in vitro dissolution
profile, especially for drugs with moderate to high 𝑘𝑎 values (0.01-0.1 min-1). It is particularly
notable that when the absorption rate constant is high (𝑘𝑎 =0.1 min-1), formulation efforts to
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increase the in vitro drug concentration peak or duration are predicted to lead to a slight decrease
in the amount of drug absorbed using Case 2 assumptions (Figure 6(f)).

Contrast this result with Case 3, where the in vivo peak drug concentration is assumed to reach
the in vitro peak value, despite depletion due to drug absorption. In this case, the amount of drug
absorbed was very sensitive to alterations in the in vitro dissolution profile, particularly for
compounds with high 𝑘𝑎 values. When 𝑘𝑎 is very large (𝑘𝑎 =0.1 min-1), formulation efforts to
increase the drug peak concentration and/or decrease the peak duration were predicted to result
in a substantial increase in drug absorption using Case 3 assumptions (Figure 6(i)). In general,
when the absorption rate constant of a drug is known or can be estimated, the current models
may be useful to quantitatively explore whether or not it would be worth the effort to formulate for
enhanced in vitro dissolution profiles.

In contrast to Case 2 and 3, Case 1 predicts that the amount of drug absorbed is influenced by
absorption rate constant, the peak concentration and its duration in a straightforward manner.
However, Case 1 only applies to a limited number of drugs which have both low solubility and
very low absorption rate constants, such as BCS IV compounds. Case 1 is of limited use since
most supersaturating drug delivery systems in development are formulated for BCS II compounds
which have low solubility but higher absorption rate constant.

Several approaches to characterizing in vitro concentration vs. time curves were considered,
including the simplest approach, the AUC approach. However, the AUC approach could not be
utilized for Case 2 and 3 without underestimating amount of drug absorbed due to significant
drug depletion. Therefore, an approximation or some estimate of a function that describes the
course of the dissolved drug concentration was required. The isosceles triangulation approach
was selected over others because it was a good representation of various experimental in vitro
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concentrations vs. time curve. Furthermore, this approach allowed the math to be significantly
simplified, yielding closed analytical solutions.

For each of these cases, the in vitro concentration time curves are quickly characterize by the
isosceles triangular approximation using just the three parameters: 1) peak drug concentration,
2) duration of the peak which is characterized by the full width at half maximum and 3) the plateau
drug concentration that often follows the peak. A comparison of the 3-parameter triangular
approximation with an equivalent rectangular peak showed that peak shape had much less
influence on estimates of drug absorption than parameters such as absorption rate constant, in
vitro peak drug concentration and its duration. In short, for the purposes of rapidly calculating the
potential effects of reformulation on bioavailability, the use of only 3 parameters to characterize
the in vitro dissolution triangle profile provides a reasonable estimate of drug absorption without
incurring large bias. Furthermore, this approach permits derivation of closed analytical solutions.

This analysis assumes the in vitro dissolution medium is carefully selected to mimic in vivo
conditions, since three out of the six parameters needed for the model are determined from the
in vitro drug concentration-time profiles.

Important factors to consider when performing

dissolution experiments are temperature, hydrodynamics and medium selection

28-33

.

For

example, the addition of bile salts and/or phospholipids has been shown to alter drug precipitation
kinetics 33 by effecting the nucleation and/or crystal growth rate 28, 53.

Two physiological parameters used in this model are small intestinal fluid volume, 𝑉𝑙 and small
intestinal transit time, 𝑇𝑙 𝑟. An increase in 𝑉𝑙 results in a proportional increase in the estimated
drug absorbed (Equations 8, 9 and 12) in all cases. However, time dependence of the small
intestinal fluid volume containing the drug will likely have more complex effects. Furthermore,
variation in small intestinal transit time also leads to variation in the amount of drug absorbed, at
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least for cases in which there is undissolved drug remaining at the end of the absorption process
as assumed in this work. Additional assumptions that limit the applicability of Equations 8, 9 and
12 are described in the Model Development section. Models may also be evaluated for nonenteric drug forms due to the slow introduction into the small intestine.

The advantage of the current approach is the small number of input parameters required to define
key aspects affecting bioavailability. Due to the limited number of input variables, the models can
be used to quantify variation in bioavailability based on known variations of small intestinal fluid
volume and small intestinal transit time, as well as potential or experimentally determined variation
in drug peak concentration and duration.

Future studies will focus on using this model

to evaluate variations in bioavailability contributed from both physiological and formulation input
parameters which may potentially lead to clinically unacceptable high variation in the performance
of the drug product.

CONCLUSION
Two alternative assumptions (i.e., equal drug peak concentrations or corresponding peak
durations in vitro and in vivo) lead to what are expected to be two extremes in effect of
reformulation on bioavailability of precipitating dosage forms. If we assume equivalent peak
duration in vitro and in vivo, the model suggests that formulation improvements will have less
impact on bioavailability than if we assume equal peak concentrations are reached. A simpler
case, wherein both the peak drug concentration and peak duration are both assumed equal in
vitro and in vivo, leads to a bioavailability estimate that lies between the extremes. The simpler
case provides a more straightforward calculation, but its applicability may be limited to drugs with
low absorption rate constant.
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Until we can reliably extrapolate in vitro dissolution to in vivo, it is useful to quantitatively explore
the effect of these two extremes in behavior on the potential range of amount of drug absorbed.
The models developed here may be a useful tool to guide the thinking of formulators; potential
outcomes of proposed strategies to either increase the peak drug concentration and/or the peak
duration can be quantitatively evaluated using Equation 8, 9 or 12 depending on assumptions.
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Figure 1. Examples of in vitro concentration-time profiles obtained from dissolution of excess
amorphous solid powder in water in a USP Type 2 dissolution apparatus at 25˚C. Adapted from
reference 34.

44
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Figure 2. Potential ways to characterize the key aspects of an in vitro drug concentration-time
profile for a supersaturating drug (a) 4 parameters: peak concentration, time to peak, plateau
concentration and time to plateau, (b) 3 parameters using an isosceles triangular peak shape:
peak concentration, time to peak, and plateau concentration, (c) 3 parameters using an isosceles
triangular peak shape: peak concentration, full width at half maximum of the peak, and plateau
concentration. (d) 3 parameters: peak concentration, peak duration and plateau concentration
using and rectangular approximation, and (e) 4 parameters: lag time, peak concentration, peak
duration and plateau concentration using a rectangular approximation.
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Table I. Definition of model terminology using the structure Abcd.
Variable

Vitro/vivo

Concentratio

Condition

Case

in vitro = in
C

n

g

Excess e

Simple 1

glass
in vivo = in

Time T

Time-Dependent
l

Maximum m

living

2
Precipitation
Concentration-

Amount X

Plateau p

3
Dependent Precipitation

Volume V

Absorbed a
In Solution/
s
Absorption occurring
In solution and
Absorption NOT n
occurring
Residence/End r
Initial o

A is the variable. The subscript b denotes in vitro, g, or in vivo, l. The lower case letter repented
by c defines a particular condition or state. The subscript d defines the Case for the assumptions
made.
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Figure 3. Illustration of model input parameters based the isosceles triangular approximation of
the in vitro experimental data for drug concentration versus time during dissolution evaluation of
a supersaturating drug.
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Figure 4. Illustration (a) of the mass balance of a supersaturating drug during in vitro dissolution
in USP type II apparatus with reference to the terminology used in the mathematical model and
(b) of the mass balance of a supersaturating drug during dissolution in vivo in the gastrointestinal
(GI) tract using terminology used in the mathematical model.
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Table II. Alphabetical listing of abbreviations.
Term
𝐶𝑔 𝑚

Description
Maximum concentration reached in

Term
𝑇𝑙 𝑚2

vitro

Description
Time maximum concentration or
amount is reached in vivo for Case 2
= 𝑇𝑔 𝑚

𝐶𝑔 𝑚2𝑟𝑡

Maximum concentration reached in

𝑇𝑙 𝑚3

vitro for Case 2rt
𝐶𝑔 𝑚⁄𝐶𝑔 𝑝 Supersaturation ratio in vitro

Time maximum concentration or
amount is reached in vivo for Case 3

𝑇𝑙 𝑝1

Time plateau concentration or
amount is reached in vivo for Case 1
= 𝑇𝑔 𝑝

𝐶𝑔 𝑝

Plateau concentration reached in

𝑇𝑙 𝑝2

vitro = solubility in vitro
𝐶𝑔 𝑠

Drug concentration in solution in vitro

Time plateau concentration or
amount is reached in vivo for Case 2

𝑇𝑙 𝑝2𝑟𝑐

Time plateau concentration or
amount is reached in vivo for Case
2rc

𝐶𝑙 𝑚⁄𝐶𝑙 𝑝

Supersaturation ratio in vivo

𝑇𝑙 𝑝2𝑟𝑡

Time plateau concentration or
amount is reached in vivo for Case
2rt

𝐶𝑙 𝑚 or

Maximum concentration reached in

𝐶𝑙 𝑚1

vivo for Case 1 = 𝐶𝑔 𝑚

𝐶𝑙 𝑚2

Maximum concentration reached in

𝑇𝑙 𝑝3

amount is reached in vivo for Case 3
𝑇𝑙 𝑟

vivo for Case 2
𝐶𝑙 𝑚3

Maximum concentration reached in

Time plateau concentration or

Small intestinal transit time or
residence time in vivo

𝑉𝑔

In vitro dissolution volume

vivo for Case 3 = 𝐶𝑔 𝑚
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𝐶𝑙 𝑛

Drug concentration in vivo in the

𝑉𝑙

absence of absorption
𝐶𝑙 𝑝

Plateau concentration reached in

Small intestinal fluid volume in vivo
dissolution volume

𝑋𝑔 𝑒

Amount of excess solid drug in vitro

vivo =𝐶𝑔 𝑝
𝐶𝑙 𝑠

Drug concentration in solution in vivo

𝑋𝑔 𝑜

Initial amount of solid drug in vitro

𝑘𝑎

First order absorption rate constant

𝑋𝑔 𝑠

Amount of drug in solution in vitro

Time maximum concentration or

𝑋𝑙 𝑎

Amount of drug absorbed in vivo

𝑋𝑙 𝑒

Amount of excess solid drug

𝑇𝑔 𝑚

amount is reached in vitro
𝑇𝑔 𝑝

Time plateau concentration or
amount is reached in vitro

𝑇𝑔 𝑟

End of experiment in vitro

available for dissolution in vivo
𝑋𝑙 𝑜

Initial amount of solid drug in vivo =
dose

𝑇𝑙 𝑚1

Time maximum concentration or
amount is reached in vivo for Case 1

𝑋𝑙 𝑠

Amount of drug in solution during in
vitro dissolution

= 𝑇𝑔 𝑚
Parameters used to describe the model are systemically abbreviated. The first letter in each
parameter is capitalized and represents the variable as shown in Table 1 (e.g. C for
concentration). The second letter in each parameter is either a subscript 𝑔 denoting in vitro or
subscript 𝑙 denoting in vivo. The third letter is lowercase and represents the referred condition.
For example, a term often used is 𝐶𝑔 𝑚, which translates to the maximum concentration reached
in vitro. Sometimes there is an addition subscripted suffix included in the parameter (1, 2, 3, 2rc
or 2rt and i, ii and iii). This refers to a specific type of case and case and its phase.

51

52

Figure 5. Comparison of the isosceles triangular approximation of an in vitro dissolution curve of
a supersaturating drug with three different sets of assumptions regarding the relationship between
in vitro and in vivo dissolution behavior. 𝐶𝑔 𝑠(𝑡) is the drug concentration at a given time in in vitro
dissolution medium. 𝐶𝑙 𝑠(𝑡) is the drug concentration at a given time in the small intestinal fluid
and 𝐶𝑙 𝑛(𝑡) is the drug concentration in vivo in the absence of absorption. (a) Case 1 as described
in the text, (b) Case 2 as described in the text, and (c) Case 3 as described in the text.
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Figure 6. Amount of drug absorbed using the assumptions of Case 1(a, b, c), Case 2 (d, e, f)
and Case 3 (g, h, I), at three values of 𝑘𝑎 (0.001, 0.01, 0.1 min-1) for a range of 𝑇𝑔 𝑚 (10-60 min)
and 𝐶𝑔 𝑚⁄𝐶𝑔 𝑝 (2-10). Note that the scale of the z-axis (total amount of drug absorbed) increases
with 𝑘𝑎 value. For 𝑘𝑎 =0.01 min-1((a), (d), (g)) the amount absorbed ranges from 0 to 0.6
milligrams, for 𝑘𝑎 = 0.01 min-1 ((b), (e), (h)) 0 to 6 milligrams and for 𝑘𝑎 = 0.1 min-1 ((c), (f), (i)) 0
to 120 milligrams.
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Figure 7. Amount of drug absorbed in each phase of the in vivo drug concentration (in the small
intestinal lumen) versus time profile. Case 1 (a, b, c), Case 2 (d, e, f), and Case 3(g, h, I), at
different 𝑘𝑎 values (0.001, 0.01, 0.1 min-1) for a range of 𝑇𝑔 𝑚 (10-60 min) and 𝐶𝑔 𝑚⁄𝐶𝑔 𝑝 (2-10).
Blue bars represent the amount of drug absorbed during phase i, red bars represent the amount
absorbed during phase ii, and green bars represent the amount absorbed during phase iii.
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Figure 8. Using Case 2 assumptions (a) the time to reach plateau drug concentration in vivo
(𝑇𝑙 𝑝2 ) and (b) the maximum drug concentration in vivo (𝐶𝑙 𝑝2) at different values of 𝑘𝑎 (0.001,
0.01, 0.1 min-1) for a range of 𝑇𝑔 𝑚 (10-60 min) with 𝐶𝑔 𝑚⁄𝐶𝑔 𝑝 held constant at 6. Using Case 3
assumptions, (c) the time to reach maximum drug concentration (𝑇𝑙 𝑚3 ). *Indicates values
approaching infinity.
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SUPPORTING INFROMATION

Supplemental 1
Derivation of Closed-Form Analytical Solutions for Drug Absorption Models
The details leading to Equations 8, 9 and 12, corresponding to Case 1, 2 and 3 are shown below.
For each case the total amount of drug absorbed is found by adding the drug absorbed during
each of the three phases of absorption defined in Figure 5.

Case 1: Phase i (𝒕 = 0 to 𝑻𝒈 𝒎, time to maximum concentration)
The concentration in solution in vitro (𝐶𝑔 𝑠(𝑡)) is calculated from the slope and intercept of phase
i of the concentration-time profile, Figure 5(a).

𝐶 𝑚

𝐶𝑔 𝑠(𝑡) = ( 𝑇𝑔𝑚 ) (𝑡)

(16)

𝑔

where 𝑇𝑔 𝑚 is defined by Equation 2 and 𝐶𝑔 𝑚 is the maximum drug concentration recorded during
in vitro dissolution.

Case 1 assumes in vivo mimics in vitro concentration (i.e., 𝐶𝑔 𝑠(𝑡) = 𝐶𝑙 𝑠(𝑡)). Substituting Equation
16 into 7 and integrating from 0 to 𝑡, the time profile of the amount of drug absorbed during phase
i (𝑋𝑙 𝑎1𝑖 (𝑡)) is:

𝑋𝑙 𝑎1𝑖 (𝑡) =

(𝑘𝑎 )(𝑉𝑙 )(𝐶𝑔 𝑚)
2(𝑇𝑔 𝑚)

(𝑡 2 )

(17)
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𝑇 𝑚

The total amount of drug absorbed during phase i (𝑋𝑙 𝑎1𝑖 |0𝑔 ) is:

𝑇 𝑚

𝑋𝑙 𝑎1𝑖 |0𝑔

=

(𝑘𝑎 )(𝑉𝑙 )(𝐶𝑔 𝑚)(𝑇𝑔 𝑚)

(18)

2

Case 1: Phase ii (t = 𝑻𝒈 𝒎 to 𝑻𝒈 𝒑, time from peak to plateau region)
During phase ii, the concentration of drug in solution in vitro (𝐶𝑔 𝑠(𝑡∗ )) is described by the slope
and intercept of phase ii of the concentration-time profile (Figure 5(a)).

𝐶𝑔 𝑠(𝑡∗ ) = −

𝐶𝑔 𝑚
(𝑡 ) + 𝐶𝑔 𝑚
𝑇𝑔 𝑚 ∗

(19)

Where 𝑡∗ = 𝑡 − 𝑇𝑔 𝑚, the time in phase ii.

Again, substituting Equation 19 in 7 where 𝐶𝑔 𝑠(𝑡∗ ) = 𝐶𝑙 𝑠(𝑡∗ ), integrating from 0 to 𝑡∗ and replacing
𝑡∗ with (𝑡 − 𝑇𝑔 𝑚), the time profile for absorption of drug during phase ii is:

(𝑡−𝑇𝑔 𝑚)2

𝑋𝑙 𝑎1𝑖𝑖 (𝑡) = (𝑘𝑎 )(𝑉𝑙 )(𝐶𝑔 𝑚) {(𝑡 − 𝑇𝑔 𝑚) − (

2(𝑇𝑔 𝑚)

)}

(20)

The total amount of drug absorbed during phase ii is:

2

𝑇 𝑝
𝑋𝑙 𝑎1𝑖𝑖 | 𝑇𝑔 𝑚
𝑔

(𝑇𝑔 𝑝 − 𝑇𝑔 𝑚)
= (𝑘𝑎 )(𝑉𝑙 )(𝐶𝑔 𝑚) {(𝑇𝑔 𝑝 − 𝑇𝑔 𝑚) − (
)}
2(𝑇𝑔 𝑚)

(21)
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Case 1: Phase iii (𝒕 = 𝑻𝒈 𝒑 to 𝑻𝒍 𝒓, the plateau region)
When there is excess solid drug remaining, the concentration of dissolved drug in vivo (𝐶𝑙 𝑝) is
assumed to be equal to that in vitro (𝐶𝑔 𝑝) during all of phase iii.

𝐶𝑔 𝑠(𝑡) = 𝐶𝑔 𝑝

(22)

Substituting Equation 22 into 7 where 𝐶𝑔 𝑠(𝑡) = 𝐶𝑙 𝑠(𝑡) and integrating from 𝑇𝑔 𝑝 to 𝑡, the time profile
for drug absorption in Case 1, phase iii becomes:

𝑋𝑙 𝑎1𝑖𝑖𝑖 (𝑡) = (𝑘𝑎 )(𝑉𝑙 )(𝐶𝑔 𝑝)(𝑡 − 𝑇𝑔 𝑝)

(23)

The total drug absorbed during phase iii is:

𝑇𝑟

𝑋𝑙 𝑎1𝑖𝑖𝑖 | 𝑇𝑔𝑙 𝑝 = (𝑘𝑎 )(𝑉𝑙 )(𝐶𝑔 𝑝)(𝑇𝑙 𝑟 − 𝑇𝑔 𝑝)

(24)

Case 1: Total Amount of Drug Absorption (𝒕 = 𝟎 to 𝑻𝒍 𝒓)
The total amount of drug absorbed using the assumptions in Case 1 is found by adding the drug
absorbed during each phase found in Equations 18, 21 and 24.

𝑇𝑟
𝑋𝑙 𝑎1 |0𝑙

= (𝑘𝑎 )(𝑉𝑙 ) {(𝐶𝑔 𝑚) (2(𝑇𝑔 𝑝) − 𝑇𝑔 𝑚 −

𝑇𝑔 𝑝2

)
2(𝑇𝑔 𝑚)
(25)

+ (𝐶𝑔 𝑝)(𝑇𝑙 𝑟 − 𝑇𝑔 𝑝) }
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Substituting for 𝑇𝑔 𝑝, (Equation 3) and rearranging yields Equation 8 in the text.

Case 2: Phase i (𝒕 = 0 to 𝑻𝒈 𝒎, time to peak)
The concentration in vivo in the absence of absorption (𝐶𝑙 𝑛(𝑡)) is assumed to equal the in vitro
drug concentration (𝐶𝑔 𝑠(𝑡)) in phase i, which is defined by Equation 26.

𝐶𝑔 𝑚

𝐶𝑔 𝑠(𝑡) = 𝐶𝑙 𝑛(𝑡) = (

𝑇𝑔 𝑚

) (𝑡)

(26)

The concentration of drug remaining in solution in vivo (𝐶𝑙 𝑠(𝑡)) is equal to the difference between
the concentration in solution in vivo in the absence of absorption (𝐶𝑙 𝑛(𝑡)) and the amount
absorbed (𝑋𝑙 𝑎2𝑖 (𝑡)) divided by the volume of the intestinal lumen (𝑉𝑙 ) as shown in Equation 27.

𝐶𝑙 𝑠(𝑡) = 𝐶𝑙 𝑛(𝑡) −

𝑋𝑙 𝑎2𝑖 (𝑡)
𝑉𝑙

(27)

Combining equations 26 and 27, the concentration of drug remaining in solution in the intestinal
lumen becomes:

𝐶 𝑚

𝐶𝑙 𝑠(𝑡) = (𝑇𝑔𝑚 ) (𝑡) −
𝑔

𝑋𝑙 𝑎2𝑖 (𝑡)
𝑉𝑙

(28)

Substituting equation 28 into Equation 7 and integrating from 0 to 𝑡 yields the time profile for the
amount of drug absorbed during phase i (𝑋𝑙 𝑎2𝑖 (𝑡)).
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𝑋𝑙 𝑎2𝑖 (𝑡) =

(𝑉𝑙 )(𝐶𝑔 𝑚)
(𝑇𝑔 𝑚)

[𝑡 + (

(𝑒 −(𝑘𝑎)(𝑡) −1)
)]
𝑘𝑎

(29)

Recalling that in Case 2, the time to reach the peak concentration in vivo (𝑇𝑙 𝑚2 ) is equal to that
in vitro (𝑇𝑔 𝑚), the total amount of drug absorbed for Case 2 during phase i is:

𝑇 𝑚

𝑋𝑙 𝑎2𝑖 |0𝑔

= (𝑉𝑙 )(𝐶𝑔 𝑚) {1 +

(𝑒 −(𝑘𝑎

)(𝑇𝑔 𝑚)

−1)

(𝑘𝑎 )(𝑇𝑔 𝑚)

}

(30)

At 𝑡 = 𝑇𝑔 𝑚, the maximum concentration in solution, 𝐶𝑙 𝑠(𝑇𝑙 𝑚2 ) = 𝐶𝑙 𝑚2 , is lower than the
concentration in the absence of absorption (𝐶𝑔 𝑚) as shown in Figure 5(b). At 𝑡 = 𝑇𝑔 𝑚, Equation
27 can be rearranged to yield an expression for the peak drug concentration in vivo (𝐶𝑙 𝑚2)
(Equation 31).

𝑇𝑔 𝑚

𝐶𝑙 𝑚2 = 𝐶𝑔 𝑚 −

𝑇 𝑚

Substituting the expression for 𝑋𝑙 𝑎2𝑖 |0𝑔

𝑋𝑙 𝑎2𝑖 |0
𝑉𝑙

(31)

(Equation 30) in Equation 31 yields an expression for

𝐶𝑙 𝑚2, the maximum concentration reached in solution in vivo which is the drug concentration at
the start of phase ii (Equation 10 in text).
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Case 2: Phase ii (𝒕 = 𝑻𝒈 𝒎 to 𝑻𝒍 𝒑𝟐 , peak to plateau)
The concentration of drug in solution in vivo in the absence of absorption (𝐶𝑙 𝑛(𝑡∗ )) can be
described by the slope and intercept of phase ii of the dissolution-time profile (Figure 5(b)).

𝐶𝑔 𝑚

𝐶𝑙 𝑛(𝑡∗ ) = − 𝑇

𝑔𝑚

(𝑡∗ ) + 𝐶𝑙 𝑚2

(32)

where 𝑡∗ = 𝑡 − 𝑇𝑔 𝑚, the time in phase ii.

Taking absorption into account, the in vivo drug concentration (𝐶𝑙 𝑠(𝑡∗ )) can be obtained by
substituting 𝐶𝑙 𝑛(𝑡∗ ) (Equation 32) into Equation 27.

𝐶𝑙 𝑠(𝑡∗ ) = −

𝐶𝑔 𝑚
𝑇𝑔 𝑚

(𝑡∗ ) + 𝐶𝑙 𝑚2 −

𝑋𝑙 𝑎2𝑖𝑖 (𝑡∗)
𝑉𝑙

(33)

Substituting Equation 33 into Equation 7, integrating from 0 to 𝑡∗ and replacing 𝑡∗ with (𝑡 − 𝑇𝑔 𝑚)
yields the time profile for the amount of drug absorbed during phase ii (𝑋𝑙 𝑎2𝑖𝑖 (𝑡∗ )).

𝑋𝑙 𝑎2𝑖𝑖 (𝑡) =

(𝑉𝑙 )(𝐶𝑔 𝑚)
(𝑇𝑔 𝑚)

{(

1 (𝐶𝑙 𝑚2 )(𝑇𝑔 𝑚)
+
) (1 − 𝑒 −(𝑘𝑎)(𝑡−𝑇𝑔𝑚) )
𝑘𝑎
(𝐶𝑔 𝑚)
(34)

− (𝑡 − 𝑇𝑔 𝑚)}
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The total drug absorbed during phase ii of Case 2 is:

𝑇𝑝

𝑋𝑙 𝑎2𝑖𝑖 | 𝑇𝑔𝑙 𝑚2 =

(𝑉𝑙 )(𝐶𝑔 𝑚)
(𝑇𝑔 𝑚)

1

{(𝑘 +
𝑎

(𝐶𝑙 𝑚2 )(𝑇𝑔 𝑚)
(𝐶𝑔 𝑚)

) (1 − 𝑒 −(𝑘𝑎)(𝑇𝑙𝑝2 −𝑇𝑔𝑚) ) −
(35)

(𝑇𝑙 𝑝2 − 𝑇𝑔 𝑚)}

The end of phase ii is defined as the time the drug concentration falls to 𝐶𝑔 𝑝, the concentration
at the plateau. Thus, the time at which the plateau concentration is reached (𝑇𝑙 𝑝2 ) can be found
by setting 𝐶𝑙 𝑠(𝑡∗ ) equal to 𝐶𝑔 𝑝 at 𝑡∗ = 𝑇𝑙 𝑝2 − 𝑇𝑔 𝑚 in Equation 33. Substituting the expression
for 𝑋𝑙 𝑎2𝑖𝑖 (𝑡∗ ) (Equation 35) into Equation 33 and rearranging yields Equation 11 in text.

Case 2: Phase iii (𝒕 = 𝑻𝒍 𝒑𝟐 to 𝑻𝒍 𝒓, the plateau region)
Making the same assumption for phase iii as for phase iii of Case 1, Equation 22 can be
substituted into 7 where 𝐶𝑔 𝑠(𝑡) = 𝐶𝑙 𝑠(𝑡) and integrated from 𝑇𝑙 𝑝2 to 𝑡. The time profile for drug
absorption in Case 2, phase iii becomes:

𝑋𝑙 𝑎2𝑖𝑖𝑖 (𝑡) = (𝑘𝑎 )(𝑉𝑙 )(𝐶𝑔 𝑝)(𝑡 − 𝑇𝑙 𝑝2 )

(36)

The total amount of drug absorbed during phase iii of Case 2 is:

𝑇𝑟

𝑋𝑙 𝑎2𝑖𝑖𝑖 | 𝑇𝑙𝑙 𝑝2 = (𝑘𝑎 )(𝑉𝑙 )(𝐶𝑔 𝑝)(𝑇𝑙 𝑟 − 𝑇𝑙 𝑝2 )

(37)
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Case 2: Total Amount of Drug Absorption (𝒕 = 𝟎 to 𝑻𝒍 𝒓)
There are two equations (9a and 9b) for calculating the total amount of drug absorbed for Case
2. When the supersaturation ratio (𝐶𝑔 𝑚⁄𝐶𝑔 𝑝) is greater than the product of 𝑘𝑎 and 𝑇𝑔 𝑚, drug
absorption occurs during all three phases so that the sum of the amounts absorbed in each phase
(Equations 30, 35 and 37) equals the total amount absorbed for Case 2 (Equations 9(a)).
However, when 𝐶𝑔 𝑚⁄𝐶𝑔 𝑝 drops below the product of 𝑘𝑎 and 𝑇𝑔 𝑚, then 𝑇𝑙 𝑝2 < 𝑇𝑔 𝑚, eliminating
phase ii. Therefore, the total amount of drug absorbed is calculated from phase i and iii only
(Equations 30 and 37) (Equation 9(b)). Before rearrangement and simplification of Equation 9(b)
by substituting 𝐶𝑙 𝑚2 (Equation 10), the total amount of drug absorbed is:

𝑇𝑟
𝑋𝑙 𝑎2 |0𝑙

(𝑒 −(𝑘𝑎)(𝑇𝑔𝑚) − 1)
= 𝑉𝑙 {(𝐶𝑔 𝑚) (1 +
)
(𝑘𝑎 )(𝑇𝑔 𝑚)
(38)
+ (𝑘𝑎 )(𝐶𝑔 𝑝)(𝑇𝑙 𝑟 − 𝑇𝑔 𝑚)}

Case 3: Phase i (𝒕 = 0 to 𝑻𝒍 𝒎𝟑 , time to peak)
In Case 3, phase i follows the same derivation and behavior as in Case 2, phase i, except that
phase i of Case 3 ends at 𝑇𝑙 𝑚3 . The time profile for the amount of drug absorbed is described by
Equation 29. The total drug absorption during phase i is similar to Equation 30, except that 𝑇𝑙 𝑚3
replaces 𝑇𝑔 𝑚 to yield:

𝑇 𝑚3

𝑋𝑙 𝑎3𝑖 |0𝑙

=

(𝑉𝑙 )(𝐶𝑔 𝑚)
(𝑇𝑔 𝑚)

[𝑇𝑙 𝑚3 + (

(𝑒 −(𝑘𝑎)(𝑇𝑙 𝑚3 ) −1)
)]
𝑘𝑎

(39)
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By definition, at 𝑇𝑙 𝑚3 , in vivo drug concentration in solution 𝐶𝑙 𝑠(𝑡), is equal to the peak drug
concentration from in vitro dissolution, 𝐶𝑔 𝑚 . Similar to Equation 27 for Case 2, Equation 40 is
appropriate for Case 3.

𝐶𝑔 𝑚 = 𝐶𝑙 𝑛(𝑇𝑙 𝑚3 ) −

𝑇 𝑚
𝑋𝑙 𝑎3𝑖 |0 𝑙 3

𝑉𝑙

(40)

𝐶𝑙 𝑛(𝑇𝑙 𝑚3 ), the in vivo peak drug concentration in the absence of absorption, can be described by
the slope of the in vitro concentration time profile in phase i as shown in Figure 5(c).

𝐶𝑔 𝑚

𝐶𝑙 𝑛(𝑇𝑙 𝑚3 ) = (

𝑇𝑔 𝑚

) (𝑇𝑙 𝑚3 )

(41)

Combining and rearranging equations 39, 40 and 41 yields an expression for the time at which
the peak drug concentration is reached in vivo (𝑇𝑙 𝑚3 ) under the assumptions defining Case 3
(Equation 13 in text).

Case 3: Phase ii (𝒕 = 𝑻𝒍 𝒎𝟑 to 𝑻𝒍 𝒑𝟑 , peak to plateau)
In phase ii, the concentration of drug in solution in vivo in the absence of absorption (𝐶𝑙 𝑛(𝑡∗∗ )) can
be described by the slope and intercept of phase ii of the in vitro drug concentration vs. time profile
(Figure 5(c)).

𝐶 𝑚

𝐶𝑙 𝑛(𝑡∗∗ ) = − 𝑇𝑔𝑚 (𝑡∗∗ ) + 𝐶𝑔 𝑚
𝑔

(42)
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where 𝑡∗∗ = 𝑡 − 𝑇𝑙 𝑚3 , the time in phase ii.

When absorption is taken into consideration, the concentration of drug in solution (𝐶𝑙 𝑠(𝑡∗∗ )) can
be determined by substituting 𝐶𝑙 𝑛(𝑡∗∗ ) from Equation 42 into Equation 27 and rearranging.

𝐶𝑙 𝑠(𝑡∗∗ ) = −

𝐶𝑔 𝑚
𝑋𝑙 𝑎3𝑖𝑖 (𝑡∗∗ )
(𝑡∗∗ ) + 𝐶𝑔 𝑚 −
𝑇𝑔 𝑚
𝑉𝑙

(43)

Substituting 𝐶𝑙 𝑛(𝑡∗∗ ) (Equation 43) into Equation 7, integrating from 0 to 𝑡∗∗ and replacing 𝑡∗∗ with
(𝑡 − 𝑇𝑙 𝑚3 ), yields the time profile for the amount of drug absorbed during phase ii.

𝑋𝑙 𝑎3𝑖𝑖 (𝑡) = (𝑉𝑙 )(𝐶𝑔 𝑚) {(1 +

1
) (1 − 𝑒 −(𝑘𝑎)(𝑡−𝑇𝑙𝑚3 ) )
(𝑘𝑎 )(𝑇𝑔 𝑚)
(44)

1
−(
(𝑡 − 𝑇𝑙 𝑚3 ))}
𝑇𝑔 𝑚

The total amount of drug absorbed during phase ii of Case 3 is:

𝑇𝑝

𝑋𝑙 𝑎3𝑖𝑖 | 𝑇𝑙𝑙 𝑚33 = (𝑉𝑙 )(𝐶𝑔 𝑚) {(1 + (𝑘

1
) (1
)(𝑇
𝑎
𝑔 𝑚)

− 𝑒 −(𝑘𝑎)(𝑇𝑙 𝑝3 −𝑇𝑙 𝑚3 ) ) −
(45)

1
(𝑇 𝑚 (𝑇𝑙 𝑝3
𝑔

− 𝑇𝑙 𝑚3 ))}
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At 𝑇𝑙 𝑝3 , the plateau concentration (𝐶𝑔 𝑝) is reached (as shown in (Figure 5(c)) and Equation 43
becomes:

𝐶𝑔 𝑚

𝐶𝑔 𝑝 = − 𝑇

𝑔𝑚

𝑇 𝑝

(𝑇𝑙 𝑝3 − 𝑇𝑙 𝑚3 ) + 𝐶𝑔 𝑚 −

𝑋𝑙 𝑎3𝑖𝑖 |𝑇𝑙 𝑚3
𝑙

𝑉𝑙

3

(46)

By combining and rearranging Equations 45 and 46, an expression can be found for the time to
reach the plateau concentration, 𝑇𝑙 𝑝3 (Equation 14 in text).

Case 3: Phase iii (𝒕 = 𝑻𝒍 𝒑𝟑 to 𝑻𝒍 𝒓, the plateau region)
Making the same assumption for phase iii as for phase iii of Case 1 and 2, Equation 22 can be
substituted into 7 where 𝐶𝑔 𝑠(𝑡) = 𝐶𝑙 𝑠(𝑡) and integrated from 𝑇𝑙 𝑝3 to 𝑡. The time profile for drug
absorption in Case 3, phase iii becomes:

𝑋𝑙 𝑎3𝑖𝑖𝑖 (𝑡) = (𝑘𝑎 )(𝑉𝑙 )(𝐶𝑔 𝑝)(𝑡 − 𝑇𝑙 𝑝3 )

(47)

The total drug absorbed during phase iii in Case 3 is:

𝑇𝑟

𝑋𝑙 𝑎3𝑖𝑖𝑖 | 𝑇𝑙𝑙 𝑝3 = (𝑘𝑎 )(𝑉𝑙 )(𝐶𝑔 𝑝)(𝑇𝑙 𝑟 − 𝑇𝑙 𝑝3 )

(48)
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Case 3: Total Amount of Drug Absorption (𝒕 = 𝟎 to 𝑻𝒍 𝒓)
There are two equations (9a and 9b) for calculating the total amount of drug absorbed for Case
3. When the time to peak (𝑇𝑙 𝑚3 ) is smaller than the small intestinal transit time (𝑇𝑙 𝑟) drug
absorption occurs during all three phases so that the sum of the amounts absorbed in each phase
(Equations 39, 45 and 48) equals the total amount absorbed for Case 3 (Equations 12(a)).
However, when 𝑇𝑙 𝑚3 > 𝑇𝑔 𝑚, phase i (Equation 39) completely dominates the absorption profile
(Equation 12(b)).
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Supplemental 2

Supplemental 2. Comparison of (a) Case 2 and Case 2rc where the same maximum drug
concentration is reached in both in vitro dissolution-time profile shapes and (b) Case 2 and Case
2rt where the time to reach plateau drug concentration is the same in both in vitro dissolution-time
profile shape. For both (a) and (b), the areas under the peaks are equal.
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Supplemental 3
Effect of Geometry of Peak Approximation on Amount of Drug Absorbed
For the peak shape analysis, the area under a rectangular peak was maintained equal to the area
of the triangular peak (i.e., during phase i+ii). There are two extreme conditions which maintain
equal areas under the rectangular vs. triangular peaks during phase i+ii.

At one extreme,

maximum drug concentration can be set equal for both the triangular and rectangular shapes. In
this scenario, the time to reach the lower plateau drug concentration is shorter for the rectangular
peak shape (Equation 49 (Supplemental 2(a), denoted Case 2rc)). Alternatively, the duration of
both in vitro phase i+ii can be set equal for both the triangular and the rectangular approximation
of the in vitro peak; to maintain equal areas, the maximum concentration for the rectangular
approximation is lower (Equation 56 (Supplemental 2(b) denoted Case 2rt)).

The equations describing the amount of drug absorbed based on the two alternative rectangular
approximations to dissolution peak shapes are shown below.

The rectangular approximation

using equal concentrations (Case 2rc) results in a moderately higher drug absorption amount
relative to the triangular approximation, Case 2 (Supplemental 3). The difference in the amount
of drug absorbed was not found to be sensitive to either absorption rate constant (𝑘𝑎 ) or maximum
supersaturation ratio (𝐶𝑔 𝑚⁄𝐶𝑔 𝑝). For example, at a moderate peak duration 𝑇𝑔 𝑚 = 30 min for any
given 𝐶𝑔 𝑚⁄𝐶𝑔 𝑝 or 𝑘𝑎 , the amount of drug absorbed using the rectangular shape for Case 2rc, is
only 7-14% greater than for the triangular shape, Case 2.

In contrast, the difference in amount of drug absorbed based on the two peak shape
approximations is more sensitive to 𝑇𝑔 𝑚 (Equation 9 vs. 55). For example, at a low 𝑇𝑔 𝑚 =10 min
(𝑘𝑎 of 0.01min-1 and 𝐶𝑔 𝑚⁄𝐶𝑔 𝑝 of 6), the difference in amount absorbed using the two peak shapes
is small, i.e. 5%, 𝑇𝑔 𝑚. However, the peak shape has more influence on the amount of drug
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absorbed when the duration of the peak is longer (𝑇𝑔 𝑚 = 60 min), with a difference of 23%
between the rectangular (2rc) and triangular peak shapes. Still, these differences are small when
compared to the large differences(150-1200%) noted between Case 2 and Case 3, or within a
given case depending on values of dissolution-related parameters such as 𝑇𝑔 𝑚 and 𝐶𝑔 𝑚⁄𝐶𝑔 𝑝
(Figure 5).

Next we consider the alternate rectangular peak shape where the time to reach the low plateau
drug concentration is set equal for both concentration-time profile approximations (Supplemental
2(b); denoted Case 2rt). At low values of 𝑘𝑎 , 0.001 min-1, there is no difference (<0.5%) in the
amount of drug absorbed based on peak shape. When 𝑘𝑎 is very low, phase i+ii areas for Case
2 and Case 2rt are identical (Supplemental 3). At intermediate values of 𝑘𝑎 (0.01 min-1), difference
between the amount of drug absorbed between Case 2rt and 2 is low, ranging from -7 to 10%. At
higher 𝑘𝑎 , 0.1 min-1, the difference in amount absorbed for the two peak shapes ranged from -8
to 28%.

Case 2rc
In the first rectangle peak shape approximation, the peak drug concentration (𝐶𝑔 𝑚) is reached
instantaneously and maintained until concentration abruptly drops to the lower plateau at time
𝑇𝑔 𝑝2𝑟𝑐 (Supplemental 2(a)). Assuming the area of the rectangle is equal to the area of the triangle
peak concentration, the peak duration for the Case 2rc (𝑇𝑔 𝑝2𝑟𝑐 ) is:

𝑇𝑔 𝑝2𝑟𝑐 = 𝑇𝑔 𝑚 −

𝐶𝑔 𝑝
𝑇𝑔 𝑝
(𝑇𝑔 𝑚 +
)
𝐶𝑔 𝑚
2

(49)
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The concentration of drug in solution (𝐶𝑙 𝑠(𝑡)) is depleted by absorption as described in Equation
50.

𝐶𝑙 𝑠(𝑡) = 𝐶𝑔 𝑚 −

𝑋𝑙 𝑎2𝑟𝑐𝑖+𝑖𝑖 (𝑡)
𝑉𝑙

(50)

Substituting Equation 50 into Equation 7 and integrating yields the time profile for the amount of
drug absorbed (𝑋𝑙 𝑎2𝑟𝑐𝑖+𝑖𝑖 (𝑡)) in phases i and ii.

𝑋𝑙 𝑎2𝑟𝑐𝑖+𝑖𝑖 (𝑡) = (𝑉𝑙 )(𝐶𝑔 𝑚)(1 − 𝑒 −(𝑘𝑎)(𝑡) )

(51)

At 𝑇𝑔 𝑝2𝑟𝑐 , the concentration 𝐶𝑙 𝑠(𝑡) drops to 𝐶𝑔 𝑝. However, in some cases depletion due to
absorption reduces the concentration, 𝐶𝑙 𝑠(𝑡) to 𝐶𝑔 𝑝 prior to 𝑇𝑔 𝑝2𝑟𝑐 . For these cases, 𝑇𝑙 𝑝2𝑟𝑐 not
𝑇𝑔 𝑝2𝑟𝑐 , defines the end of phase i+ii.

Combining Equations 50 and 51 at 𝑡 = 𝑇𝑙 𝑝2𝑟𝑐 ,

rearrangement yields:

𝑇𝑙 𝑝2𝑟𝑐 =

𝐶𝑔 𝑚
1
𝑙𝑛 (
)
𝑘𝑎
𝐶𝑔 𝑝

(52)

The amount of drug absorbed during phases i and ii (𝑋𝑙 𝑎2𝑟𝑐𝑖+𝑖𝑖 |𝑡0 ) for Case 2rc can be found by
substituting the smaller value, 𝑇𝑔 𝑝2𝑟𝑐 (Equation 49) or 𝑇𝑙 𝑝2𝑟𝑐 (Equation 52), for 𝑡 in Equation 51.
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𝑋𝑙 𝑎|𝑡0 = (𝑉𝑙 )(𝐶𝑔 𝑚)(1 − 𝑒 −(𝑘𝑎)(𝑡) )

(53)

Once the lower plateau is reached, the concentration of dissolved drug remains equal to 𝐶𝑔 𝑝 for
the entire phase iii, as in Case 2. The total amount of drug absorbed during phase iii is shown in
Equation 54 (similar to Equation 37 in Case 2.)

𝑇𝑟

𝑋𝑙 𝑎2𝑟𝑐𝑖𝑖𝑖 |𝑡 𝑙 = (𝑘𝑎 )(𝑉𝑙 )(𝐶𝑔 𝑝)(𝑇𝑙 𝑟 − 𝑡)

(54)

where 𝑡 is 𝑇𝑔 𝑝2𝑟𝑐 or 𝑇𝑙 𝑝2𝑟𝑐 , whichever is smaller.

𝑇𝑟

By adding Equation 53 and 54, the total amount absorbed for all three phases, 𝑋𝑙 𝑎2𝑟𝑐 |0𝑙 is:

𝑇𝑟

𝑋𝑙 𝑎2𝑟𝑐 |0𝑙 = (𝑉𝑙 ){(𝐶𝑔 𝑚)(1 − 𝑒 −(𝑘𝑎)(𝑡) ) + (𝑘𝑎 )(𝐶𝑔 𝑝)(𝑇𝑙 𝑟 − 𝑡)}

(55)

where 𝑡 is 𝑇𝑔 𝑝2𝑟𝑐 or 𝑇𝑙 𝑝2𝑟𝑐 , whichever is the smaller.

Case 2rt
In the alternate rectangular peak shape approximation, the in vitro time to reach the lower plateau
concentration (𝑇𝑔 𝑝) is the same for both triangular and rectangular approximations. While the
maximum peak concentration for the triangular approximation is 𝐶𝑔 𝑚, the maximum peak
concentration using the rectangular approximation a lower value, 𝐶𝑔 𝑚2𝑟𝑡 (Supplemental 2(b)) to
maintain equal peak areas. The lower value, 𝐶𝑔 𝑚𝑟𝑡 for the peak concentration is:
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𝐶𝑔 𝑚2𝑟𝑡 = (

𝑇𝑔 𝑚
𝐶𝑔 𝑝
) (𝐶𝑔 𝑚 − 𝐶𝑔 𝑝) +
𝑇𝑔 𝑝
2

(56)

The amount of drug absorbed in phases i and ii (𝑋𝑙 𝑎2𝑟𝑡𝑖+𝑖𝑖 (𝑡)) can be found by mass balance
(Equation 57) which is analogous to Equation 27.

𝐶𝑙 𝑠(𝑡) = 𝐶𝑔 𝑚2𝑟𝑡 −

𝑋𝑙 2𝑟𝑡𝑖 + 𝑖𝑖(𝑡)
𝑉𝑙

(57)

Substituting Equation 57 into Equation 7 and integrating yields the time profile for the amount of
drug absorbed (𝑋𝑙 2𝑟𝑡𝑖+𝑖𝑖 (𝑡)) in phases i and ii.

𝑋𝑙 2𝑟𝑡𝑖+𝑖𝑖 (𝑡) = (𝑉𝑙 )(𝐶𝑔 𝑚2𝑟𝑡 )(1 − 𝑒 −(𝑘𝑎)(𝑡) )

At 𝑇𝑔 𝑝, the concentration, 𝐶𝑙 𝑠(𝑡) drops to 𝐶𝑔 𝑝.

(58)

However, in some cases depletion due to

absorption reduces the concentration, 𝐶𝑙 𝑠(𝑡) to 𝐶𝑔 𝑝 prior to 𝑇𝑔 𝑝. For these cases, 𝑇𝑙 𝑝2𝑟𝑡 and not
𝑇𝑔 𝑝, defines the end of phase i+ii. 𝑇𝑙 𝑝2𝑟𝑡 can be calculated by combining Equations 57 and 58
and by recognizing that 𝑡 = 𝑇𝑙 𝑝2𝑟𝑡 , 𝐶𝑙 𝑠(𝑡) = 𝐶𝑔 𝑝.
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𝑇𝑙 𝑝2𝑟𝑡 =

𝐶𝑔 𝑚2𝑟𝑡
1
𝑙𝑛 (
)
𝑘𝑎
𝐶𝑔 𝑝

(59)

Since the approximated rectangle peak shape is the same area as the corresponding
approximated isosceles triangle, the amount of drug absorbed for phases i and ii (𝑋𝑙 𝑎2𝑟𝑡𝑖+𝑖𝑖 |𝑡0 ) for
Case 2rt can be found by substituting the smaller value, 𝑇𝑔 𝑝 (Equation 49) or 𝑇𝑙 𝑝2𝑟𝑡 (Equation
59), for 𝑡 in Equation 58.

𝑋𝑙 𝑎2𝑟𝑡𝑖+𝑖𝑖 |𝑡0 = (𝑉𝑙 )(𝐶𝑔 𝑚2𝑟𝑡 )(1 − 𝑒 −(𝑘𝑎)(𝑡) )

(60)

Again, the assumption for phase iii is the same as in Case 2rc and Case 2, where once the lower
plateau is reached, the concentration of dissolved drug remains equal to 𝐶𝑔 𝑝 for the entire phase.
The total amount of drug absorbed for phase iii is:
𝑇𝑟

𝑋𝑙 𝑎2𝑟𝑡𝑖𝑖𝑖 |𝑡 𝑙 = (𝑘𝑎 )(𝑉𝑙 )(𝐶𝑔 𝑝)(𝑇𝑙 𝑟 − 𝑡)

(61)

where 𝑡 is 𝑇𝑔 𝑝 or 𝑇𝑙 𝑝2𝑟𝑡 , whichever is the smaller.

The total amount absorbed during all three phases is the sum of Equations 60 and 61.

𝑇𝑟

𝑋𝑙 𝑎2𝑟𝑡 |0𝑙 = (𝑉𝑙 ){(𝐶𝑔 𝑚2𝑟𝑡 )(1 − 𝑒 −(𝑘𝑎)(𝑡) ) + (𝑘𝑎 )(𝐶𝑔 𝑝)(𝑇𝑙 𝑟 − 𝑡)}

(62)
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where 𝑡 is 𝑇𝑔 𝑝 or 𝑇𝑙 𝑝2𝑟𝑡 , whichever is the smaller.
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Supplemental 4

Supplemental 4. Comparison of the amount of drug absorbed using assumptions for Case 2,
Case 2rc and Case 2rt at three values of 𝑘𝑎 : (a) 0.001 min-1, (b) 0.01 min-1, and (c) 0.1 min-1. The
values of 𝑇𝑔 𝑚 range from 10-60 min and 𝐶𝑔 𝑚⁄𝐶𝑔 𝑝 ranges from 2-10.
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CHAPTER 3
Quantitative Probability Modeling of Bioavailability for Compounds that Precipitate in the
Gastrointestinal Tract
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ABSTRACT
Purpose
To calculate a population probability distribution of bioavailability of drugs from supersaturating
oral dosage forms (i.e., drugs that precipitate during the transit through the intestine) based on
known or anticipated variations in absorption and drug release parameters.

Methods
Discrete, 7-level frequency distributions were generated for small intestinal transit time, intestinal
volume, absorption rate constant and in vitro supersaturation extent and duration.

All

combinations of these parameters with their corresponding probabilities of occurrence were used
in a set of equations from our previously developed biopharmaceutical model to generate an
expected probability distribution of bioavailability. The model considers three cases relating the
in vitro and in vivo dissolution. Case 1 assumes in vivo and in vitro profiles are the same. Case
2 assumes drug peak concentrations in vitro and in vivo are equal while Case 3 assumes peak
durations are equivalent. The contribution of variation from each input parameter was evaluated.
Additionally, the effects of formulation changes on variation in bioavailability were also
investigated.

Results
The largest contribution to variation in bioavailability is due to absorption input variation,
particularly the reported variation in intestinal fluid volume and intestinal transit time. There was
less variation when small intestinal fluid volume was considered as a pocket; the ratio of the
90th:10th percentile was only 2, whereas when the drug was assumed to be distribute in the entire
small intestinal volume, the ratio was much higher, 5. Potential outcomes of proposed formulation
strategies to either increase the peak drug concentration and/or the peak duration were
quantitatively evaluated.

Altering the formulation to increase the peak duration by double
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predicted to provide only a modest improvement in bioavailability.

However, formulation

modification to double the peak drug concentration to a peak concentration corresponding to a
median supersaturation of 6 (from 3) would significantly improve bioavailability and perhaps more
importantly reduce the expected variation in bioavailability.

Conclusion
Reported population variation in absorption parameters provides the major contribution to
variation in bioavailability in supersaturating dosage forms. The assumptions regarding the
translation of in vitro dissolution profiles to in vivo release have a large effect on predictions of
variation in bioavailability. The model can assist formulators in making decisions regarding
formulation changes in supersaturating oral dosage forms, by providing quantitative answers to
what-if questions.
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INTRODUCTION
A significant fraction of drug candidates are poorly soluble (e.g., Biopharmaceutical/
Developability Classification System (B/DCS) II & IV compounds), making developability a
challenge.1-4 Several formulation and form selection strategies have been used to improve the
dissolution rate of the orally administered form (e.g., salt form, amorphous solid dispersion and
co-crystals).5 However, the more-stable poorly-soluble form often precipitates from solution
reducing the bioavailability enhancement one hoped to gain.

The bioavailability enhancement

should be linked to both the degree of supersaturation and the duration that the supersaturation
can be maintained without precipitation.

The performance of supersaturating systems can be affected by the process by which some
highly soluble forms are prepared. For example, Greco found that the type of method used to
prepare amorphous indomethacin (melt-cooling vs. cryo-grinding) affected the type of polymorph
that crystallized and the kinetics of solution-mediated phase transformation .6 Similarly, Murphy
and co-workers reported that grinding affected the transformation of the more soluble
carbamazepine anhydrate to the less soluble dihydrate7. Many authors have described the use
of polymers as a solid dispersion carrier or pre-dissolved in the dissolution medium, to retard the
precipitation event.3, 8-12 For example, Konno et. al revealed that dissolution of felodipine was
dependent on fraction (and type) of polymer in the amorphous solid dispersion, that is, the higher
fraction of polymer in the dispersion, the higher the resulting concentration of felodipine.13 Other
factors such as how the dispersion was prepared and whether the preparation resulted in an
entirely amorphous system, have also been found to affect dissolution results.14 In short, we are
improving our understanding of what controls the degree of supersaturation and its duration, and
how processing affects these potentially important parameters for improving bioavailability.
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The link between supersaturation and its duration to bioavailability is less clear. For example, in
a review of solid dispersions, Kaushal and co-workers show a table summarizing the in vitro
dissolution enhancement and the resultant enhancement in bioavailability.12
dissolution measures were unrelated bioavailability in that case.

Clearly, the

The link between in vitro

dissolution profiles of precipitating forms and their bioavailability is complex and not completely
understood. Therefore, we cannot currently gauge the expected variability in bioavailability
across the patient population that we should expect from a given variation during in vitro
dissolution testing. There are several software packages for modeling bioavailability from known
in vitro dissolution behavior, but the models are not specific to precipitating forms.15 However,
these software packages are continually being refined to do so. Additionally, with so many input
parameters to provide, it is a challenge to determine a probability of any given bioavailability value
occurring in an individual across the entire patient population.

Our approach is to model the main effects with a sparsely parameterized model, (previously
reported),15 such that sources of variation can be accounted for. The goal is to map the variation
in in vitro dissolution profile to expected variation in the entire patient population. If the expected
variation across the patient population is too high, relative to the therapeutic range of the drug,
project managers may decide to avoid supersaturating systems for that particular product.
Alternatively, the process could be controlled to produce a product having less variability in the
dissolution profile such that the expected variation in bioavailability across the patient population
falls within tolerable risk limits. Here we wish to extend the analysis to product performance of
oral dosage forms, particularly bioavailability.

MODEL DEVELOPMENT
Closed form analytical solutions that relate in vitro concentration profiles to the amount of drug
absorbed using several alternate assumptions were developed.15 In brief, in vitro concentration
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profiles were described by a set of 3 parameters that were used as inputs to absorption models.
Three absorption models were developed based on alternate assumptions:

the drug

concentration in the intestinal lumen: 1) peaks at the same time and concentration as in vitro, 2)
peaks at the same time as in vitro, or 3) reaches the same peak concentration in vitro. The
outcomes of the three assumptions (also referred to as cases), particularly those of the second
and third cases, provide different predictions of bioavailability that can be considered.

Parameterization of In Vitro Drug Concentration-Time Profiles
Each in vitro drug concentration-time profile of an amorphous form differs in concentration at
peak, duration of the peak, peak shape and plateau concentration. All of the nuances of each
curve can be captured with a sufficiently large number of parameters. However, the goal of
obtaining a closed-form analytical solution for the bioavailability of an amorphous formulation
demands a more parsimonious parameterization of the in vitro curves. Therefore an isosceles
triangular approximation was utilized to quickly characterize in vitro concentration time curves
using just the three parameters: 1) peak drug concentration, 2) duration of the peak which is
characterized by the full width at half maximum and 3) the plateau drug concentration that often
follows the peak.
Mathematical Models for the Three Cases of Absorption for Precipitating Drugs
Based on the three sets of assumptions regarding the relationship between in vitro and in vivo
dissolution of amorphous drugs, mathematical models were constructed to relate a typical in vitro
amorphous drug dissolution-time profile to expected absorption in vivo.

The following

assumptions are made to simplify all three models:
1. The small intestinal lumen can be considered a single mixing tank at a constant
volume.
2. Drug absorption is a first order process with respect to concentration.
3. Drug dissolution and absorption occur in the small intestine only.
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4. The in vitro dissolution curve is approximated as an isosceles triangle or a well
behaved peak.
5. Concentration in solution in vitro is equal to the concentration in solution in the
gastrointestinal tract.
6. After drug precipitation is complete and the plateau concentration is reached,
absorption is no longer dissolution rate limited.1
7. Precipitation is non-pH dependent.

Summary of Three Cases for In Vivo Dissolution Behavior
Depending on the drug properties and the conditions in the small intestine, three cases based on
above assumptions can be explored using the isosceles triangular approximation of the in vitro
dissolution.

Case 1. The dissolution vs. time curve in vivo is assumed to mirror that in vitro. Using the 3parameter of the in vitro curve, the peak drug concentration in vivo occurs at the same time and
concentration as seen in vitro. (Figure 1a)
Case 2: The duration of the elevated drug concentration in vivo corresponds to the in vitro
dissolution behavior. The peak concentration in vivo occurs at the same time in vitro, but due to
absorption, the peak drug concentration is lower in vivo than in vitro (Figure 1b).
Case 3: Precipitation in vivo occurs at the same concentration as seen in vitro, but due to
absorption, the time to reach peak concentration in vivo occurs at a later time than in vitro (Figure
1c).

1

Drug precipitates to what is thought to be very small particles, perhaps in the nanometer
range. These many minute drug particles have a very large surface area, making it less likely
that dissolution is rate limiting.
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Case 1 applies to BCS IV compounds, which have both low solubility and very low absorption
rate constants. Case 2 and 3 applies to BCS II compounds, which have low solubility but
absorption rate constants that leads to significant depletion of drug from gastrointestinal fluid. The
two cases provide very different relationships between the in vitro and in vivo dissolution
behaviors and it is not known with certainty which case is a better representation. However, the
drug concentration behavior in vivo is likely bracketed by assumptions a) equivalent duration of
the peak in vitro and in vivo, (Case 2) and equal peak concentrations in vitro and in vivo, (Case
3).

Calculation of Amount of Drug Absorbed
The 3-parameter approximation to the concentration profile has two discontinuities. For
simplicity in the derivation of the amount of drug absorbed, the profile is divided into three phases.
•

Phase i: The period between initial drug release and peak concentration.

•

Phase ii: The time from peak drug concentration to the plateau concentration.

•

Phase iii: The period over which the plateau concentration extends (where the drug in
solution is in equilibrium with any remaining solid drug).

The total amount of drug absorbed is the sum of the amount of drug absorbed from each phase.
Equations have been programmed to allow quick calculations. The calculation also takes into
consideration 4 relevant time variables/events. 𝑇𝑔 𝑚 2 is the time to maximum drug concentration;
𝑇𝑙 𝑝 is the time to reach plateau concentration; 𝑇𝑙 𝑟 is small intestinal residence time; and 𝑇𝑙 ∗3 is
the time beyond which there is no remaining solid drug. Since there are 4 time-based parameters

2

See Table 4 in Appendix A for list of abbreviated model terms.

3

𝑇𝑙 ∗ is calculated differently for each phase. Derivation of an example 𝑇𝑙 ∗ (for Case 2, phase
i, 𝑇𝑙 ∗2𝑖 ) can be found in SI.
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corresponding to 4 key events, there are 24 (i.e., 4!) possible orders in which the events can
occur. Further details are shown in Supporting Information (SI) section.

METHODS
Variations in 5 parameters (3 based on human physiology and 2 related to processing) were
estimated from literature data. The literature data were used to construct seven-level discrete
distributions of each of the 5 parameters for use in calculating the potential variation in
bioavailability using each of three cases. Each parameter is described below.

Physiological Parameters
1. Small Intestinal Fluid Volumes (𝑽𝒍 ): A large variability in small intestinal fluids volumes
has been reported from a study in which water-sensitive magnetic resonance images of
12 healthy human subjects were quantified by Schiller and co-workers.16. The lowest
small intestinal fluid volume was 11 ml and the highest, 319 mL.16 Similar results were
found by Marciani et. al.17 A seven level discrete distribution of small intestinal fluid
volumes (Figure 2(a)) was generated from data of Schiller et al. and Marciani et al.,
combining both fasted and fed results. From this combined data set, the median volume
was 77mL. Schiller et. al also pointed out that small intestinal fluid volume was divided
into smaller pockets of fluid throughout the small intestine. On average, it was noted that
each patient had typically <100mL fluid scattered in four to six pockets.16 A seven-level
discrete distribution of small intestinal fluid volumes as smaller pockets are represented
by Figure 2(f).
2. Small Intestinal Transit Times (𝑻𝒍 𝒓): Yu et al. reported a mean intestinal transit time of
199 min with a standard deviation of 78 min based on date collected from 400 human
subjects from various studies. Additionally, the median small intestinal transit time was
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191 min, the minimum 30 min and the maximum 570 min.18 Using these results, of small
intestinal transit times (Figure 2(b)) was generated.
3. First order absorption rate constant: The absorption rate constant, 𝑘𝑎 is proportional to
the effective permeability of drug through the human small intestine, 𝑃𝑒𝑓𝑓 (Equation 1).
𝑘𝑎 =

2𝑃𝑒𝑓𝑓
𝑟

(1)

where 𝑟 is the radius of the small intestine19. The 𝑘𝑎 distribution (skewed) presented in
Figure 2(c) is based on the variation found in the radius, 𝑟.20 Human small intestinal radius
distribution with a median of 1.42 cm with a range is 0.95-1.55 cm was used for 𝑘𝑎
distribution.20 A seven-level discrete distribution of 𝑘𝑎 was based on 𝑃𝑒𝑓𝑓 of 0.026 min-1
reported21 for carbamazepine, as an example B/DCS II compound.

Processing-Related Parameters
4. Degree of supersaturation (σ): A seven-level discrete distribution (Figure 2(d)) of the
peak drug concentration, 𝐶𝑔 𝑚, relative to the plateau concentration (often the drug
solubility), 𝐶𝑔 𝑝, was generated based on previous experience. The mean degree of
supersaturation was based on the results of Murdande et al. which showed that nine neat
amorphous drugs dissolved to a maximum concentration equivalent to a degree of
supersaturation of 2-6.22 Figure 2(d) shows a normal distribution with a mean/median
degree of supersaturation of 3 and relative standard deviation of 20%.
5. Time to reach maximum concentration (𝑻𝒈 𝒎): A distribution reflecting the variation in
the duration of the peak concentration, 𝑇𝑔 𝑚, (Figure 2(e)) was based on experience from
our lab.6, 22 Figure 2(e) shows a normal distribution with a mean/median time to reach
maximum concentration of 25 mins and relative standard deviation of 20%.
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Calculating Bioavailability Variation

To determine the variation in bioavailability based on non-Gaussian distributions, all 16,807 (i.e.,
75) combinations of input parameters were evaluated. When both 𝑘𝑎 and 𝑉𝑙 are dependent on 𝑟
a total of 2401 (i.e., 74) combinations were generated for each set of data. All combinations for
each set of bioavailability data were used as inputs for the bioavailability calculation. However,
all combinations were not equally probable. The probability of each combination to occur was the
product of the probabilities of each parameter used in that combination. The bioavailability of a
dose of a hypothetical drug with low solubility (𝐶𝑔 𝑝) of 0.01 µg/mL was calculated for each of these
combinations. The bioavailability values along with their probability of occurrence were used to
determine the cumulative probabilities (and percentiles) of bioavailability or amount of drug
absorbed.

RESULTS
Preliminary findings showed that reported variations in physiological parameter small intestinal
fluid volumes (𝑉𝑙 ) and transit times (𝑇𝑙 𝑟) provide the major contribution to variation in bioavailability
in supersaturating dosage forms (Figure 3).

The ratio of the 90th:10th percentile for both

physiological parameters was approximately 4. This was unsurprising, since the lowest small
intestinal fluid volume was 11 mL and the highest, 319 mL,16 and the range of small intestinal
transit times, was 30 to 570 min.18 Conversely, the variation of absorption rate constant (𝑘𝑎 ), the
third physiological parameter, contributed very little to the variation in bioavailability. The variation
in both processing parameters, the time to reach maximum concentration (𝑇𝑔 𝑚) and degree of
superstation (σ), contributed some variation, a ratio of approximately 2 between the 90th:10th
percentile.
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Examining the Schiller et al paper more critically, the authors point out that small intestinal fluid
volume was divided into smaller pockets of fluid throughout the small intestine. On average, it
was noted by Schiller et al that each patient had typically <100mL fluid scattered in four to six
pockets.16 This led to re-evaluation of the distribution of 𝑉𝑙 in Figure 2(c).

Based on the information that small intestinal fluid volume is divided in multiple pockets, a new
distribution was generated for 𝑉𝑙 . With a median volume of 77 mL and assuming 𝑉𝑙 is equally
divided into 4 pockets, the volume of each pocket of small intestinal fluid is about 20 mL.
Approximating the shape of the pockets of fluid in the small intestine as cylindrical, an estimate
of the variation of 𝑉𝑙 can be found from the variation in the radius of the small intestine (in the
same way variation for 𝑘𝑎 was established, Figure 2(c)) resulting in covariance between the two
parameters (Figure 2(f)).
To isolate and calculate the variation due only to the physiological parameters, the amount of
drug absorbed (𝑋𝑙 𝑎𝑠𝑎𝑡 ) without accounting for supersaturation was calculated using the Maximum
Absorbable Dose (MAD) 23-24 concept (Equation 2).
𝑋𝑙 𝑎𝑠𝑎𝑡 = (𝑘𝑎 )(𝑉𝑙 ) (𝐶𝑔 𝑝)(𝑇𝑙 𝑟)

(2)

Bioavailability of the hypothetical drug and its variation based on the variation in the three
physiological parameters (𝑉𝑙 , 𝑇𝑙 𝑟, and 𝑘𝑎 ) was determined in two ways. One set of simulations
utilized distributions from Figure 2a, b and c which assumed the drug distributed in the entire
small intestinal volume. The second set of simulations assumed drug was distributed in a single
pocket of fluid characterized by the distribution from Figure 2(f) rather than Figure 2(a). The
median amount of drug absorbed was much smaller when the total dose of the drug as distributed
in one pocket compared to the entire small intestinal volume, 1.2. vs. 4.5 mg (Figure 4), since a
larger fraction of drug undissolved in the smaller volume. Furthermore, there was less variation
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when 𝑉𝑙 was considered as a pocket; the ratio of the 90th:10th percentile was only 2, whereas when
the drug was assumed to be distribute in the entire small intestinal volume, the ratio was much
higher, 5. The lower variation is more consistent with clinical variations.

Thus, the lower variation in intestinal volumes seemed reasonable. All results shown below
assume the drug is in one pocket of volume, 𝑉𝑙 (Figure 2(f)).

Formulation Strategy for B/DCS II Compound
If an immediate release tablet of the crystalline form of the hypothetical drug (solubility of 0.1
µg/mL) were to be administered, the median Maximum Absorbable Dose calculated in the
previous section would be 1.2 mg, with 0.7 mg for 10th percentile and 1.5 mg for 90th percentile.
This suggests that doses beyond 1.5 mg of the crystalline form of the drug would not be fully
absorbed for at least 90% of the population. However, if the target dose were 2 mg, then
formulation efforts would be needed to achieve 100% oral bioavailability. In such cases, the
mathematical model described in this paper could provide useful information to guide the efforts
of formulators; potential outcomes of proposed strategies to either increase the peak drug
concentration and/or the peak duration can be quantitatively evaluated.

The mean and range (25th %ile to 75th %ile) in bioavailability for four formulations of the
hypothetical drug (Table 2) were calculated from distributions of 𝑇𝑙 𝑟, 𝑉𝑙 , 𝑘𝑎 , σ and 𝑇𝑔 𝑚. The same
distributions of physiological parameters (Figure 2(b), (c) and (f)) were used for all calculations.
The four formulations differed in the input parameters that might result from a difference in
processing or formulation (σ and 𝑇𝑔 𝑚). The first hypothetical formulation simulated an in vitro
release profile that reached a median supersaturation (σ) of 3 with a distribution in supersaturation
shown in Figure 2(d) and median 𝑇𝑔 𝑚 (a measure of the duration of elevated drug concentration)
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of 25 min with a distribution shown in Figure 2(e). The second hypothetical formulation was
designed to improve bioavailability by doubling the peak resulting in a median degree of
supersaturation, σ, of 6 (Figure 5(a)). The third hypothetical formulation was focused not on
increasing the supersaturation, but rather on addressing the duration of the elevated drug
concentration, which was longer (i.e., 𝑇𝑔 𝑚 was twice the value for formulations 1 and 2) (50 vs.
25 min) (Figure 5(b)). The forth formulation provided both the higher supersaturation of
formulation 2 and the longer duration of formulation 3.

The dose of 1 mg is essentially 100% absorbed, which is predictable from the Maximum
Absorbable Dose calculation (i.e., 1.2 mg). However, since the models used here explicitly
acknowledge a distribution in physiological parameters affecting bioavailability, there is some
range around the 100% value. The median bioavailability determined using the assumptions in
the Case 2 model is always lower than for Case 3 (see 2 mg dose in Table 2).

If the target dose

is 2 mg, then efforts may be needed to improve formulation to achieve a 100% bioavailability.
Using Case 3 assumptions that precipitation is a concentration-dependent phenomenon, we find
all hypothetical formulation strategies to improve bioavailability result in a median bioavailability
of 95-100% (Table 2). Thus, one might infer that formulation 1 is sufficient to achieve 100%
bioavailability and no further efforts are needed.

However, if the variability expected from

formulation 1 is not clinically acceptable (where 25th%ile -75th%ile is 85-100%) for this hypothetical
drug, then formulation or processing changes to double the peak drug concentration would be
expected to lower the variation (see formulation #2, where 25th%ile -75th%ile is 99-100%) to
clinically acceptable levels.
In contrast, using the assumptions in the Case 2 model (i.e., precipitation is a time-dependent
phenomenon), formulation #1 would be predicted to have a lower and more variable bioavailability
(where the median is 82% and range between 25th%ile -75th%ile is 57-91%). If this Case applies,
then efforts would be needed to improve formulation to achieve a higher, less variable
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bioavailability. Increasing the peak drug concentration (median σ from 3 to 6) would be expected
to improve the bioavailability from 82 to 93% (formulation #1 vs #2). On the other hand, increasing
peak duration (median 𝑇𝑔 𝑚 from 25 to 50 min) would be predicted to lower the bioavailability from
82 to 78% (formulation #1 vs #3). The results of this simple model suggest that efforts be focused
on doubling the peak concentration (formulation #2) rather than extending the duration of a peak
.

Efforts to extend the peak duration (formulation #4) do not provide further bioavailability

advantage (Table 2 and Figure 6).

Formulation Strategy for B/DCS IV Compound
In the foregoing analysis, we considered bioavailability for a B/DCS II compound, where
absorption reduced the hypothetical drug concentration in vivo from what would be expected from
an ideal biorelevant in vitro dissolution profile.

In this section we consider formulation

development for a drug that has both low solubility and low absorption rate constant, such as
B/DSC IV compound. Again, four enabling formulations were considered where the median of
three physiological parameters 𝑇𝑙 𝑟, 𝑉𝑙 , σ and 𝑇𝑔 𝑚 and their distributions were maintained constant
(Figure 2(b), 2(f), 2(d) vs. 5(a) and 2(e) vs. 5(b)). The distribution of 𝑘𝑎 was again is based on
the variation found in the radius, 𝑟.20 However, the 𝑃𝑒𝑓𝑓 selected is a lower value, 0.001 min-1,21
such as that of cyclosporine, a B/DCS IV compound (Figure 7).

An absorption half-life corresponding to 𝑘𝑎 of 0.001 min-1 is nearly 12 hrs, which is 4 times the
median small intestinal transit time. With a low 𝑘𝑎 , there is negligible drug depletion from the
intestinal lumen and the drug concentration in small intestinal fluid mirrors the ideally biorelevant
in vitro drug release curve. Thus, for poorly permeable compounds, Case 1 applies.

The

bioavailability data for a 0.4 mg and 1.0 mg dose are shown in Table 3.
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The calculated Maximum Absorbable Dose based on median values of physiological parameters
was 0.4 mg. If a dose of 0.4 mg is required, no formulation efforts are needed to improve
bioavailability. However, if a higher dose, i.e. 1 mg, were to be required to achieve therapeutic
effects, then additional formulation efforts would be required to assure sufficient drug is absorbed.
A formulation that has a median σ of 3 and median 𝑇𝑔 𝑚 of 25 min (formulation #1) would be
expected to provide a median bioavailability of 67% with a wide variation. Altering the formulation
to double the peak duration would be predicted to provide only a modest improvement in
bioavailability, 74 vs. 67% (formulation #3 vs. #1). However, formulation modification to double
the peak drug concentration to a peak concentration corresponding to a supersaturation of 6
would significantly improve bioavailability from 67 to 94% (formulation #1 vs #2), and perhaps
more importantly reduce the expected variation in bioavailability. However, further formulation
development efforts to double both the peak concentration and the duration would not be
expected to provide further bioavailability advantage.

CONCLUSIONS
The reported variations in physiological parameters provide the major contribution to variation in
bioavailability in supersaturating dosage forms (i.e., those in which drug precipitates in the
intestinal lumen). The assumptions regarding the translation of in vitro dissolution profiles to in
vivo release have a major impact on predictions of variation in bioavailability. Nevertheless, the
newly developed models can potential assist formulators in making decisions regarding which
formulation changes in supersaturating oral dosage forms to pursue.

The models provide

quantitative answers to what-if questions about how formulation changes may affect
bioavailability.
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SUPPORTING INFORMATION
Further details on calculating amount of drug absorbed.
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APPENDIX A
Appendix Table 1. A list of abbreviating terms used for modeling.
Term
𝐶𝑔 𝑚

Description
Maximum concentration reached in vitro

Term
𝑇𝑙 𝑝

Description
Time plateau concentration or amount is
reached in vivo

𝐶𝑔 𝑝

Plateau concentration reached in vitro =

𝑇𝑙 𝑝2

solubility in vitro
𝐶𝑙 𝑚2

Maximum concentration reached in vivo for

reached in vivo for Case 2
𝑇𝑙 𝑝3

Case 2
𝑘𝑎

First order absorption rate constant

Time plateau concentration or amount is

Time plateau concentration or amount is
reached in vivo for Case 3

𝑇𝑙 𝑟

Small intestinal transit time or residence
time in vivo

𝑇𝑔 𝑚

Time maximum concentration or amount is

𝑇𝑙 ∗

reached in vitro
𝑇𝑔 𝑝

Time plateau concentration or amount is

solid drug i in vivo
𝑉𝑙

reached in vitro
𝑇𝑙 𝑚3

Time maximum concentration or amount is

Time where there is no more excess

Small intestinal fluid volume in vivo
dissolution volume

𝑋𝑙 𝑎

Amount of drug absorbed in vivo

reached in vivo for Case 3
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Figure 1. Relationship between in vitro dissolution profile and concentration of drug
dissolved in the intestinal fluid in vivo. Case 1 assumes the two profiles are the same.
Case 2 assumes the time to peak concentration is the same in vivo as in vitro. Case 3
assumes drug reaches the same peak concentration in vivo as in vitro.
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Figure 2. Distribution of (a) small intestinal fluid volumes, 𝑉𝑙 ; (b) small intestinal transit time, 𝑇𝑙 𝑟;
(c) absorption rate constant, 𝑘𝑎 ; (d) degree of supersaturation, σ; (e) time to reach maximum
concentration, 𝑇𝑔 𝑚; (f) small intestinal fluid volumes assuming a pocket. The numbers shown in
each the x-axis in each graph represent the average of the range of each of the 7 levels.
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Figure 3. Variation in bioavailability of a hypothetical drug due to the variation in each parameter
(Figure 2(a) through 2(e)) while all others parameters are constant at their median value. A total
dose of 30 mg and Case 3 assumptions were used. The whiskers represent 10th and 90th
percentile, and the boxes show the 25th and 75th percentiles.
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Figure 4. Variation between calculated bioavailability using the MAD equation, where the drug
distributed in either the entire small intestinal volume or a pocket of fluid. Variation of the three
physiological parameters (𝑽𝒍 , 𝑻𝒍 𝒓, and 𝒌𝒂 ) were utlitized (Figure 2a, b and c vs. Figure 2f, b and
c). The “whiskers” represent 10th and 90th percentile and the boxes show the 25th and 75th
percentiles.
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Figure 5. Distribution of (a) degree of supersaturation (σ) for testing in model where median is 6
and (b) time to reach maximum concentration (𝑇𝑔 𝑚 ) for testing in model where median is 50 min.
Both distributions have a relative standard deviation of 20%, same as Figure 2(d) and 2(e).
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Table 2. The bioavailability distributions generated for BCS II compound where the
median value is shown and the 1st and 3rd quartile (25 and 75 percentile) are in
parenthesis.
Bioavailability (%)
Formulation

𝑻𝒈 𝒎

#

(min)

N/a

N/a

σ

1

“Case”

Dose
1 mg

2 mg

100

59

(68-100)

(34-61)

100

82

(96-100)

(57-91)

100

97

(99-100)

(85-100)

100

93

(99-100)

(70-99)

100

100

(99-100)

(99-100)

100

78

(95-100)

(53-89)

100

95

(97-100)

(73-100)

100

93

(99-100)

(71-99)

100

100

(99-100)

(97-100)

MAD

Case 2
1

3
Case 3
25
Case 2

2

6
Case 3

Case 2
3

3
Case 3
50
Case 2

4

6
Case 3
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Figure 6. Formulation strategy flow chart for B/DCS II compound. Median value is shown and 25
and 75 percentile are in parenthesis. A dose of 2 mg and Case 2 assumptions were used.
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Figure 7. Distribution of rate of absorption (𝑘𝑎 ) of B/DCS IV compound.
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Table 3. The median calculated bioavailability for a hypothetical BCS IV compound. The range of
the 1st and 3rd quartile (25 and 75 percentile) is in parenthesis.
Bioavailability (%)
Formulation
#

N/a

𝑻𝒈 𝒎

σ

“Case”

Dose

(min)

N/a

1

1

3

0.4 mg

1 mg

100

44

(64-100)

(25-46)

95

67

(86-96)

(49-78)

95

94

(86-96)

(85-96)

95

74

(84-96)

(56-88)

95

94

(86-96)

(83-95)

MAD

1

25
2

6

3

3

1

1

50
4

6

1
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SUPPORTING INFORMATION (SI)

Calculating Amount of Drug Absorbed
The total amount of drug absorbed is the sum of the amount of drug absorbed from each phase.
Equations have been programmed into an MSExcel® spreadsheet to allow quick calculations.
The spreadsheet preparation also takes into consideration 4 relevant time variables/events. 𝑇𝑔 𝑚 4
is the time to maximum drug concentration; 𝑇𝑙 𝑝 is the time to reach plateau concentration; 𝑇𝑙 𝑟 is
small intestinal residence time; and 𝑇𝑙 ∗5 is the time when all drug is in solution. Since there are
4 time parameters corresponding to 4 key events, there are 24 (i.e., 4!) possible orders in which
the events can occur.

For example, a list of all possible permutations of the events for Case 2 is shown in SI Table 1.
The first permutation lists the order as 𝑇𝑔 𝑚 < 𝑇𝑙 𝑝2 < 𝑇𝑙 𝑟 < 𝑇𝑙 ∗; when the events occur in this
order, the drug concentration reaches peak at 𝑇𝑔 𝑚, declines to a plateau concentration at
𝑇𝑙 𝑝2 , and remains constant until the end of small intestinal residence time, 𝑇𝑙 𝑟, as shown in Figure
1.

So when 𝑇𝑔 𝑚 < 𝑇𝑙 𝑝2 < 𝑇𝑙 𝑟 < 𝑇𝑙 ∗, all three phases of absorption occur.

In contrast,

permutation #10 shows the case in which the small intestinal transit time, 𝑇𝑙 , is less than the time
at which the peak concentration occurs, 𝑇𝑔 𝑚, resulting in absorption in phase i only up until 𝑇𝑙 𝑟.

4

See Table 4 in Appendix A for list of abbreviated model terms.

5

𝑇𝑙 ∗ is calculated differently for each phase. Derivation of an example 𝑇𝑙 ∗ (for Case 2, phase
i, 𝑇𝑙 ∗2𝑖 ) can be found in the next section.
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SI Table 1. A list of all possible permutation for four events for Case 2
Number

Time

Time

Time

Time

Of

of 1st

of 2nd

of 3rd

of 4th

permutation

event

event

event

event

1

𝑇𝑔 𝑚

𝑇𝑙 𝑝2

𝑇𝑙 𝑟

2

𝑇𝑔 𝑚

𝑇𝑙 𝑟

3

𝑇𝑙 𝑝2

4

Phase i

Phase ii

Phase iii

𝑇𝑙 ∗

0 → 𝑇𝑔 𝑚

𝑇𝑔 𝑚 → 𝑇𝑙 𝑝2

𝑇𝑙 𝑝2 → 𝑇𝑙 𝑟

𝑇𝑙 𝑝2

𝑇𝑙 ∗

0 → 𝑇𝑔 𝑚

𝑇𝑔 𝑚 → 𝑇𝑙 𝑟

no phase iii

𝑇𝑔 𝑚

𝑇𝑙 𝑟

𝑇𝑙 ∗

0 → 𝑇𝑙 𝑝2

no phase ii

𝑇𝑙 𝑝2 → 𝑇𝑙 𝑟

𝑇𝑙 𝑟

𝑇𝑔 𝑚

𝑇𝑙 𝑝2

𝑇𝑙 ∗

0 → 𝑇𝑙 𝑟

no phase ii

no phase iii

5

𝑇𝑙 𝑝2

𝑇𝑙 𝑟

𝑇𝑔 𝑚

𝑇𝑙 ∗

0 → 𝑇𝑙 𝑝2

no phase ii

𝑇𝑙 𝑝2 → 𝑇𝑙 𝑟

6

𝑇𝑙 𝑟

𝑇𝑙 𝑝2

𝑇𝑔 𝑚

𝑇𝑙 ∗

0 → 𝑇𝑙 𝑟

no phase ii

no phase iii

7

𝑇𝑔 𝑚

𝑇𝑙 𝑝2

𝑇𝑙 ∗

𝑇𝑙 𝑟

0 → 𝑇𝑔 𝑚

𝑇𝑔 𝑚 → 𝑇𝑙 𝑝2

𝑇𝑙 𝑝2
→ 𝑇𝑙 ∗2𝑖𝑖𝑖

8

𝑇𝑔 𝑚

𝑇𝑙 𝑟

𝑇𝑙 ∗

𝑇𝑙 𝑝2

0 → 𝑇𝑔 𝑚

𝑇𝑔 𝑚 → 𝑇𝑙 𝑟

9

𝑇𝑙 𝑝2

𝑇𝑔 𝑚

𝑇𝑙 ∗

𝑇𝑙 𝑟

0 → 𝑇𝑙 𝑝2

no phase ii

no phase iii
𝑇𝑙 𝑝2
→ 𝑇𝑙 ∗2𝑖𝑖𝑖

10

𝑇𝑙 𝑟

𝑇𝑔 𝑚

𝑇𝑙 ∗

𝑇𝑙 𝑝2

0 → 𝑇𝑙 𝑟

no phase ii

no phase iii

11

𝑇𝑙 𝑝2

𝑇𝑙 𝑟

𝑇𝑙 ∗

𝑇𝑔 𝑚

0 → 𝑇𝑙 𝑝2

no phase ii

𝑇𝑙 𝑝2 → 𝑇𝑙 𝑟

12

𝑇𝑙 𝑟

𝑇𝑙 𝑝2

𝑇𝑙 ∗

𝑇𝑔 𝑚

0 → 𝑇𝑙 𝑟

no phase ii

no phase iii

𝑇𝑔 𝑚

𝑇𝑙 ∗

𝑇𝑙 𝑝2

𝑇𝑙 𝑟

0 → 𝑇𝑔 𝑚

𝑇𝑔 𝑚
no phase iii
→ 𝑇𝑙 ∗2𝑖𝑖
xxx 6
𝑇𝑔 𝑚
𝑇𝑔 𝑚

𝑇𝑙 ∗

𝑇𝑙 𝑟

𝑇𝑙 𝑝2

0 → 𝑇𝑔 𝑚

no phase iii
→ 𝑇𝑙 ∗2𝑖𝑖

6

𝑇𝑙 ∗ cannot occur in phase ii if there is excess drug at the end of phase i (highlighted in pink).
Reducing the total number of permutation form 24 to 22.
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13

𝑇𝑙 𝑝2

𝑇𝑙 ∗

𝑇𝑔 𝑚

𝑇𝑙 𝑝2
𝑇𝑙 𝑟

0 → 𝑇𝑙 𝑝2

no phase ii
→ 𝑇𝑙 ∗2𝑖𝑖𝑖

14

𝑇𝑙 𝑟

𝑇𝑙 ∗

𝑇𝑔 𝑚

𝑇𝑙 𝑝2

0 → 𝑇𝑙 𝑟

no phase ii

15

𝑇𝑙 𝑝2

𝑇𝑙 ∗

𝑇𝑙 𝑟

𝑇𝑔 𝑚

0 → 𝑇𝑙 𝑝2

no phase ii

no phase iii
𝑇𝑙 𝑝2
→ 𝑇𝑙 ∗2𝑖𝑖𝑖

16

𝑇𝑙 𝑟

𝑇𝑙 ∗

𝑇𝑙 𝑝2

𝑇𝑔 𝑚

0 → 𝑇𝑙 𝑟

no phase ii

no phase iii

17

𝑇𝑙 ∗

𝑇𝑔 𝑚

𝑇𝑙 𝑝2

𝑇𝑙 𝑟

0 → 𝑇𝑙 ∗2𝑖

no phase ii

no phase iii

18

𝑇𝑙 ∗

𝑇𝑔 𝑚

𝑇𝑙 𝑟

𝑇𝑙 𝑝2

0 → 𝑇𝑙 ∗2𝑖

no phase ii

no phase iii

19

𝑇𝑙 ∗

𝑇𝑙 𝑝2

𝑇𝑔 𝑚

𝑇𝑙 𝑟

0 → 𝑇𝑙 ∗2𝑖

no phase ii

no phase iii

20

𝑇𝑙 ∗

𝑇𝑙 𝑟

𝑇𝑔 𝑚

𝑇𝑙 𝑝2

0 → 𝑇𝑙 ∗2𝑖

no phase ii

no phase iii

21

𝑇𝑙 ∗

𝑇𝑙 𝑝2

𝑇𝑙 𝑟

𝑇𝑔 𝑚

0 → 𝑇𝑙 ∗2𝑖

no phase ii

no phase iii

22

𝑇𝑙 ∗

𝑇𝑙 𝑟

𝑇𝑙 𝑝2

𝑇𝑔 𝑚

0 → 𝑇𝑙 ∗2𝑖

no phase ii

no phase iii

To configure a cell in the MSExcel® spreadsheet to calculate the amount of drug absorbed in a
particular phase using the equation appropriate for the correct order of time variables, a logic tree
was created for each phase of each case; the logic trees were converted to if/then conditions in
MSExcel®. An example logic tree is shown in SI Figure 2.
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SI Figure 2. Logic tree for Case 2 phase i where numbers above each arrow corresponds to the
permutations numbered in Table 1. Equation 1 is the time profile for drug absorption in Case 2,
phase i. Equation 2 is the amount of drug absorbed after 𝑻𝒍 ∗𝟐𝒊 .

Equations SI 1 and 2 describe the amount of drug absorbed in phase i of Case 2. Derivations are
found in following section (Calculating 𝑇𝑙 ∗2𝑖 ).

𝑋𝑙 𝑎2𝑖 (𝑡) =

(𝑉𝑙 )(𝐶𝑔 𝑚)
𝑇𝑔 𝑚

[𝑡 + (

(𝑒 −(𝑘𝑎)(𝑡) −1)
)]
𝑘𝑎

𝑋𝑙 𝑎𝑇𝑙 ∗2𝑖→𝑇𝑙 𝑟 = (𝑋𝑙 𝑜 − 𝑋𝑙 𝑎2𝑖 (𝑇𝑙 ∗2𝑖 ))(1 − 𝑒 −𝑘𝑎(𝑇𝑙 𝑟−𝑇𝑙 ∗2𝑖 ) )

(SI 1)

(SI 2)
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Calculating 𝑻𝒍 ∗𝟐𝒊
In the model, the total amount of drug in vivo (𝑋𝑙 𝑜) is equal to the amount of drug in solution
(𝑋𝑙 𝑠(𝑡)), amount of drug in the solid (𝑋𝑙 𝑒(𝑡)) as well as amount absorbed (𝑋𝑙 𝑎(𝑡)), Equation SI 3.
𝑋𝑙 𝑜 = 𝑋𝑙 𝑠(𝑡) + 𝑋𝑙 𝑒(𝑡) + 𝑋𝑙 𝑎(𝑡)

(SI 3)

If there is no more excess drug (when 𝑋𝑙 𝑒(𝑡) equals zero) any time during Case 2 phase i,
Equation SI 3 becomes:
𝑋𝑙 𝑜 = 𝑋𝑙 𝑠2𝑖 (𝑇𝑙 ∗2𝑖 ) + 𝑋𝑙 𝑎2𝑖 (𝑇𝑙 ∗2𝑖 )

(SI 4)

Where Tl ∗2𝑖 is defined as the exact moment when there is no more excess drug.
We know that the amount of drug in solution 𝑋𝑙 𝑠(𝑡) is equal to the product of 𝐶𝑙 𝑠(𝑡) and 𝑉𝑙 so that
Equation SI 4 when 𝑡 = 𝑇𝑙 ∗2𝑖 is:
𝑋𝑙 𝑜 = 𝐶𝑙 𝑠2𝑖 (𝑇𝑙 ∗2𝑖 ) 𝑉𝑙 + 𝑋𝑙 𝑎2𝑖 (𝑇𝑙 ∗2𝑖 )

(SI 5)

Combining Equation SI 1 (previously mentioned in text), SI 6 and 7 (derived in model development
manuscript) with Equation SI 5 when 𝑡 = 𝑇𝑙 ∗2𝑖 yields Equation SI 8.
𝑋𝑙 𝑎(𝑡)
𝑉𝑙

(SI 6)

𝑋𝑙 𝑎𝑖 (𝑡)
𝑉𝑙

(SI 7)

𝐶𝑙 𝑠(𝑡) = 𝐶𝑙 𝑛(𝑡) −

𝐶𝑙 𝑠𝑖 (𝑡) =

𝐶𝑔 𝑚
𝑇𝑔 𝑚

𝑡−
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𝐶𝑔 𝑚
𝑋𝑙 𝑎𝑖 (𝑇𝑙 ∗2𝑖 )
(𝑇𝑙 ∗2𝑖 ) −
𝑋𝑙 𝑜 = [
] 𝑉𝑙 + 𝑋𝑙 𝑎𝑖 (𝑇𝑙 ∗)
𝑇𝑔 𝑚
𝑉𝑙

(SI 8)

An equation (Equation SI 9) for calculating 𝑇𝑙 ∗2𝑖 is found by simplifying, rearranging Equation 9
and solving for 𝑇𝑙 ∗2𝑖 .

𝑇𝑙 ∗2𝑖 =

(𝑋𝑙 𝑜)(𝑇𝑔 𝑚)

(SI 9)

(𝑉𝑙 )(𝐶𝑔 𝑚)

If at any time during phase i no excess solid drug is present, the amount of drug absorbed up to
this point (𝑇𝑙 ∗2𝑖 ) is determined by Equation SI 1 when t=𝑇𝑙 ∗2𝑖 .

Additional absorption from the

remaining drug already in solution after 𝑇𝑙 ∗2𝑖 is assumed to follow 1 minus exponential decay
from 𝑇𝑙 ∗2𝑖 to 𝑇𝑙 𝑟 (Equation SI 10).
𝑋𝑙 𝑎𝑇𝑙 ∗2𝑖→𝑇𝑙 𝑟 = 𝐶𝑙 𝑠2𝑖 (𝑇𝑙 ∗2𝑖 ) 𝑉𝑙 (1 − 𝑒 −𝑘𝑎(𝑇𝑙 𝑟−𝑇𝑙 ∗ ) )

(SI10)

Combining Equation 11 with 7, 8 and 10 yields Equation 2 previously mentioned in text.
If 𝑇𝑙 ∗2𝑖 does occur in phase i of Case 2, then the total amount of drug absorbed (𝑋𝑙 𝑎2𝑖 ) is
calculated by adding Equation SI 1 when 𝑡 = 𝑇𝑙 ∗2𝑖 and Equation SI 2.
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CHAPTER 4
Biorelevant Media Slows the Solution-Mediated Phase Transformation of Amorphous
Spironolactone*

*This is a published manuscript from the Journal of Pharmaceutical Sciences (2018, 107 (1),
426-435), used intact for this thesis chapter.
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ABSTRACT
Solution-mediated phase transformation (SMPT) can reduce the high drug concentration
expected from amorphous formulations, eliminating the improvement in drug absorption one
hoped to gain from this high energy drug state. The differences in SMPT of a supersaturating
system were compared in biorelevant media (Fasted State Simulated Intestinal Fluid (FaSSIF)
and Fed State Simulated Intestinal Fluid (FeSSIF)) and United States Pharmacopeia (USP)
compendial medium, Simulated Intestinal Fluid without pancreatin (SIFsp).

Amorphous

spironolactone underwent SMPT to the same hydrate of spironolactone in all three media which
was confirmed by the decrease in dissolution rates assessed in a flow-through dissolution
apparatus, as well as by the appearance of crystals on the amorphous solid surface detected by
polarized light microscopy. Longer duration of supersaturation which may lead to greater in vivo
oral drug absorption, was found in both biorelevant media, compared to compendial (average >90
vs. 20 min), indicating that the presence of surfactants in biorelevant media delays crystal growth.
Surface profiles and polarized light micrographs suggest that 1) a significant increase in surface
area due to 3D crystal formation, 2) amorphous areas remaining exposed on the surface and 3)
a lower nucleation rate are potential reasons for an elevated dissolution rate even after SMPT.
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INTRODUCTION
A significant fraction of drug candidates suffer from limited aqueous solubility and/or poor
dissolution properties (e.g., Biopharmaceutical/Developability Classification System (B/DCS) II &
IV compounds) in their crystalline forms.1-4 In the amorphous (i.e., non-crystalline, glassy) form,
solids can dissolve to achieve supersaturated drug concentrations.5-9 The supersaturated state is
of interest, because the increase in concentration can drive higher drug flux across the intestinal
mucosa, potentially resulting in greater oral bioavailability.10-13

However, compounds in

supersaturated states are thermodynamically unstable and the system can return to the
equilibrium (low concentration) state by precipitation/crystallization. Crystallization of a more
stable form on the surface of the metastable form, while in solution, (i.e., solution-mediated phase
transformation, SMPT), can greatly reduce the apparent solubility and dissolution rate
enhancement of an amorphous solid.13-16 Considerable time, material and effort are expended to
determine whether an amorphous approach will provide the required bioavailability improvement.

Surfactants significantly alter the duration of the supersaturated state, either prolonging or
delaying SMPT by affecting the nucleation and/or crystal growth rate of the lower solubility
form1.17-23 Brewster et. al showed that surfactants like tocopheryl polyethylene glycol succinate
and Tween 20 at concentrations above critical micelle concentration (CMC) delay SMPT (i.e.,
slow the rate of amorphous to crystalline conversion ).21 Chen et al. reported that Tween 80 at
concentrations below the CMC promoted SMPT of the free base form of an experimental drug to
its chloride salt crystalline form. However, at concentrations above CMC, there was no effect on
time to conversion.19 Sodium taurocholate and Triton X100 were found to inhibit crystallization,
whereas sodium dodecyl sulfate and Polysorbote 80 were shown to promote crystallization of

1

These experiments were performed in single aqueous solutions (i.e., water, HCl or USP pH
6.8 buffer). Experiments performed by Brewster et al. included co-solvents, e.g. DMSO to
generate supersaturation.
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celecoxib from amorphous solid dispersion.24

Sodium lauryl sulfate

(SLS) and sodium

taurocholate (NaTc), both anionic surfactants, used at concentrations above CMC, promoted
conversion of anhydrous carbamazepine to the less soluble dihydrate during dissolution.20 SMPT
was an order of magnitude faster in the presence of SLS than in NaTc. Greco et al. reported the
complex effect of SLS on the SMPT of haloperidol mesylate to haloperidol free base. There was
a minimum in apparent conversion rate of haloperidol mesylate at 5 mM SLS; however, the time
course of SMPT increased at SLS concentrations either above or below this “critical value”. 23
Therefore, the surfactant is a key variable and may significantly affect dissolution and ultimately,
bioavailability.

Media containing surfactants have been developed to mimic intestinal conditions, e.g., Fasted
State Simulated Intestinal Fluid (FaSSIF) and Fed State Simulated Intestinal Fluid (FeSSIF)
(Table 1).

The compositions of these biorelevant media were based on literature and

experimental data in dogs and humans for the pH, buffer capacity, osmolality, surface tension
and the solubilization capacity of bile salt and lecithin micelles.25-28 The pH of FaSSIF and FeSSIF
were based on the range of pH throughout the small intestine in the absence and presence of
food in humans. Buffer capacities were obtained from a fistulated dog model at midgut which
suggested the buffer capacity is greater after a large meal. It has also been reported that the
surface tension in the small intestine is considerably lower than water.25 In the small intestine,
secretion of bile results in substantial concentration of bile salts and lecithin, which form mixed
micelles even in the fasted state. NaTc was selected to represent the bile salts in biorelevant
media due to its comparatively low pKa value (1.8) and solubility at physiological pH values.

Our research goal was to quantify and understand the differences in SMPT of apparent
supersaturating systems (particularly the amorphous form) in biorelevant media (i.e., dissolution
media containing both NaTc and lecithin) as compared to USP compendial medium (Table 1).
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Spironolactone (SPIR) (Figure 1a) was selected as a model drug since it is a poorly soluble, high
permeability drug that falls into B/DCS II(a).29 Furthermore, SPIR is non-ionizable, eliminating
any complications arising from the difference in pH values of fed vs. fasted biorelevalant
dissolution media (Table 1).30

EXPERIMENTAL SECTION
Preparation of Amorphous SPIR
Initially, amorphous SPIR was generated by melt-quenching (MQ) of SPIR (≥98% USP grade,
PCCA, Houston, TX), Form II.31-33 An aluminum pan containing crystalline SPIR was placed in a
pre-heated oven at 214-217 °C, (i.e., 6-9 °C above melting temperature), for 3 min. The melted
drug was then immediately quenched cooled in liquid nitrogen. In a dry glove bag, the resulting
glass was ground in a mortar and pestle and passed through a 200 μm sieve. Due to the inability
to prepare additional batches of fully amorphous SPIR by MQ, a subsequent batch of amorphous
material was generated by spray drying (SD). SPIR dissolved in acetone was atomized at a feed
rate of 1.3 mL/min using nitrogen as an atomizing gas at 31 L/min in a mini spray dryer (Bend
Research, Bend, OR). Using an inlet temperature of 65°C, the outlet temperature was ~30°C.
The spray-dried material was placed under vacuum at room temperature for 72 hours to remove
any residual solvent before further use.

Each batch was subdivided and transferred into air-tight vials under dry nitrogen before storage.
The amorphous nature of each batch was confirmed by an absence of birefringence under
polarized light, the presence of glass transition temperature ( 𝑇𝑔 ) on differential scanning
calorimetry (DSC) analysis and lack of Bragg peaks in powder X-ray diffractograms. Chemical
purity of the amorphous material was assessed by a reverse-phase gradient HPLC method.
There was ≤0.5% chemical degradation occurred during melting or spraying.
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Preparation of SPIR Hydrate
Crystalline SPIR (0.5 g) was fully dissolved in 20 mL of acetone. The SPIR solution was then
added to 0.5 L of water, which immediately led to the formation of needle-like crystals. Crystals
were isolated by filtration and either allowed to air dry, (i.e., to produce the dehydrated hydrate of
SPIR) or placed in a chamber and equilibrated at 100% RH in a vacuum sealed desiccator to
retain the hydrated state. This method was adapted from Takata, et. al and produced material
with Bragg peaks that matched the SPIR channel hydrate.34

Physical Characterization of Solids
Several techniques were explored to characterize and identify the solid forms generated in this
report. Solid samples (7-8 mg) were weighed into hermetically sealed aluminum pans. DSC
samples of amorphous material were prepared in a glove bag purged with dry nitrogen. All DSC
analyses were conducted under a dry nitrogen purge. The 𝑇𝑔 and melting temperatures of
samples was determined by scanning at 10 °C/min from -20 °C to 240 °C in a differential scanning
calorimeter (Q1000, TA Instruments, New Castle, DE).

Polarized light microscopy (PLM)

images were captured using either an Olympus BH-2 or BX50 microscope with camera (Olympus
America Inc., Center Valley, PA). PLM images were used to confirm absence of birefringence in
amorphous material samples. The solvent content of the amorphous material produced by MQ
or SD was determined by Karl Fischer titration (KF831, Metrohm, Riverview, FL) or a dynamic
vapor sorption (DVS) (Q5000, TA Instruments, New Castle, DE) to be <1%.

Polymorph identification required the use of additional techniques: 1) powder X-ray diffractometry
(PXRD), 2) attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) and
3) dynamic vapor sorption (DVS) analysis. PXRD samples (10-20 mg) were prepared in a
standard poly methyl methacrylate sample holder (cavity diameter 40 mm and 5 mm depth).
Diffractograms were captured at room temperature (Bruker D2 Phaser, Madison, WI) operating
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with CuKα radiation at 30 kV and 10 mA. PXRD data were collected at an interval of 0.02° using
a scanning rate of 0.4°/min over a 2θ range of 5 – 40°. Solids were also analyzed by FTIR (Model
Magna IR 560, Nicolet Instruments Technologies Inc., Westbury, WI) with an attenuated total
reflectance (ATR) accessory equipped with diamond ZnSe crystal (Golden Gate, Specac,
Cranston, RI) using OMNIC software (Version 6.0, Thermo Nicolet Corp., Madison, WI). 64 scans
were recorded with a resolution of 1 cm-1.

Water sorption and desorption isotherms at 25 °C

were measured using DVS. The moisture uptake of 3 mg samples was measured as a function
of relative humidity (RH) from 0–90% at 10% increments with weight change criterion of less than
0.001% per min.

HPLC method
Reverse-phase high pressure liquid chromatography (HPLC) (HP Series 1100, Agilent
Technologies in Santa Clara, CA) was used: 1) to determine purity of amorphous SPIR batches
and 2) to measure SPIR in the dissolution medium. For both purposes, 40 µL of each sample
was injected onto a C18 guard column (3.5 µm, 3.9 mm × 150 mm, Xterra®, Waters Corporation,
Milford, MA) and C18 column (3.5 µm, 3.9 mm × 15 mm, Symmetry®, Waters Corporation) in
series. Column temperature was regulated at 25°C and SPIR was detected at 245 nm. Mobile
phase A consisted of 0.2% trifluoroacetic acid 30% acetonitrile in water; Mobile phase B contained
0.2% trifluoroacetic acid 90% acetonitrile in water. For purity determination of melt-quenched
material, separations were conducted using a linear gradient elution at 1.5 mL/min, starting with
mobile phase A and ending with mobile phase B at 30 min. For concentration of SPIR in
dissolution medium, a step method of 30% mobile phase A in B for 5 min, 100% mobile phase B
for 10 min, and 30% mobile phase A in B for 3 min was used with a flow rate of 1 mL/min. This
method was utilized to prevent interference from excipients (e.g., lecithin) presence in dissolution
media. A standard curve was prepared in mobile phase B at a concentration range of 0.2-100
μg/mL.
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Bulk conversion of amorphous solids
SMPT only occurs at the very surface of amorphous solid, limiting detection by PRXD and ATRFTIR due electromagnetic ray depth penetration and amount of material required for detection.
In order to identify the form after SMPT, bulk conversion of amorphous solids were analyzed.
Amorphous SPIR (MQ, 75 mg) was added to 300 mL of each dissolution medium (Table 1).
Suspensions were vigorously stirred at room temperature for 2 hours before filtering through a
0.45 µm membrane (nylon, 47mm, Whatman (Pittsburgh, PA)). Solids remaining on filter were
immediately analyzed by PXRD. ATR-FTIR scans were collected after recovered solids were
dried in a desiccator, overnight at room temperature.

Examination of SMPT during dissolution in a flow-through apparatus
The dissolution rate, its time course and the microscopically documented conversion of
amorphous SPIR to a crystalline form were determined using a flow-through apparatus adapted
from a previous version.35 The composition for each dissolution medium is described in Table 1.
In addition to the components listed for USP compendial medium, Simulated Intestinal Fluid
without pancreatin (SIFsp), the solution was adjusted as necessary to pH 6.8 ± 0.1 with 0.1 M
sodium hydroxide or 0.1 M phosphoric acid solution. SIFsp solutions were sparged with helium
for 15-30 min before use. To prepare both types of biorelevant media (version 1), FaSSIF and
FeSSIF, commercially available freeze-dried powder (Biorelvent.com, London, UK) was used.
Biorelevant media reconstituted from the freeze-dried product has been reported to yield less
variation in dissolution experiments.36-37 Manufacturer’s directions for producing, storing, and
using the biorelevant media were followed with one exception:

Biorelevant solutions were

sparged with helium to eliminate bubbles prior to the addition of NaTc/lecithin powder to prevent
alterations in micelle properties.

126

Drug was compacted using a low tonnage press (2 Ton E-Z™, International Crystal Laboratories,
Garfield, NJ) such that the compact was flush with the surface of the flow channel in the
apparatus. SIFsp, FaSSIF or FeSSIF were delivered to the flow-through apparatus via syringe
pump (KDS 200 Series, KDScientific, Holliston, MA) at 0.5 mL/min (Figure 2). Fractions (0.5mL)
of effluent were collected every min and immediately diluted with mobile phase for analysis by
HPLC. All such dissolution experiments were performed at room temperature (20±1°C).

The flow-through apparatus allows measurement of dissolution flux (i.e., rate of mass loss per
area) by collecting fractions of the effluent for analysis. In the case of B/DCS II/IV, less than 1 %
of drug dissolves from the drug solid surface during the exposure to the flowing dissolution fluid,
so that the surface area remains constant. During SMPT of compacted amorphous solids, crystals
grow directly on the exposed surface of compact. Therefore, a decrease in dissolution rate is
indicative of the amorphous to crystalline conversion. To analyze the time course of the dissolution
profiles in a quantitative manner, both extent and duration of supersaturation were determined by
fitting an exponential decay (Equation 1) to dissolution rate data.23, 35

𝑑𝑚
= 𝐴𝑒 (−𝑡⁄𝜏𝑟 ) + 𝐶
𝑑𝑡

where

𝑑𝑚
𝑑𝑡

(1)

is the dissolution rate from the 0.13 cm2 surface of the compact, 𝑡 is time of exposure

to the flowing dissolution medium, 𝐴 + 𝐶 is the dissolution rate of the amorphous form (before
conversion), 𝐶 is the dissolution rate after conversion and 𝜏𝑟 is the time for 63% of the phase
transformation from amorphous to crystal has occurred on solids surface. Reported conversion
times are equal to 99% conversion at 5𝜏𝑟 . Computer software was used to fit Equation 1 to each
individual dissolution rate vs. time profile. The goodness-of-fit (R2) was 0.96±0.03 for amorphous
SPIR.
127

The surface of the amorphous compact during and after dissolution was characterized using
several methods. Images of the surface of compacted amorphous solid as it underwent
dissolution and crystallization were captured using PLM. In addition, compact surfaces after
exposure to flowing dissolution medium (and after the removal of excess liquid) were analyzed
by ATR-FTIR to identify the form of the crystalline phase that coated the surface.

The surface

topography of drug compact before and after exposure to dissolution medium were determined
using an optical non-contact 3-dimensional surface profiler, (Zygo® NewView™ 5000, ZygoTM
Corporation, Middlefield, CT). A 50x objective lens (total magnification of 1000x) was utilized for
measurements resulting in a lateral resolution of <1 µm and vertical resolution of <0.1 µm.

RESULTS AND DISCUSSION
A miniaturized flow-through dissolution apparatus reported by Greco et.al was used to allow
observation of the surface of dissolving SPIR solid forms using a microscope.35 This apparatus
allowed direct measurement of dissolution rates and simultaneous visual observation of
transformations (i.e., SMPT) (Figure 2). For a solid that does not undergo SMPT the dissolution
rate is constant. In contrast, for a solid that does undergo SMPT, with conversion to a more poorly
soluble form, (i.e., amorphous transforms to crystalline), the dissolution rate decreases. Since
the solution close to the surface is supersaturated, readily suppling dissolved drug for the formation
and growth of crystals, the crystalline form often nucleates (i.e., heterogeneously) and grows
directly on the amorphous solid in the apparatus.

Homogenous nucleation is unlikely to occur

since fresh dissolution medium is continuously flowing over the solid drug surface. The surface
area of poorly soluble drug remains constant. Therefore, the collection of fractions of dissolved
drug allows the quantification of conversion time. In addition, sink conditions can be maintained
and the hydrodynamics is well characterized.35 This apparatus is ideal for observing SMPT in situ
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by monitoring changes in solid surface via microscope (e.g., stereo-, polarized light or Raman
microscope).

Amorphous SPIR underwent SMPT to a lower solubility crystalline form in both USP compendial
(SIFsp) and biorelevant media (FaSSIF and FeSSIF) as confirmed by the decrease in dissolution
rates (green squares in Figure 3) as well as emergence of birefringence under polarized light
(Figures 4). Micrographs, taken at the end of each dissolution experiment, show solids surfaces
that are covered in crystalline material. It was also noted that there are similar patterns of
birefringence post dissolution in both biorelevant media (Figure 4b and 4c), but different when
compared to the solid surface in compendial medium (Figure 4) (“flower petal” vs. “dragonfly
wing” pattern).

The initial rates of dissolution of amorphous SPIR were 1.5-2 times higher in biorelevant media
than in compendial medium. It was also noted that the dissolution rate for Form II - increased with
increasing surfactant concentrations (1.8 in SIFsp, 3.3 in FaSSIF, and 6.7 µg/min*cm2 in FeSSIF).
Similarly, Takata et. al reported a higher solubility for Form II in FaSSIF vs. SIFsp (45 vs. 34
µg/mL at 37˚C) due to solubilization of drug into micelles.34

However, micelle-facilitated

dissolution is dependent on the rate of fluid flow (i.e., bile flow), as well as the composition and
size of micelles.38-39 Thus, the dissolution rates of the drug in solution containing surfactants is
not necessarily directly proportional to solubility of the drug.38, 40

A prolonged duration of higher dissolution rates in the gastrointestinal tract from a drug
administered as an amorphous dispersion potentially leads to a significant improvement in oral
bioavailability.12 In the current study, the duration of apparent supersaturation was found to be
significantly longer in biorelevant media vs. compendial (average 20 vs. ≥90 min for the 99%
SMPT) (Figure 3 and Table 2). SMPT, a kinetic phenomenon, occurs in three steps, 1) dissolution
129

of metastable phase, 2) nucleation of thermodynamically more stable phase and 3) growth of more
stable phase, often directly on the metastable solid surface.41-43 It is traditionally assumed that
the concentration of free drug at the dissolving surface equals the solubility of drug in that phase.
In the case of the amorphous compact, the solution at the surface is supersaturated (i.e., higher
concentration at the surface) with respect to the stable crystalline form. Microscopic defects in
the compact surface likely serve as a heterogeneous nucleation substrate, decreasing the energy
barrier required for the formation of nuclei22, 43, reducing the possibility that nucleation being the
rate limiting step. Therefore, the kinetics of SMPT would be predominately governed by the crystal
growth rate.

Conversion times (99% SMPT) were much shorter during dissolution of amorphous SPIR in SIFsp
than in either of the biorelevant media, 19.7±4.4 vs. 92.8±44.7 and 135.0±36.5 minutes,
respectively (Table 2). The large standard errors for the characteristic times of conversion are
representative of nucleation processes that are stochastic in nature. Lecithin and NaTc in the
dissolution medium delayed SMPT, suggesting an inhibition of the growth rate of a poorly soluble
crystalline form. NaTc may be competing with SPIR at the growing crystal surface, due to
similarity in molecular structures (Figure 1a vs. 1b), acting as a crystal impurity, which could
“poison” or slow the process of crystallization 44-45 by delaying the next crystal growth layer due to
competition.

An alternate explanation assumes that the crystal growth rate is not rate-limiting. Instead, if the
concentration of drug at the growing crystal surface is assumed to be in equilibrium with that
surface, the rate of crystal growth is limited by the flux of drug from the amorphous surface to the
growing crystalline surfaces during SMPT. As dissolved SPIR at the amorphous solid surface
diffuses away from the surface, it may be depleted either (1) by the growing crystal or (2)
equilibrium partitioning into micelles (reducing the free drug concentration). In SIFsp, there is no
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loss of free drug by partitioning in micelles (path 2); all free drug diffuses to the growing crystal.
Without depletion of free drug by uptake into micelles, the higher flux of free drug at the solid
surface is expected to result in a faster growth of crystalline solids (i.e., faster SMPT)

41

, coating

the amorphous surface and eliminating the amorphous advantage in dissolution rate. Both the
above mechanism as well as the mechanism invoking poisoning of growth by taurocholate may
be responsible for the differences in the duration of apparent supersaturation between compendial
and biorelevant media are plausible and likely to co-exist.

The terminal plateau in dissolution rates after SMPT of the amorphous form (parameter 𝐶 in
Table 2) was expected to be equal to that of the initial crystalline form (Form II); however, in
compendial medium, the terminal dissolution rate was 50% higher than the dissolution rate of
Form II. This sustained elevation in dissolution rate (green squares vs. red diamonds after 15
minutes in Figure 3a) suggested that the crystalline form deposited on the amorphous surface
during SMPT in the presence of SIFsp was a metastable polymorph rather than Form II.

PXRD of the crystalline form on the amorphous compact surface after dissolution was not
possible due to the large sample size (>20 mg) required. Instead, x-ray diffractograms of the
solids recovered by filtration after two hours of stirring excess amorphous powdered material in
each of the dissolution media were collected2. Diffractograms of the solids recovered from all
three dissolution media were identical (Figure 5). However, the powder X-ray diffraction patterns
of these recovered solids differed from that of Form II, and matched the pattern reported for
SPIR hydrate reported by Takata, et. al.34 The ATR-FTIR spectra of the amorphous solid, Form

2

It should be noted that the characterization of solids were performed on samples generated
from an equilibrium batch system. Phase-transformation in non-sink vs. sink condition (i.e., in
the steady state flow-through system, which is of primary interest), may differ. However, there
is some evidence of hydrate formation on the surface of amorphous solid during dissolution
which is discussed later.
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II and SPIR hydrate show distinct differences in spectral regions between 1700-1650 cm-1 (Figure
6). For amorphous SPIR material, one broad peak dominates this region, whereas there are two
distinct peaks present in both Form II and SPIR hydrate.

The carbonyl (of unsaturated cyclic

ketone) peak in Form II shifted to a lower wavenumber in the hydrate, (from 1670 to1660 cm-1),
consistent with the interaction with water.34, 46 In addition, PXRD showed subtle shifts (towards
higher angles) in the diffraction angles after dehydration of SPIR hydrate and, upon rehydration,
the peaks shifted back (Figure 5 and Supporting Information, SI Figure 1). In addition, water
sorption studies of the recovered solids (presumably the hydrate) showed a gradual sorption and
desorption of water with an increase and decrease in % water vapor over the sample (Supporting
Information, SI Figure 2). This reversibility in powder X-ray diffraction peak shifts and the
nonstoichiometric water sorption/desorption behavior suggest a channel hydrate is formed
during dissolution. The channels that contain water at higher water activities remain open
(although slightly smaller) even after dehydration and do not collapse to the more stable Form II
on dehydration.

It has also been reported that dissolution of metastable forms of SPIR will

convert to a relatively poorly soluble hydrated phase in the presence of water.32,

34

Data

presented here and in the literature leads to the conclusion that amorphous SPIR transformation
phase is a channel hydrate, independent of type of dissolution medium.

The dissolution rates of compacts of SPIR channel hydrate were evaluated in the flow-through
apparatus (blue triangles in Figure 3). The dissolution rates of the channel hydrate were equal to
or slightly lower than Form II (1.7 vs. 1.8 in SIFsp; 2.8 vs. 3.3 in FaSSIF; and 6.7 vs. 6.7
µg/min*cm2 in FeSSIF), (Table 2). Thus, while the form of SPIR after SMPT was confirmed to be
the hydrate, the formation of a hydrate on the surface of the dissolving amorphous SPIR does not
account for the elevated terminal dissolution rate.
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Instead, the elevated terminal dissolution rate of melt-quenched amorphous SPIR may be due to
the morphology of crystal growth on the surface of amorphous SPIR. The channel hydrate
crystals grew as spherulites on the amorphous solid during dissolution in all three media (Figure
4). However, the details in the appearance of the spherulites differed between compendial and
biorelevant media (Figure 4a vs. b and c). Spherulites are composed of many needle-like crystals,
growing outward from a single point, a nucleus, like spokes in a bicycle wheel. Each of the
crystals was needle-like, indicating that at least one face grew much faster than others.
Spherulites such as these are reported to form in highly non-equilibrium conditions (e.g.,
quenching melts to form crystalline solids) and in a variety of materials (metal alloys, polymers,
minerals, etc.).47-48

The details in the appearance of spherulites are affected by the rate of crystal growth. D’Alkaine
and Otaguro captured the image of a single spherulite of polystyrene grown in two stages at two
different growth rates by adjusting the temperature between stages (Figure 7).49 Grown slowly
over 16 hours at 140 ˚C, the polystyrene spherulite had a smooth looking appearance (i.e., higher
density of needles) (Figure 7a), especially when compared to the rapid additional growth over 3
hours at higher temperature, 180 ˚C (Figure 7b). In the current work, the presence of surfactants
in the dissolution medium, rather than temperature, slowed the crystal growth rate, yielding a
higher density of each spherulite (Figure 4b and 4c). Faster crystal growth rate in SIFsp yielded
fewer, but larger and less dense spherulites, appearing rougher in texture (Figure 4a).

The rapid formation of less dense spherulites in SIFsp can account for the elevated terminal
dissolution rate.

Mosharraf and Nystrom work suggest that two phases can coexistence50,

however it is unlikely at equilibrium, but could be possible during steady state dissolution into sink
conditions. Faster growing, less dense spherulites leave open interstitial areas between crystals
where amorphous material is exposed. A closer look at the PLM image taken at the end of
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dissolution in SIFsp (white circles in Figure 4a) showed that the surface of the amorphous compact
was not fully covered by crystalline material, i.e., small areas between crystals where amorphous
material was present, even though the dissolution rate had reached a plateau. In contrast, the
grain boundaries between spherulites in amorphous drug compacts exposed to fed and fasted
biorelevant media, are tighter, leaving little to no amorphous material exposed (Figure 4b and 4c).
Approximately 20% exposed amorphous material (and 80% conversion to SPIR hydrate) would
account for the elevated terminal dissolution rate seen in SIFsp dissolution studies.

The differences in spherulite appearance discussed above led to further investigation (via
profilometry and ATR-FTIR) into the analysis of surface topology after the amorphous drug
compact was exposed to dissolution media, especially to SIFsp. Profilometry of the surface of
amorphous SPIR compact exposed to SIFsp for 5 min in the flow-through apparatus shows crystal
growth as high as 3-6 µm from the amorphous surface, and valleys (between crystals), as deep
as 3 µm (Figure 8). This suggests that the layer of crystals formed on the amorphous solid surface
in SIFsp, is thicker than expected perhaps due to growth of a second face of crystals.

ATR-FTIR spectra of the solid surfaces of amorphous SPIR after dissolution in either FaSSIF or
FeSSIF showed a broad peak at 1700-1650 cm-1 (same as green in Figure 6), matching that of
the amorphous solid. The absence of peaks for either crystalline SPIR (Form II or the hydrate)
suggest that the crystalline layer covering the amorphous surface is very thin. In contrast, the
drug surface after dissolution in the compendial medium showed two distinct peaks, one albeit
nonsymmetrical (light blue, Figure 6), suggesting the presence of crystalline material at the depth
of infrared penetration. For ATR-FTIR used in this study, the theoretically depth of infrared
penetration is calculated to be 1-1.3 µm within 2000-1500 cm-1 region.51 It has been reported that
dissolution of metastable forms of SPIR will only convert to a relatively poorly soluble hydrated
phase in the presence of water, Form II will remain Form II during dissolution.32, 34 Therefore, this
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nonsymmetrical peak at 1670-1660 cm-1 in ATR-FTIR spectrum of amorphous SPIR surface after
dissolution in SIFsp, indicates the conversion to hydrate SPIR (and not Form II). This suggests
that a thicker crystal layer is formed during dissolution of amorphous SPIR in compendial vs.
biorelevant media due to the infrared penetration depth of ATR-FTIR. The greater thickness of
the crystalline layer may be due to growth of a second crystal face, perpendicular to the surface,
allowing height of crystals that are formed at the amorphous surface during dissolution in SIFsp
to be >1.3 µm. Furthermore, this suggests that it is this second face of the SPIR hydrate that is
inhibited by NaTc and/or lecithin in FaSSIF or FeSSIF.

In any case, both profilometry and ATR-FTIR analysis indicate a significant change in surface
texture after dissolution which would lead to an increase in surface area of the crystalline phase,
which would also contribute to the elevated terminal dissolution rate for amorphous SPIR in SIFsp.
An increase in surface area of 65% (from 0.13 to 0.21 cm2) would account for the elevated terminal
dissolution rate of 2.8 vs.1.7 µg/min.cm2. Ultimately, the reason for elevation in dissolution rate of
amorphous SPIR in SIFsp, is most likely a combination of the two mechanisms: an increase in
surface area and exposed amorphous material.

Additional studies required another batch of amorphous SPIR to be made. However, it became
impossible to produce a fully amorphous batch by melt-quenching (MQ). An alternative method,
spray-drying (SD), was used to generate amorphous SPIR material. DSC, PXRD, HPLC and
PLM analysis of both MQ and SD amorphous SPIR material (SI Figures 3-6) suggests that the
materials produced by the different methods were equivalent with one exception. The main
difference between the two materials was particle size (<2 µm for SD vs. <200 µm for MQ).
However, a high force is used to directly compact the material so that the surface is flush with the
bottom of the flow channel in the flow-through dissolution apparatus, eliminating the effect of the
particle size.
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SD amorphous SPIR compacts dissolving in SIFsp showed a 20% lower initial dissolution rate
than the MQ material. However, the terminal dissolution rates between the SD and MQ SPIR
were equal and elevated, as compared to the hydrate form (Table 2). Between SPIR batches,
the compact cover (Figure 2) used to compact the material against such that its surface was flush
with the flow channel was stored under ambient conditions for an extended period of time.
Therefore, a jewelry polishing cloth was used to polish the compact cover. This led to an
unexpected loss of the previously noted elevated terminal dissolution rate with SIFsp medium,
such that the new terminal dissolution rate equaled that of SPIR channel hydrate.

Treatment of the compact cover with the jewelry polishing cloth led to a difference in the
appearance of spherulites during dissolution. The solid surface of the SD amorphous SPIR
compact after dissolution in SIFsp was covered with smaller spherulites, (5-25 µm in diameter),
much smaller than those seen on surface of the compact of MQ amorphous SPIR after dissolution
(200-300 µm). The less dense (i.e., appearing rougher in texture) spherulites formed during
dissolution at the surface of SD amorphous SPIR (Figure 9) were similar in appearance to
spherulites formed at the surface of MQ amorphous SPIR after dissolution in SIFsp (Figure 4a),
suggesting that the crystal growth rate was not necessarily affected. However, the increase in
the number of spherulites per area, (as compared to MQ amorphous SPIR material, Figure 4a vs.
9), suggests significantly faster nucleation. Zhou et. al, reported a similar finding during their
study of long chain branching polypropylene crystallization behaviors at 140 ˚C. A large number
of nuclei quickly generated, restricting spherulite growth, so the spherulite size of long chain
branching polypropylene samples was much smaller than without the presence of a nucleating
agent.52 The rapid formation of smaller spherulites on the SD amorphous SPIR in compendial
medium is expected to result in less residual exposed amorphous surface, explaining why the
terminal plateau dissolution rate equals that of hydrate SPIR.
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Altering the method in which amorphous material is produced or the condition of compact cover
impacted SMPT kinetics. The extent of supersaturation differs between the two processed
amorphous materials (i.e., melt-quench versus spray-dry).

Changes in the compact cover

affected the nucleation rate. In either case, this change in SMPT behavior described here
emphasizes the details that can affect SMPT and duration of supersaturation during dissolution.

CONCLUSIONS
A miniaturized flow-through dissolution apparatus was used, under sink conditions, to allow direct
measurement of dissolution rates to determine the effects of dissolution medium composition on
solution-mediated phase transformation (SMPT) of amorphous spironolactone (SPIR). Both
biorelevant media slowed crystal growth of SPIR hydrate on the amorphous surface during
dissolution extending the period of higher dissolution rate, which would be expected to improve
bioavailability.

Two mechanisms were proposed for the extended period of apparent

supersaturation due to biorelevant media: 1) lower flux of free drug at the surface of the growing
crystal due to drug uptake into micelles and 2) poisoning of crystal growth by taurocholate, both
resulting in a slower growth of crystalline solids. A third possible mechanism for the SMPT is that
the crystallization occurs in the amorphous layer plasticized by the aqueous dissolution fluid. A
follow-up manuscript will explore this mechanism, but in the absence of surfactant.

Additionally, faster crystallization during dissolution in SIFsp resulted in a crystal pattern that left
a portion of the underlying amorphous material exposed. This exposed amorphous phase and/or
an increase in the total surface area due to greater 3-D crystal growth in SIFsp were proposed as
reasons for the unexpected dissolution rate after SMPT that was higher than that of the crystalline
form.

However, the elevated dissolution rate post SMPT was not reproduced when the

amorphous SPIR was prepared using a different method and the surface used for compaction
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was altered slightly. This processing artifact may have some significance towards manufacturing
and processing of drug products for supersaturating systems.
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Table 1. Summary of compendial and biorelevant dissolution media (version 1) used for in vitro
dissolution studies.36
USP
Composition
FaSSIF
FeSSIF
SIFsp
Sodium taurocholate (mM)
3
15
Lecithin (mM)
0.75
3.75
Sodium chloride (mM)
132
203
pH
6.8
6.5
5.0
Buffer capacity
18
12
72
(mEq L-1ΔpH-1)
(PO4)
(PO4)
(C2H3O2)
Surface tension (mN m-1)
72
54
48
-1
Osmolality (mOsmol kg )
113
270
670
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Figure 1. (a) SPIR and (b) sodium taurocholate chemical structures.

140

Figure 2. Flow-through dissolution apparatus (top). Close up of flow-through compact cover and
bottom housing (lower left). Bottom portion of flow-through housing with compacted amorphous
SPIR material, which is illuminated from behind via a flash light; transparency allows monitoring
of surface during dissolution by PLM (lower right).
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Figure 3. Dissolution rates of all three SPIR forms: (red diamonds) Form II, n=3; (green
squares) melt-quenched amorphous n=5; and (blue triangles) channel (dehydrated) hydrate,
n=3 in (a) SIFsp, (b) FaSSIF and (c) FeSSIF. Error bars represent standard deviation. Form II
and SPIR hydrate show slightly higher dissolution rates within the first 5 min. This phenomenon
has been attributed to surface smoothing.35
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Figure 4. PLM images of MQ amorphous SPIR compact surface taken at the end of dissolution
experiments in a) SIFsp, b) FaSSIF and c) FeSSIF. White circles show areas of amorphous SPIR
not covered by a crystalline phase. For FeSSIF, this small amorphous area is atypically, i.e., not
found in other samples. A time-lapse video in Audio/Video Interleaved (.avi) format is available
for 4(a) and 4(b).
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Table 2. Parameters for Form II, hydrate and amorphous SPIR. Dissolution rate =𝐴𝑒 (−𝑡⁄𝜏𝑟) + 𝐶.
Average and standard error of goodness-of-fit (R2) was 0.96 ±0.03 for amorphous SPIR.
𝐴

𝐶

τr , 63% SMPT

99% SMPTc

(µg/cm2min)

(µg/cm2min)

(min)

(min)

Amorphous (MQ)

6.0±0.3a

2.8±0.1

3.9±0.9

19.7±4.4

Amorphous (SD)

4.5±0.6

2.8±0.1

3.3±0.6

16.7±3.0

4.2±0.6

1.6±0.1

3.4±0.7

16.8±3.4

18.6±8.9

92.8±44.7

27.0±7.3

135.0±36.5

Initial phase

Amorphous (SD)b

Medium

SIFsp

Form IIb

1.8±0.0

Hydrateb

1.7±0.1

Amorphous (MQ)
Form II

8.9 ±0.9
FaSSIF

3.3±0.0

Hydrate

2.8±0.1

Amorphous (MQ)
Form II
Hydrate

2.8±0.3

8.9±0.3
FeSSIF

6.2±0.1
6.7±0.2
6.7±0.0

a

Standard error of n=5 for amorphous, n=3 for Form II and hydrate. bCompact cover polished

with jewelry polishing cloth prior to use. cThe conversion times are from the highest dissolution
rate to the plateau dissolution rate (99% conversion, 5𝜏𝑟 ).
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Figure 5. Powder X-ray diffractograms of the Form II (red) and solids recovered from SIFsp
(green), FaSSIF (purple), FeSSIF (blue). Greater amounts of residual moisture decrease
intensity of peaks and shifts them slightly towards the lower angles.
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Figure 6. ATR-FTIR spectra of Form II (red), hydrate (blue), amorphous SPIR (green), and
amorphous SPIR surface after dissolution in SIFsp (light blue). 1690 cm-1 and 1670-1660 cm-1
band relates to the stretching vibration of C=O bond of thioacetyl and C=O bond of unsaturated
cyclic ketone of SPIR.
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Figure 7. Reprinted from D'Alkaine, C. V. and Otaguro, H., The Effect of Step Isothermal
Crystallization on the Polymer Crystalline Morphology: The Case of Isotactic Polystyrene.
Polímeros 2001, 11, 234-239.
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Figure 8. PLM image taken of compact surface (400x magnification) after 5min dissolution in
SIFsp (top).
magnification).

Open blue rectangle is depicted in the profilometry image (middle, 1000x
The surface profile (bottom) shows the height variations for line indicated in

profilometry image.
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Figure 9. PLM image (400x magnification) of SD amorphous SPIR compact surface taken at end
of dissolution experiment in SIFsp.
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SUPPORTING INFORMATION
Characterization of SPIR channel hydrate by PXRD and DVS

SI Figure 1. Powder X-ray diffractograms of SPIR channel hydrate stored in different conditions:
100% RH (turquoise) vs. ambient conditions (purple). Greater amounts of residual moisture
decrease intensity of peaks and shifts them slightly towards the lower angles.
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SI Figure 2. Weight change vs. relative humidity graph illustrating nonstoichiometric water
sorption and desorption behavior. This and the PXRD results suggest that both the 1/3 hydrate
and the dehydrated hydrate are isostructural and that the straight channels holding the water
molecules are retained after dehydration.
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Characterization of MQ vs. SD amorphous SPIR material
The amorphous nature of each batch was characterized and compared. The glass transition
temperature (𝑇𝑔 ) detected in the MQ and SD were similar (91 vs 88˚C, respectively) (SI Figure 3
and 4). Powder X-ray diffraction pattern from both depict the typically halo seen for amorphous
samples (SI Figure 5). PLM images taken after MQ and SD lacked birefringence (SI Figure 6).
Chemical purity of the amorphous material was assessed by a reverse-phase gradient HPLC
method. There was ≤0.5% chemical degradation occurred during melting or spraying.
DSC, PXRD, HPLC and PLM analysis of both MQ and SD amorphous SPIR material suggests
that the materials produced by the different methods were equivalent with one exception. The
main difference between the two materials was particle size (<2 µm for SD vs. <200 µm for MQ).
However, a high force is used to directly compact the material so that the surface is flush with the
bottom of the flow channel in the flow-through dissolution apparatus, eliminating the effect of the
particle size.
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SI Figure 3. DSC scans of MQ amorphous material. 𝑇𝑔 detected at 91 ˚C.

153

SI Figure 4. DSC scans of SD amorphous material. 𝑇𝑔 detected at 88 ˚C.
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SI Figure 5. Powder X-ray diffraction patterns for MQ and SD SPIR material.
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SI Figure 6. PLM image of a) immediately after MQ (but before grinding and passing through
200 µm sieve in dry glove bag) and b) SD material.
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Determination and further explanation of dissolution rate parameters
To analyze the time course of the dissolution profiles in a quantitative manner, each dissolution
rate data set was fitted to exponential decay equation (Equation 1).
𝑑𝑚
= 𝐴𝑒 (−𝑡⁄𝜏𝑟 ) + 𝐶
𝑑𝑡
where

𝑑𝑚
𝑑𝑡

(1)

is the dissolution rate from the 0.13 cm2 surface of the compact, 𝑡 is time of exposure

to the flowing dissolution medium, 𝐴 + 𝐶 is the dissolution rate of the amorphous form (before
conversion), 𝐶 is the dissolution rate after conversion and 𝜏𝑟 is the time for 63% of the phase
transformation from amorphous to crystal has occurred on solids surface.

A+C is the y-intercept at time zero of the dissolution rate vs. time plot. Extrapolation to zero
time is used to find the dissolution rate prior to any conversion. Thus, it is the dissolution rate of
the amorphous form. By itself, A is the difference between amorphous dissolution rate, A+C,
and the dissolution rate of the converted surface, C, as illustrated in SI Figure 7.

SI Figure 7. Schematic of dissolution profile analysis where the blue line is the curve that is
fitted to dissolution rate vs. timepoints (red squares).
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CHAPTER 5
The Effects of Temperature on Solubility and Solution-Mediated Phase Transformation of
Amorphous Spironolactone
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ABTRACT
Amorphous solid forms of poorly-soluble drugs are used to increase solubility with hopes to
increase absorption and bioavailability, thus making a newly discovered drug a better candidate
for development. For some drugs there is a poor correlation between predictors of crystallization
rate of amorphous drugs in dry state vs. “wet” state (i.e., during dissolution).

For example,

amorphous spironolactone (SPIR) is considered an intermediate to slow re-crystallizer in solid
state.

However, during dissolution, solution-mediated phase transformation (SMPT) from

amorphous to crystalline form occurs rapidly.

At temperatures near the glass transition

temperature, the molecular mobility of amorphous solids increases resulting in faster
crystallization due to greater mobility. We propose that in the dissolution environment, with water
activity near unity, it is the glass transition temperature of the hydrated amorphous solid at the
surface that is relevant. Experimental glass transition temperatures of the dry and the hydrated
amorphous state (𝑇𝑔ℎ𝑦𝑑 ) were determined to be 92 and 55°C, respectively, but 𝑇𝑔ℎ𝑦𝑑 at the surface
is expected to be much lower.

Over a range of temperatures (4, 13, 22, 36 and 44°C), a

miniaturized flow-through dissolution apparatus, under sink conditions, was used to monitor the
decline in dissolution fluxes that accompany solution-mediated crystallization.

Time for 99 %

conversion of amorphous SPIR to channel hydrate was less than 20 minutes at 44, 36 and 22°C.
However, the conversion time was much slower at 13 and 4°C (76 and 331 minutes). Both the
significant increase in rate constant of crystallization and the change in temperature dependence
of SMPT shown between low and high temperature regions suggest a glass transition
temperature between the two regions and that the glass transition temperature at the surface is
lower than the bulk.
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INTRODUCTION
A significant fraction of early discovery drug candidates suffer from limited aqueous solubility
and/or poor dissolution performance (e.g., Biopharmaceutical/Developability Classification
System (B/DCS) II & IV compounds) of their crystalline forms.1-4 Approaches to improve solubility
and oral bioavailability include generating the amorphous form of the drug. Amorphous (i.e., noncrystalline, glassy) solids can dissolve to achieve high (supersaturated) drug concentrations. 5-9
The supersaturated state is of interest, because the increase in concentration can drive faster
drug permeation across the intestinal mucosa, potentially resulting in greater bioavailability. 10-13
However, the supersaturated state is thermodynamically unstable and the system will return to
the equilibrium (low concentration) state by precipitation and crystallization. Crystallization of a
more stable form on the surface of the metastable form like the amorphous form, while in solution,
(i.e., solution-mediated phase transformation, SMPT), can greatly reduce the apparent solubility
and dissolution rate enhancement of an amorphous solid.

Prediction of the rate of crystallization using experimentally or theoretically accessible factors has
been an active area of research. Initial work focused on crystallization tendency of compounds
from the neat amorphous solid (“dry”) state. Zhou et al.14 reported a reduced crystallization
temperature (

𝑇𝑐 −𝑇𝑔

𝑇𝑚 −𝑇𝑔

)as one such factor1, where a low reduced crystallization temperature showed

some correlation with faster re-crystallization in the amorphous solid. Baird et al.15-16 surveyed a
broad library of compounds, identifying factors such as molecular weight and rigidity of chemical
structure, as molecular structural factors that showed good correlation with crystallization
tendency.

1

𝑇c is the crystallization temperature, 𝑇m is the melting temperature, and 𝑇g is the glass
transition temperature determined using DCS.
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The prediction of crystallization of amorphous forms in dry state and the concepts derived from
those prediction efforts provide some guidance for understanding amorphous conversion in the
aqueous environment.8, 17 However, due to the complication of drug dissolving in the aqueous
medium and the aqueous medium interacting with amorphous solid, further work is needed to
identify additional factors that lead to better prediction of crystallization rate of amorphous drugs
when in “wet” state (i.e., during dissolution). For example, amorphous spironolactone (SPIR) is
considered an intermediate to slow re-crystallizer in solid state. Amorphous material, which was
generated for a previous study, remained amorphous for over a 1 year at room temperature without
detection of crystals by polarized light microscopy.18 However, crystallization starts immediately
(to a channel hydrate) upon exposure to an aqueous medium during dissolution.18

In addition to the factors that affect crystallization tendency in the solid state, such as molecular
weight and rigidity8, 17, 19, two mechanisms for crystallization of amorphous solids in aqueous
environments have been suggested. One mechanism is based on a thermodynamic argument
and the other has a kinetic basis. However, the two mechanisms predict conflicting effects of
temperature on the rate of crystallization (Figure 1).

The thermodynamic-based mechanism

suggests that a higher degree of supersaturation provides a greater driving force for
crystallization.20-22 Hancock and Parks5 first developed an equation for quantifying the solubility
advantage (or maximum degree of supersaturation) of amorphous compounds based on thermal
properties of amorphous and crystalline forms of drugs.5 Murdande et. al expanded on the
Hancock and Parks model by including experimental data for heat capacity, water sorption of
amorphous solids, and differences in the extent of ionization due to the different concentrations
achieved by crystalline and amorphous forms.8 Both the Hancock and Parks model and the
Murdande et. al theoretical approach predict an inverse relationship between degree of
supersaturation and temperature. Thus, this thermodynamic mechanism predicts a decrease in
the rate of crystallization as temperature increases (red line, Figure 1).
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The kinetic mechanism is based on molecular mobility in the solid. As water is absorbed into the
amorphous solid during dissolution,2 particularly near the surface of the dissolving solid, the
glass transition temperature (𝑇𝑔 ) of the amorphous phase is reduced and mobility within the solid
increases. If the 𝑇𝑔 of the hydrated amorphous drug (𝑇𝑔ℎ𝑦𝑑(𝑟𝑎𝑡𝑒) ) decreases to near or below the
temperature of dissolution, there would be sufficient mobility in the amorphous material to
crystallize.23-24 This mechanism predicts that the crystallization rate increases as the dissolution
temperature increases (blue line, Figure 1).5, 7 If both mechanisms contribute to the rate of
crystallization during dissolution, then there may be an optimal temperature range where
crystallization rate is a minimum as illustrated in dotted purple line in Figure 1. Ultimately, both
mechanisms may contribute to the rate of conversion of amorphous form to crystalline form,
reducing dissolution rate.

The goal of the present research was to elucidate the contributions of 1) degree of supersaturation
at the dissolving amorphous surface (𝑅𝑠 𝑒𝑥𝑝𝑡) and 2) the glass transition temperature of the
hydrated amorphous drug (𝑇𝑔ℎ𝑦𝑑 ) to the rate of crystallization of drug on the neat amorphous solid
during dissolution. By determining the crystallization rate over a range of temperatures for a
single compound, rather than determining the crystallization rates of compounds with different
glass transition temperatures, the complications of molecular structural factors is eliminated,
allowing the study of supersaturation and 𝑇𝑔ℎ𝑦𝑑 vs. dissolution temperature in the absence of other
complicating factors.

2

Amorphous form is considered hygroscopic relative to the crystalline form.
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Spironolactone (SPIR), a poorly soluble, non-ionizable and high permeability drug that falls into
B/DCS II(a)25, was selected as a model drug.

SPIR crystallization tendencies in “dry” vs. “wet

state, significantly differ. Amorphous spironolactone (SPIR) is considered an intermediate to slow
re-crystallizer in the solid state.

However, during dissolution, solution-mediated phase

transformation (SMPT) from amorphous to crystalline form (i.e., to a channel hydrate) occurs
rapidly.

EXPERIMENTAL SECTION
Materials
The method of preparation of spray-dried amorphous spironolactone (SPIR) and dehydrated
SPIR hydrate (i.e., the crystalline form identified after SMPT) (≥98% purity, USP grade, PCCA,
Houston, TX), were previously described.18 Crystalline SPIR hydrate was allowed to dry in a
desiccator under house vacuum overnight (i.e., to produce the dehydrated hydrate of SPIR).
Previously work showed that the hydrate formed during dissolution is a hydrate that has channels
in its crystal structure which are occupied by water molecules and are retained after
dehydration.18, 26 Since compaction of the channel hydrate proved difficult (with some of the
moisture forced out of the hydrate), the compact described in the next section used the
dehydrated channel hydrate prepared as described above.

Examination of Solution-Mediated Phase Transformation during Dissolution in a FlowThrough Apparatus
The dissolution flux (µg/cm2min), its time course and the microscopically documented conversion
of amorphous SPIR to a crystalline form were determined using a flow-through dissolution
apparatus as previously described.18, 27 For this portion of the work, the dissolution apparatus
was temperature-controlled using customized heating units.
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Amorphous SPIR or the dehydrated SPIR channel hydrate (4-5 mg) was compacted (750 lbs,
held for 1 min) using a low tonnage press (2 Ton E-Z™, International Crystal Laboratories,
Garfield, NJ) such that the compact was flush with the surface of the flow channel in the
apparatus. All amorphous SPIR compacts were translucent before exposure to the water in the
flow-through dissolution apparatus. Water was delivered to the entrance of the channel via
syringe pump (KDS 200 Series, KDScientific, Holliston, MA) at 0.5 mL/min. Fractions (0.5mL) of
effluent were collected and immediately analyzed by HPLC as described later.

Temperature Control of Flow-through Dissolution Apparatus
Customized heating units (Hi-Watt Inc., Fraser, MI) and/or a cold room maintained the
temperature (4, 13, 22, 36 and 44°C) of the flow-through dissolution cell. The heating units were
wire-wound elements imbedded in silicone rubber.

Additional information on the custom

fabricated heating units can be found in the Supporting information (SI) in the section
“Temperature Control of Flow-through Dissolution Apparatus”.

The conditions used for dissolution experiments at each temperature are summarized in Table 1.
For experiments performed at 4°C, the syringe filled with the dissolution medium (water), the flowthrough dissolution apparatus, and the tubing connecting the two were allowed to thermally
equilibrate in the cold room for at least 2 hr. For dissolution at 36 and 44°C, water-filled syringes
and 7cm inlet tubing were placed in an oven at 5 to 10°C above the dissolution temperature for
at least 2 hrs. For any dissolution studies where the use of heating units was necessary to
maintain the desired temperature, the flow-through dissolution apparatus was preheated for 10
mins before flow of the dissolution medium was initiated.
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To find the heating unit settings that produced the target dissolution temperatures, preliminary
dissolution experiments were performed as described above. Thermocouples (Part#, OMEGA
Engineering, Inc, Norwalk, CT) were placed directly inside the flow channel of the flow-through
dissolution apparatus, approximately 2.5 cm upstream and 0.5 cm downstream of the compact.
Temperatures were controlled at the target temperature ± 1°C, as confirmed by thermocouple
readings. The dissolution medium (water) in a beaker was sparged with helium through a fritted
port for 30 mins just prior to use to eliminate bubble formation in the flow channel during
dissolution. No bubbles were observed during dissolution.

Analysis of Effluent from the Flow-through Dissolution Apparatus
Fractions (0.5 mL) of the effluent from the flow-through apparatus were analyzed by reversephase high pressure liquid chromatography (Series 1100, Agilent Technologies in Santa Clara,
CA). Aliquots (40 µL) of effluent were injected onto a HPLC guard column in series with a
separation column (C18 guard column, 5 µm, 3.9 mm × 20 mm, and C18 column, 5 µm, 2.1
mm × 150 mm, Symmetry®, Waters Corporation, Milford, MA). Mobile phase consisted of 0.2%
trifluoroacetic acid and 70% acetonitrile in water. Column temperature was 25°C and flow rate
was 0.2 mL/min. SPIR was detected at 245 nm with an elution time of 6 min. A standard curve
was prepared in mobile phase at a concentration range of 0.2-100 μg/mL.

The flow-through apparatus allowed measurement of dissolution flux (i.e., rate of mass loss per
area) by collecting fractions of the effluent for analysis. In the case of a B/DCS II/IV drug such as
spironolactone, less than 1 % dissolved from the drug solid surface during the exposure to the
flowing dissolution fluid, so that the surface area remained constant.

The thickness of the

compacts was measured to be 0.8 to 1 mm. During SMPT of compacted amorphous solids,
crystals grew directly on the exposed surface of the compact. Therefore, a decrease in dissolution
flux was indicative of the amorphous to crystalline conversion. To analyze the time course of the
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dissolution profiles in a quantitative manner, both extent and duration of the dissolution flux were
determined by fitting an exponential decay (Equation 1) to dissolution flux data using OriginPro
(version 8.0, OriginLab Corporation, Northampton, MA) as previously reported.27-29

𝑑𝑚
𝑑𝑡 = 𝐴𝑒 (−𝑡⁄𝜏) + 𝐶
𝑎𝑟𝑒𝑎

where

𝑑𝑚
𝑑𝑡

(1)

is the dissolution rate from the 0.13 cm2 surface area of the compact, 𝑡 is time of

exposure to the flowing dissolution medium, 𝐴 + 𝐶 is the dissolution flux of the amorphous form
(before conversion), 𝐶 is the dissolution flux after conversion and 𝜏 is the time at which 63% of
the phase transformation from amorphous to crystal has occurred on the solid surface in the
flow-through apparatus.

Time for 99% conversion are 5𝜏. Equation 1 was fitted to each

individual dissolution flux vs. time profile. The goodness-of-fit (R2) ranged from 0.97 to 1.00 for
amorphous SPIR. The mean and standard error of the mean for each parameter (𝐴, 𝐶 and 𝜏)
obtained from curve fitting were calculated from the replicate dissolution flux vs. time profiles at
each temperature. Further details on the calculation of mean and standard error can be found
in SI in the section “Calculating Standard Error of the Mean”.

Characterization of Surface and Bulk Phase Transformation
Images of the surface of compacted amorphous solid during or after it underwent dissolution and
crystallization were captured using either a polarized light microscope (PLM) or a
stereomicroscope. PLM images were captured with a BX50 microscope and camera (Olympus
America Inc., Center Valley, PA). Stereomicroscopic images were taken with a SZ61microscope
and camera (Olympus America Inc., Center Valley, PA). Images taken with either PLM or
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stereomicroscope were digitally captured with ImagePro software (Media Cybernetics, Rockville,
MD).

Raman spectra of bulk solid directly compacted in the flow-through dissolution apparatus were
collected at room temperature before and after dissolution at 36 and 44°C using incident light at
785 nm (PhAT System Raman spectrometer with iC Raman™ software, Kaiser Optical Systems,
Inc., Ann Arbor, MI). The noncontact optic had a working distance of 10 cm with a 5 cm spacer
attached to the probe head and a 3 mm optic head. Each sample was scanned once for 15 mins.
The depth of penetration for analyzing compacted solids was reported to be 1.7-2.0 mm,30 which
is greater than the depth of the compacted solid.

Determination of the Glass Transition Temperature (𝑻𝒈 ) of the Amorphous Solid
Containing Water
To assess how the reduction in 𝑇𝑔 due to absorbed water affects the dissolution of amorphous
spironolactone, the 𝑇𝑔ℎ𝑦𝑑 , the 𝑇𝑔 of the hydrated amorphous drug, was found by extrapolating to
100% RH the experimentally determined 𝑇𝑔 of amorphous SPIR as a function of the relative
humidity (%RH) with which it was equilibrated. The percent of water absorbed by amorphous
SPIR at each %RH was determined at 25 C using a dynamic vapor sorption analyzer (DVS;
Q5000, TA Instruments, New Castle, DE). Amorphous SPIR (5-10 mg) was compacted directly
into a pan (high volume stainless steel DSC bottom pan, Part# 900825.902, TA Instruments, New
Castle, DE). Each hand compacted sample was dried in the DVS (0% RH for 3 hours) before
being exposed to 0, 50, 65, 75, 85 or 95% RH until a mass change of less than 0.2 µg/min was
reached. An empty DSC pan was placed on the reference DVS pan as a counter weight.
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Immediately after unloading from the DVS, samples were hermetically sealed and analyzed by
modulated differential scanning calorimetry (DSC, Q1000, TA Instruments, New Castle, DE) to
determine 𝑇𝑔 . Each sample was heated from -50 to 100C at 1°C/min with an oscillation period
of 60 sec and amplitude of 0.625C. 𝑇𝑔ℎ𝑦𝑑 was determined by extrapolating to 100% RH a plot of
𝑇𝑔 vs. %RH. Thus, 𝑇𝑔ℎ𝑦𝑑 was used as the potential 𝑇𝑔 of SPIR exposed to water during dissolution,
(i.e., at 100% RH when water activity is 1.)

Determination of the Time Course of Water Sorption into Compacted Discs of
Amorphous SPIR
To support the findings of SMPT in the flow-through dissolution apparatus, water sorption
isotherms of highly compacted amorphous SPIR material (i.e., discs) were obtained.

The

amorphous discs were compacted to the same pressure used to press compacts in the flowthrough dissolution apparatus. Amorphous SPIR (14-15 mg) was compacted directly into a DSC
pan (high volume stainless steel DSC top pan, Part# 900825.902, TA Instruments) using a low
tonnage press (2500-2700 lbs, held for 1min) with a custom-made stainless steel punch and
holder. All amorphous SPIR compacts were translucent before being exposed to moisture in the
DVS. Each compacted sample was placed in the DVS at 98%RH and 13, 22 36 or 44C until the
rate of mass increase was less than 0.2 µg/min. An empty pan was placed on the reference DVS
pan as a counter weight. Raman spectra of the compacted discs were collected immediately at
room temperature upon their removal from the DVS as described above. Each disc was scanned
once for 2 mins.

To quantitatively analyze the time course of the DVS water sorption vs. time profiles at each
temperature, Equation 2 was fitted to the water sorption versus time data:
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𝑚 = 𝐴(1 − 𝑒 (−𝑡⁄𝜏𝐷𝑉𝑆) )

(2)

where 𝑚 is the mass of water absorbed, 𝑡 is time of exposure to water vapor (at 98%RH) at a
given temperature, 𝐴 is the equilibrium mass of absorbed water at 98% RH, and 𝜏𝐷𝑉𝑆 is the time
for sorption of 63% of the equilibrium water uptake.

RESULTS
Examination of SMPT During Dissolution in a Flow-Through Apparatus
A miniaturized flow-through dissolution apparatus27 allowed observation of SMPT at the surface of
dissolving SPIR solid forms using a microscope.18 This apparatus also allowed measurement of
dissolution flux versus time, providing further evidence of SMPT. In this apparatus, the dissolution
flux of a solid compact that does not undergo SMPT is constant. In contrast, for a solid that does
undergo SMPT, with conversion to a more poorly soluble form, (i.e., amorphous transforms to
crystalline), the dissolution flux decreases. Since the solution at the surface of a dissolving
amorphous solid is supersaturated relative to the lower solubility form, readily supplying dissolved
drug for the formation and growth of crystals, the crystalline form often nucleates (i.e.,
heterogeneously) and grows directly on the amorphous solid. In the apparatus, homogenous or
heterogeneous nucleation elsewhere in the dissolution fluid is unlikely to occur since fresh
dissolution medium is continuously flowing over the solid drug surface, diluting any dissolved drug
further from the surface.

Amorphous SPIR underwent SMPT to a lower solubility crystalline form at each dissolution
temperature as confirmed by a decrease in dissolution flux (green squares in Figure 2).
Amorphous SPIR was previously shown to transform to a channel hydrate during dissolution in the
flow-cell.18 The terminal dissolution flux (i.e., the lower plateau in dissolution flux associated with
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complete transformation) of amorphous SPIR at each dissolution temperature matches that of a
compact of the channel hydrate (blue triangles in Figure 2), where the initial crystalline material
used to determine the dissolution flux of the channel hydrate at each temperature was the
dehydrated channel hydrate, due to the difficulty in compressing the hydrated form. It was
assumed that at the dissolution interface, the dehydrated channel hydrate rehydrated prior to
dissolving. The time for 99% conversion of amorphous SPIR to the channel hydrate was less than
20 minutes at 44, 36 and 22°C. However, the conversion time was much longer at 13 and 4°C (76
and 331 mins, respectively) (Table 2). Moreover, the degree of supersaturation (defined by the
ratio of initial dissolution flux of the amorphous form to the constant dissolution flux of the
crystalline channel hydrate, 𝑅𝑠 𝑒𝑥𝑝𝑡 (

𝑨+𝑪𝒂𝒎𝒐𝒓𝒑𝒉𝒐𝒖𝒔
𝑪𝒄𝒓𝒚𝒕𝒂𝒍𝒍𝒊𝒏𝒆

), decreased with increasing temperature as

predicted by theory,5, 7 but only in the temperature range of 4 to 22°C (Table 2). 𝑅𝑠 𝑒𝑥𝑝𝑡 values
abruptly increased after 22°C and then decreased as temperature further increased, leading to
two sets of data with a discontinuity at between 13 and 36°C.

Polarized light micrographs, taken at the end of each dissolution experiment, show solid surfaces
that are covered by crystals in the form of spherulites (Figure 3). Spherulites are composed of
many needle-like crystals, growing outward from a single point, like spokes in a bicycle wheel.
The appearance of such spherulites depends on the crystal growth rate. Slower crystal growth
produces smoother appearing, denser spherulites. Rough appearing, less dense spherulites
occur due to rapid crystal growth. Altering temperature or composition of the dissolution medium
has been shown to affect crystal growth rates and the appearance of spherulites.29, 31-33

Patterns of birefringence in the PLM images of the amorphous SPIR compacts were captured postdissolution, immediately after disassembly of the flow-through dissolution apparatus and water
removal from the compact surface. At each dissolution temperature the PLM images were distinct
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(Figure 3). At the lowest dissolution temperature (4°C, Figure 3a), the spherulites were smoothest
in appearance, indicating the slowest crystal growth consistent with slow amorphous to crystalline
conversion (Figure 2). At higher dissolution temperatures (13 and 22°C), the spherulites of the
channel hydrate of SPIR that formed on the amorphous solid surface became progressively less
dense. This observation agrees with the dissolution flux vs. time profiles (Figure 2), where the
duration of elevated dissolution fluxes decreased with increasing dissolution temperature. The
pattern of birefringence at the two higher dissolution temperatures (36°C and 44°C) was less
clearly that of spherulites, particularly at 44°C. Cracks at solid surface were more noticeable after
a few mins due to water evaporation (Figure 3d). The cracks may indicate a more fragile (perhaps
thinner) layer of hydrate was formed at the solid surface. The PLM image taken after 40 mins of
dissolution at 44°C showed pale colors (Figure 3d). After 70 mins of dissolution at 44°C, the entire
compact was white in color (by stereomicroscope and under PLM), indicating a thick layer of crystal
had formed (Figure 3f).34

Unlike the samples dissolving at lower temperatures (4, 13, and 22°C), at 44°C the initial
translucent amorphous solid compact became opaque during dissolution (Figure 4).

Some

opaque/white patches, which may indicate crystallization within the bulk solid, were noticeable at
or near the surface of the compact, (i.e., liquid/solid interface) that was exposed to the dissolution
fluid at 10-20 mins; by 70-90 mins, the entire solid compact was opaque. At 36°C, opaque patches
were not evident until 30-45 mins of exposure to the dissolution fluid (Figure 5), which was later
than seen at 44°C (Figure 4). The time for the compact to become completely opaque at 36°C
(120-140 mins) was also greater (Figure 5). In the absence of the dissolution medium, opaque
patches were not visually detected until 3 hours at both 36 (SI Figure 3) and 44°C. No opaque
patches were detected during 4.5 hours of dissolution at 4C and 3 hours at either 13 or 22°C (SI
Figure 3).
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Raman spectra of the intact compacts were collected to discern whether the opacity was
associated with crystallization within the bulk at the higher dissolution temperatures. Amorphous
SPIR prior to exposure to the dissolution medium had a broad peak at 1669 cm-1 (green line in
Figure 6). At 20 mins of dissolution at 44°C, the peak shifted to a lower wavenumber, 1666 cm1

, suggesting a mix of both amorphous and SPIR channel hydrate is present (red line in Figure

6).

At 90 mins of dissolution at 44°C, there were two distinct peaks at 1690 and 1663 cm-1,

identifying the solid as SPIR channel hydrate (blue line in Figure 6).

Similar findings at a

dissolution temperature of 36°C (SI Figure 4), but not at the lower dissolution temperatures
suggest that the bulk solid underwent the same phase conversion at the two higher dissolution
temperatures even though the 𝑇𝑔 of the SPIR with adsorbed water remains above the
temperature range of dissolution (discussed in detail in the next subsection).

Glass Transition Temperature of the Amorphous Solid Containing Water
During dissolution of the amorphous forms of poorly water-soluble compounds, water absorption
into the amorphous solid is expected to proceed prior to dissolution, reducing the 𝑇𝑔 of the
amorphous solid. The extent of water sorption into at least the outer layers of this relatively slowly
dissolving solid is expected to proceed to a water activity of essentially unity, which is equal to
that of the surrounding aqueous dissolution medium in the case of poorly soluble drugs.

To

assess the effect of absorbed water during dissolution on molecular mobility in the amorphous
phase, a 𝑇𝑔ℎ𝑦𝑑 was identified by extrapolation of experimentally determined 𝑇𝑔 of amorphous SPIR
samples equilibrated at a range of % RH (Figure 7 and (SI Figure 6 and 7).

Glass transition

temperatures of the dry and the hydrated amorphous state were determined to be 92 and 55C,
respectively (Figure 7a). The small amount of water, 2.2%, absorbed at 95%RH reduced the 𝑇𝑔
of amorphous SPIR by 36 degrees. The 𝑇𝑔 of amorphous SPIR vs. % water uptake (Figure 7b)
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revealed an almost linear relationship, indicating very weak or no specific interactions between
water and SPIR.

Determination of the Time Course of Water Sorption in Compacted Discs of Amorphous
SPIR
To further explore the bulk crystallization of the amorphous compacts that occurred at the higher
dissolution temperatures, but not at the lower temperatures, the next step was quantification of
the time course of water sorption into compacted amorphous SPIR. The time constant for water
uptake to its equilibrium value decreased dramatically as temperature increased (Table 3 and
associated water sorption isotherms in SI Figure 8). The measured time constant at the higher
temperatures were very short, 3 hrs at 44°C and 7 hrs at 36°C. On the other hand, the time to
reach equilibrium water uptake was much longer at the lower temperatures, 21 hrs at 22°C, 63
hrs at 18°C and, 107 hrs at 4°C.

DISCUSSION
The main objective of the present study was to determine whether the crystallization rate of
amorphous SPIR during dissolution is governed (a) primarily by the ratio of the amorphous to
crystalline solubility, 𝑅𝑠 𝑒𝑥𝑝𝑡, (a measure of the thermodynamic driving force for conversion), (b)
primarily by mobility in the solid (as reflected by the difference between the dissolution
temperature and the glass transition temperature of the solid, or (c) a combination of the two.

In the case of spironolactone, dissolution is not complicated by any reactions such as acid/base
or dimerization. Thus, in the case of dissolution of spironolactone in water, the dissolution flux
should be directly proportional to solubility of the form at the dissolving surface. The degree of
supersaturation of the amorphous form relative to the crystalline form to which the amorphous
surface converted is defined by the ratio of initial dissolution flux of the amorphous form to the
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constant dissolution flux of the crystalline form, 𝑅𝑠,𝑒𝑥𝑝𝑡 . The degree of supersaturation found by
evaluating the dissolution curves (Figure 8a) decreased with increasing temperature as predicted
by theory5, 7, but only in the temperature range of 4 to 22˚C (Table 2 and Figure 8a).
Unexpectedly, the degree of supersaturation abruptly increased after 22˚C and then decreased
at higher dissolution temperatures, leading to two sets of data with a discontinuity between 22˚C
and 36°C (Figure 8a).

The characteristic times of conversion increase with temperature (𝜏 for 4°C was 66.2±4.3; for
13˚C, 15.2±1.4; for 22˚C, 3.9±0.3) (Table 2), indicating faster crystallization at higher dissolution
temperatures. Since SMPT followed first order kinetics, 1/𝜏 was used as a measure of the rate
constant for the crystal growth that reduced the dissolution rate of the drug from the surface. The
rate constant for crystallization (1/𝜏) increased with increasing dissolution temperature for
amorphous SPIR (Figure 8b). This function is consistent with the blue line in Figure 1, suggesting
a kinetic mechanism based on molecular mobility in the solid. Furthermore, the difference in the
shape of the curves for 𝑅𝑠 𝑒𝑥𝑝𝑡 vs. temperature and crystallization rate constant vs. temperature
(Figure 8) argues against the degree of supersaturation controlling the crystallization rate.

Supporting the mechanism of molecular mobility in the solid, transformation to the channel hydrate
was detected throughout the compact during dissolution at both 36 and 44°C, as earlier as 10 mins
and 30mins, respectively, (vs. without dissolution medium, approximately 3 hours). At the higher
temperatures, water was able to diffuse below the surface and into the solid compact, in order for
bulk conversion to occur. Such bulk transformation was not seen in the compacts dissolving at
the three lower temperatures; only surface conversion was noted.
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An abrupt increase in solid state mobility is usually accompanied by a glass transition. 24 In this
case, when the logarithm of the crystallization rate constant was plotted as a function of the
reciprocal temperature (Figure 9), the change in slope would suggest a glass transition
temperature within 13-36°C.

However, the experimentally determined glass transition

temperature of the hydrated amorphous state was 55°C, (Figure 7), well outside the region where
the sudden change in slope suggested a glass transition.

The glass transition temperature of surfaces has been reported to be lower than that measured
in the bulk. Kajiyama et. al reported that the 𝑇𝑔 at the surface of amorphous solids surrounded
by a gaseous environment is significantly lower than the 𝑇𝑔 of the bulk based on their study of
the molecular motion as a function of temperature of monodisperse polystyrene films. 35 The
authors showed that 𝑇𝑔 of the surface was considerably lower (40-80 K) than that of the bulk.
Brian and Yu reported that the surface diffusion coefficient is at least 107 times the bulk diffusion
coefficient for amorphous nifedipine surrounded by a gaseous phase, indicating a highly mobile
surface.36

Other glass formers (indomethacin, o-terphenyl and tris-naphthyl benzene) had

surface diffusion coefficients that were >2 orders of magnitude greater than the diffusion
coefficient of their bulk.37 The higher thermal molecular motion at the amorphous solid surface
could be explained in terms of an excess free volume in the vicinity of the solid surface.35 While
these studies were of vapor/solid interfaces, the current study focuses on a solution/solid
interface, where the excess free volume in the vicinity of the interface is expected to be lower than
at a vapor/solid interface. Therefore, if the surface 𝑇𝑔 is lower at the dissolving amorphous SPIR
interface, the magnitude of the difference in 𝑇𝑔 of the surface from 𝑇𝑔 of the bulk is expected to
be much lower than for the vapor/solid interface.
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Looking at the plot of 𝑙𝑛 1/𝜏 vs. reciprocal temperature (Figure 9) in a different way, the change
in slope can be used to calculate an apparent change in the activation energy for the crystallization
process. The apparent activation energy drops from 106 kJ/mol in the lower temperature range
to 25 kJ/mol at the higher temperatures, suggesting a change in the rate controlling step for
crystallization. An explanation for the difference in activation energies is based on temperature
effect on both 1) the diffusion of dissolved SPIR from supersaturated solid surface to the growing
crystal and 2) the integration of SPIR molecule as part of the growing crystal. Both the diffusion
and integration steps are temperature dependent and this dependency can be characterized by
corresponding activation energies. The rate of integration process increases much more rapidly
with temperature than does the diffusion step.38 Thus, the crystal growth rates are more likely to
be integration controlled at low temperatures and diffusion controlled at higher temperatures,
where the activation energy for the diffusion is much lower than that of integration (8-20 vs. 4060 kJ/mol).38

CONCLUSION
The goal of this research was to determine the contribution(s) of the molecular mobility of the
hydrated amorphous drug and degree of supersaturation to the rate of solution-mediated phase
transformation.

By determining the dissolution rate over a range of temperatures for a single

compound, rather than determining the dissolution rates of compounds with different glass
transition temperatures, the complications of molecular structural factors was eliminated. This
allowed the study of supersaturation and mobility of the hydrated amorphous solid vs. dissolution
temperature in the absence of other complicating factors. The data presented strongly argue
against the degree of supersaturation (i.e., the ratio of the amorphous to crystalline solubility) as
the sole determinant of the rate of SMPT. Rather, the evidence points to a mobility-related
mechanism for the rate of SMPT during dissolution. However, efforts to support this mechanism
with data relating to the mobility in the solid, i.e., glass transition temperature data, were found to
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be not conclusive. If the glass transition of the surface is assumed to be lower at the dissolving
surface, as is suggested for other solids in a gaseous environment, perhaps the glass transition
argument still supports the proposed mechanism. The concomitant bulk crystallization at the
higher dissolution temperatures associated with lower apparent activation energy and fast SMPT
suggest a change in mechanism from the slow SMPT with higher apparent activation energy and
only surface crystallization. Both the bulk crystallization and lower apparent activation energy are
supportive of generally higher mobility in the solid amorphous spironolactone compact. However,
a more conclusive result will require additional research.
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Table 1. Summary of the conditions used for dissolution experiments at each temperature.
Temperature of
Target

Ambient

temperature

Temperature

Temperature

medium before

Use of heating

setting of

start of

units

heating units

(±1°C)
dissolution (°C)

(°C)

4

4°C (cold room)

4

No

NA

13

4°C (cold room)

22

Yes

23

22

22±1°C

22

No

NA

36

22±1°C

40-45

Yes

45

44

22±1°C

50-55

Yes

53
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Figure 1. Schematic of rate of crystallization vs. temperature for different mechanisms: when
degree of supersaturation dominates (red line), when 𝑇gℎ𝑦𝑑 dominates (blue line), and when both
mechanisms effect rate of crystallization (purple dotted line).
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Figure 2 Dissolution fluxes of amorphous (green squares, n=6) and channel (dehydrated) hydrate
(blue triangles, n=3) at (a) 4, (b) 13, (c) 22, (d) 36, and (e) 44°C. Error bars represent standard
deviation. Greater variability was noted at increasing dissolution temperatures, most likely due to
the stochastic nature of the nucleation process and the shorter duration of supersaturation.

184

Table 2. Parameters for the dissolution of amorphous and crystalline SPIR. Dissolution flux
=𝐴𝑒 (−𝑡⁄𝜏) + 𝐶. Goodness-of-fit (R2) ranged from 0.97 to 1.00 for amorphous SPIR.
𝝉,
99%
Initial

𝑨

Temp.

𝑪

𝑨+𝑪
𝑹𝒔𝒆𝒙𝒑𝒕 c

form

2

2

2

(C) (µg/cm min) (µg/cm min) (µg/cm min)

63%
SMPTd
SMPT
(min)
(min)

4.4±0.1b

Amorphous

1.3±0.1

5.7±0.1

4.4±0.1 66.2±4.3 330.9±21.4

6.6±0.3

4.1±0.2 15.2±1.4

76.2±6.8

6.2±0.2

3.6±0.1

3.9±0.3

19.6±1.5

14.7±0.3

4.8±0.1

2.6±0.1

12.9±0.5

15.7±0.4

4.2±0.1

2.0±0.2

9.9±0.8

4
Crystallinea

1.3±0.1

Amorphous

5.1±0.3

1.5±0.1

13
Crystalline

1.6±0.0

Amorphous

4.6±0.2

1.6±0.1

22
Crystalline

1.7±0.0

Amorphous

11.7±0.2

3.0±0.1

36
Crystalline

3.0±0.1

Amorphous

11.9±0.4

3.7±0.2

44
Crystalline

3.7±0.0

a

Dehydrated channel hydrate;

b

Error shown is the Error Propagation (calculation in SI), where n=6 for amorphous SPIR and

n=3 for the SPIR anhydrate;
𝑚𝑎𝑥. 𝑑𝑖𝑠𝑠. 𝑓𝑙𝑢𝑥 (𝑎𝑚𝑜𝑟𝑝ℎ𝑜𝑢𝑠)
𝑓𝑙𝑢𝑥 (𝑐𝑟𝑦𝑠𝑡𝑎𝑙𝑙𝑖𝑛𝑒)

c

𝑅𝑠𝑒𝑥𝑝𝑡 = 𝑡𝑒𝑟𝑚𝑖𝑛𝑎𝑙 𝑑𝑖𝑠𝑠.

𝑨+𝑪𝒂𝒎𝒐𝒓𝒑𝒉𝒐𝒖𝒔

=(

𝑪𝒄𝒓𝒚𝒕𝒂𝒍𝒍𝒊𝒏𝒆

);

d

The 99% conversion times is the time for the dissolution flux to decline from its initial value (𝐴 +

𝐶) to 𝐶 + 0.01𝐴 (5𝜏).

185

Figure 3. PLM images (400x magnification) of amorphous SPIR compact surface taken at the
end of dissolution experiments after (a) 280mins at 4C, (b) 170 mins at 13C, (c) 40mins at 22C,
(d) 40mins at 36C, and (e) 40mins at 44C.

The flow-through dissolution apparatus was

disassembled and water removed before PLM images were captured. Black arrows indicate
apparent cracks in the crystalline phase growing on the underlying amorphous solid surface. (f)
PLM image (200x magnification) taken after 70mins at 44C, showing the edge of the compact,
which is flush with the bottom of flow channel in the stainless steel flow-through dissolution
apparatus.
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Figure 4. Stereomicroscopic images of amorphous SPIR during dissolution in water at 44C. At
t=0, the amorphous material is transparent. Opaque patches first noted at t=15 to 20mins. (The
orange color of the transparent solid is from the rubber silicone heating element directly
underneath the flow-through dissolution apparatus.)
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Figure 5. Stereomicroscopic images of amorphous SPIR during dissolution in water at 36C. At
t=0, the amorphous material is transparent. Opaque patches first noted at t=20-30mins.

188

Figure 6. Raman spectra of amorphous SPIR solid in flow-through dissolution apparatus after
t=0, 20 and 90 mins of dissolution at 44˚C. At t=0 (green) the solid compact was identified as
amorphous and at t=90 mins (blue), as SPIR channel hydrate. Spectrum captured after t=20 mins
(red) of dissolution has contributions from both amorphous and hydrate form. 1690 cm-1 and 16701660 cm-1 band relates to the stretching vibration of C=O bond of thioacetyl and C=O bond of
unsaturated cyclic ketone of SPIR.

Characterization of amorphous and channel hydrate

(dehydrated) forms matches reference spectra (SI Figure 5).
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Figure 7. 𝑇𝑔 of amorphous SPIR as a function of (a) % RH and (b) % water uptake. Error bars
represent standard deviation (n=3).
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Table 3. Water sorption (98%RH) results of amorphous SPIR compacted discs (n=1).
Temp

𝝉 𝑫𝑽𝑺 a

Appearance

Phasec

(˚C)

(hr)

(post)

(post)

4

-

-

-

106.5

Partly

Partly

(0.88)b

Transparent

Amorphousd

Opaque

Hydrate

Opaque

Hydrate

Opaque

Hydrate

Opaque

Hydrate

13

63.4
18
(0.93)
20.7
22
(0.91)
6.7
36
(0.98)
3.1
44
(0.99)
Water uptake fitting to exponential growth equation; mass of water sorbed = 𝑨(𝟏 − 𝒆(−𝒕⁄𝝉𝑫𝑽𝑺) );

a

b

Goodness-of-fit, R2, in parenthesis;

c

Raman spectra of samples collected as shown in SI Figure 9;

d

Raman taken after 3 days;

e

Calculations based on assuming physical restriction of compacted disc minimizing expansion of

the channel hydrate and water uptake at 98%RH is similar to 100% RH.
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Figure 8. (a) 𝑅𝑠 𝑒𝑥𝑝𝑡 and (b) 1/𝜏 (a rate constant for crystallization) vs. temperature. Analysis of
variances for a single factor (temperature) was performed on 𝑅𝑠 𝑒𝑥𝑝𝑡 values which resulted in a
p-value less than the level of significance (α= 0.05), indicating a significance difference between
dissolution temperatures for amorphous SPIR.
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Figure 9. 𝑙𝑛 1/𝜏 vs. reciprocal of temperature plot from dissolution studies. Error bars represent
standard error of the mean (n=6).
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SUPPORTING INFORMATION

SI Section on Temperature Control of Flow-through Dissolution Apparatus
The dissolution apparatus was accessorized with customized heating units to allow dissolution at
various temperatures (SI Figure 1). Temperature of each heating unit is monitored and adjusted
from a control console (Hi-Watt Inc.). One heating unit has metal grommets built into the sheath
of the silicone material, which allowed it to be securely wrapped around the syringe during
dissolution. The second customized heating unit sits directly under the predominately stainless
steel composed flow-through dissolution apparatus and on top of an insulator (a thin slab of
polyvinyl chloride).

SI Figure 1. Picture of heater for flow-cell (top) and syringe (bottom).
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SI Section on Calculating Standard Error of the Mean
By fitting the equation, dissolution rate =𝐴𝑒 (−𝑡⁄𝜏) + 𝐶 to the dissolution rate time course data from
the flow cell, each parameter (𝐴, 𝐶 and 𝜏) was obtained with a standard error (𝑆𝐸) associated with
it. This was used to calculate error propagation (SI Table 1) for terms listed in Table 2.

SI Table 1. Explanation for calculation of mean and error propagation from parameters obtained
from dissolution time course curves.
Term

Mean

Standard Error of the Mean

𝐴

∑𝒏𝒊=𝟏 𝐴𝒊
̅=
𝒙
𝒏

̅
𝝏𝒙
√∑ ((
)𝒔 )
𝝏𝑨𝒊 𝑨𝒊
𝒊=𝟏

̅
𝝏𝒙
√∑ ((
)𝒔 )
𝝏𝑪𝒊 𝑪𝒊
𝒊=𝟏

𝟐

𝒏

∑𝒏𝒊=𝟏(𝐴𝒊 + 𝐶𝒊 )
̅=
𝒙
𝒏

𝐴+𝐶

𝑅𝑠𝑒𝑥𝑝𝑡

̅=
𝒙

∑𝒏𝒊=𝟏(𝐴𝒊 + 𝐶𝒊 )
)
𝒏
𝒂𝒎𝒓𝒐𝒑𝒉𝒐𝒖𝒔
(

∑𝒏𝒊=𝟏 𝐶𝒊
𝒏

𝒊=𝟏

𝒊=𝟏

𝟐

𝒊=𝟏

𝒊=𝟏

̅
𝝏𝒙
+ (∑ ((
)𝒔 ) )
𝝏𝑪𝒊 𝑪𝒊

𝒉𝒚𝒅𝒓𝒂𝒕𝒆

𝒊=𝟏

𝒉𝒚𝒅𝒓𝒂𝒕𝒆

τr

SMPT)

𝒂𝒎𝒐𝒓𝒑𝒉𝒐𝒖𝒔
𝟐

𝒏

√

(63%

𝟐

𝒏

̅
̅
𝝏𝒙
𝝏𝒙
(∑ ((
) 𝒔𝑨𝒊 ) + ∑ ((
)𝒔 ) )
𝝏𝑨𝒊
𝝏𝑪𝒊 𝑪𝒊

)

∑𝒏 𝜏𝒊
̅ = 𝒊=𝟏
𝒙
𝒏

𝟐

𝒏

̅
̅
𝝏𝒙
𝝏𝒙
√∑ ((
) 𝒔𝑨𝒊 ) + ∑ ((
)𝒔 )
𝝏𝑨𝒊
𝝏𝑪𝒊 𝑪𝒊
𝒏

(

𝟐

𝒏

∑𝒏𝒊=𝟏 𝐶𝒊
̅=
𝒙
𝒏

𝐶

𝟐

𝒏

𝒏

𝟐

̅
𝝏𝒙
√∑ (( ) 𝒔𝜏𝒊 )
𝝏𝜏𝒊
𝒊=𝟏

195

Term

Mean

Standard Error of the Mean

5τr
(99%

̅=
𝒙

∑𝒏𝒊=𝟏 𝟓𝜏𝒊
𝒏

SMPT)
𝐿𝑛 (1/𝜏)

̅=
𝒙

∑𝒏𝒊=𝟏 𝒍𝒏

𝟏
𝝉𝒊

𝒏

The number or replicates (𝑛) differ between amorphous (𝑛=6) and channel hydrate (𝑛=3).
Sample standard deviation (s) is equal to standard error multiplied by the square root of the
number of replicates (𝑆𝐸 = 𝑠⁄ ).
√𝑛
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SI Figure 2. Stereomicroscopy images taken of amorphous SPIR during dissolution at 36C
without water. At t=0, the amorphous material is transparent. Opaque patches (blue circles) first
noted at t=180mins.
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SI Figure 3. Raman spectrum taken after 3hrs of dissolution at 22C. A broad peak at 1668cm-1
identifies the form as amorphous.

Characterization of amorphous form matches reference

spectrum (SI Figure 5).
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SI Figure 4. Raman spectrum of amorphous SPIR solid in flow-through dissolution apparatus after
t=140 mins of dissolution at 36˚C. Two distinct peaks present at 1690 and 1663 cm--1, identifying
the solid as SPIR channel hydrate. Characterization of hydrate form matches reference spectrum
(SI Figure 5).
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SI Figure 5. Reference Raman spectra for amorphous SPIR (green), SPIR dehydrated channel
hydrate (blue) and SPIR Form II. Form II is the crystalline material used in the preparation of
amorphous material by spray-drying. 1690 cm-1 band relates to the stretching vibration of C=O
bond of thioacetyl. 1670-1660 cm-1 band relates to the stretching vibration of C=O bond of
unsaturated cyclic ketone of SPIR.
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Sample: 26Jul2017_2ton compact_13C 98%RH

File: 26Jul2017_2ton compaction_13degC at 9...
Operator: Mary
Run Date: 2007-08-03 04:03
Instrument: TGA Q5000 V3.17 Build 265

TGA

14.7910 mg
(a) Size:
Method: flow cell like expt

Comment: SD SPIR compacted with 2 ton press like for flow cell expt
15.2

100

15.1

15.0

0.3363mg
(2.274%)
80

14.9

Relative Humidity (%)

Weight (mg)

90

70
14.8

14.7
0

200

400

600

Universal V4.1D TA Instruments

Time (hr)

(b)

Sample: 31Oct2017_2ton compaction_22degC
Size: 13.7470 mg
Method: flow cell like expt

60
1000

800

File: 31Oct2017_2ton compaction_22degC at 9...
Operator: Mary
Run Date: 2007-11-08 04:42
Instrument: TGA Q5000 V3.17 Build 265

TGA

102.5

100

102.0

Weight (%)

101.5

2.363%
(0.3249mg)

60

101.0

Relative Humidity (%)

80

40
100.5

100.0
0

20

40

60

80

100

Time (hr)

120

140

160

20
180

Universal V4.1D TA Instruments
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Sample: 19Oct2017_2ton compaction_36degC

File: 19Oct2017_2ton compaction_36degC at 9...
Operator: Mary
Run Date: 2007-10-27 08:06
Instrument: TGA Q5000 V3.17 Build 265

TGA

14.6420 mg
(c) Size:
Method: flow cell like expt
102.0

98

101.5

Weight (%)

101.0

1.417%
(0.2075mg)

96

100.5

Relative Humidity (%)

97

95
100.0

99.5

94
0

10

20

30

40

50

Universal V4.1D TA Instruments

Time (hr)

(d)

Sample: 17Sep2017_2ton compact_44C 98%RH
Size: 15.6180 mg
Method: flow cell like expt

60

File: 17Sep2017_2ton compaction_44degC at 9...
Operator: Mary
Run Date: 2007-09-25 00:24
Instrument: TGA Q5000 V3.17 Build 265

TGA

101.2

100

101.0

80

1.060%
(0.1655mg)

100.6

60
100.4

Relative Humidity (%)

Weight (%)

100.8

100.2
40

100.0

99.8

20
0

5

10

15

Time (hr)

20

25
Universal V4.1D TA Instruments

SI Figure 8. Water sorption isotherm of highly compacted discs of amorphous SPIR at 98% RH
and (a) 13, (b) 22, (c) 36 or (d) 44˚C.
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SI Figure 9. Raman spectra of highly compacted discs of amorphous SPIR post DVS at 98%RH
and: 13 ˚C after 3 days (purple line), 22 ˚C after 7 days (blue line which is right underneath the
orange line), 36 ˚C after 3 days (orange line), 44˚C after 1 day (red line).
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CHAPTER 6
Conclusions
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SUMMARY
Poorly soluble drugs are increasingly formulated into supersaturating drug delivery systems for
oral administration. The supersaturated state is of interest, because the increase in concentration
can drive higher drug permeation across the intestinal mucosa, potentially resulting in greater oral
bioavailability. However, compounds in supersaturated states (e.g., amorphous form) are
thermodynamically unstable and the system will return to the equilibrium (low concentration) state
by precipitation/crystallization.

Crystallization of a more stable form on the surface of the

metastable (amorphous) form, while in solution, (i.e., solution-mediated phase transformation,
SMPT), can greatly reduce the apparent solubility and dissolution rate enhancement of an
amorphous solid.

Considerable time and effort is invested to determine whether an amorphous approach will
provide the desired bioavailability improvement. Early prediction of the potential for success of
the amorphous route would reduce experimentation time and development costs for solid oral
dosage forms of poorly soluble drugs.

Therefore, understanding the factors that govern

crystallization of amorphous forms during dissolution may provide an additional tool for better
prediction, saving time, material, effort and cost. Key factors, through experimentation and
modeling, that affect SMPT were studied in this work.

In order to understand factors that potentially affect SMPT through modeling, a sparsely
parameterized biopharmaceutical model was developed. From the mathematical model and in
vitro dissolution data, equations were derived to obtain quick estimates of the dose absorbed
compounds that precipitate in the GI tract. The closed-form analytical solutions that relate in vitro
concentration profiles of supersaturating system to the amount of drug absorbed using several
alternate assumptions require only six parameters. Three parameters define the key features of
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the in vitro drug concentration time profile. An additional three parameters focus on physiological
parameters related to drug absorption.

The advantage of the current approach is the small number of input parameters required to define
key aspects affecting bioavailability. Due to the limited number of input variables, the models
were more easily used to quantify variation in bioavailability based on known variations of small
intestinal fluid volume and small intestinal transit time, as well as potential or experimentally
determined variation in drug peak concentration and duration. The results showed that the largest
contribution to variation in bioavailability is physiological, i.e., in vivo parameters, particularly the
reported variation in small intestinal fluid volume and transit time

The sparsely parameterized model developed in this study allows for key sources of variation to
be accounted for, making it useful for pharmaceutical formulators when making decisions as to
whether an amorphous approach is expected to provide sufficient bioavailability enhancement,
with acceptable variability. Additionally, the mathematical models developed here may be a
useful tool to guide the thinking of formulators; potential outcomes of proposed strategies to either
increase the peak drug concentration and/or the peak duration can be calculated using one of
several assumptions. However, additional refinements to the model may be needed. Non-pH
dependent precipitation (i.e., drug is non-ionizable) was assumed for the purpose of developing
the initial mathematical models to explore potential effects of supersaturation and precipitation on
oral bioavailability of poorly soluble compounds. Since not all drug compounds and candidates
are non-ionizable, pH dependent precipitation should be investigated in future work.
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To experimentally investigate the factors that affect the in vitro peak drug concentration and
duration, i.e., the rate of SMPT, a miniaturized flow-through dissolution apparatus was employed,
under sink conditions. This apparatus allowed direct measurement of dissolution rates and was
used to determine the effects of dissolution medium composition on SMPT of amorphous
spironolactone. Two biorelevant media slowed crystal growth of SPIR hydrate on the amorphous
surface during dissolution extending the period of higher dissolution rate, which would be
expected to improve bioavailability. Two mechanisms were proposed for the extended period of
apparent supersaturation due to biorelevant media: 1) lower flux of free drug at the surface of the
growing crystal due to drug uptake into micelles and 2) poisoning of crystal growth by
taurocholate, both resulting in a slower growth of crystalline solids.

The model compound spironolactone does not necessarily need to be converted to a higher
energy form (e.g., amorphous) due to complete oral absorption from micronized crystalline
material in humans. However, there are many drugs and drug candidates that have the four rings
of the steroid family (i.e., a gonane) as part of their molecular structure, including bile salts
naturally found in GI fluid. Based on literature data and this dissertation research on amorphous
spironolactone, the presence of sodium taurocholate, an anionic surfactant and bile salt used in
biorelevant dissolution media, has a positive effect in significantly delaying the rate of SMPT for
steroid-like compounds.

The delay in conversion from supersaturated solution to a saturated

solution, would lead to a greater flux of drug through GI lumen and greater oral bioavailability.

Literature reports show that dissolution media containing elevated sodium lauryl sulfate, often
have a negative effect, resulting in faster SMPT and rapid loss of solubility advantage of
supersaturated systems.

Sodium lauryl sulfate, also an anionic surfactant, is routinely used in

USP dissolution medium (7% in all dissolution medium methods listed in USP database of
monographs.)

More often, a simpler solution, i.e. buffered water without the presence of
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surfactants, is used for dissolution studies. However, the surfactant is a key variable and may
significantly affect dissolution which is used as a surrogate measurement for bioavailability.

A third possible mechanism for the SMPT is that the crystallization is promoted by higher
molecular mobility in the amorphous layer plasticized by absorbed aqueous dissolution fluid.
However, current theory suggests that a higher degree of supersaturation (which decreases with
temperature) provides a greater driving force for crystallization.

Thus, mobility and

supersaturation mechanisms provide conflicting effects of temperature on the rate of
crystallization. Thus, the goal was to determine the contribution(s) of the molecular mobility of
the hydrated amorphous drug and degree of supersaturation to the rate of SMPT. The dissolution
rate was determined over a range of temperatures for a single compound, rather than determining
the dissolution rates of compounds with different glass transition temperatures, so that the
complications of molecular structural factors (e.g., molecular weight and rigidity) were eliminated.
This allowed the study of supersaturation and mobility of the hydrated amorphous solid vs.
dissolution temperature in the absence of many known complicating factors.

The data presented strongly argue against the degree of supersaturation (i.e., the ratio of the
amorphous to crystalline solubility) as the sole determinant of the rate of SMPT. Rather, the
evidence points to a mobility-related mechanism for the rate of SMPT during dissolution.
However, efforts to support this mechanism with data relating to the mobility in the solid, i.e., glass
transition temperature data of bulk material, were not found to be directly conclusive. As is
suggested for other solids in a gaseous environment, a key determinant of mobility, the glass
transition temperature, of the surface may be lower at the dissolving surface. However, a more
conclusive result will require extensive additional study, including experiments to determine the
surface mobility relative to the bulk of amorphous spironolactone.

Nevertheless, SMPT was
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found to be dramatically affected by temperature, where an increase in temperature led to
markedly faster SMPT, resulting in rapid loss of solubility advantage.

One of the goals of dissolution testing is to predict in vivo performance of solid oral dosage forms.
Formulation scientists employ dissolution testing to help screen drug candidates and formulations
that produce the most suitable drug release profile. However, in vitro experimental conditions are
not good mimics for in vivo conditions. The improved understanding of the differences between
in vitro and in vivo conditions and factors that affect the rate of SMPT for supersaturated system
found by the work in this dissertation, provide guidance for the selection of more appropriate in
vitro dissolution conditions.
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